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Protein-­‐drug   conjugates   are   emerging   as   a   powerful   tool   for   the   targeting   of   specific   cell  
populations,  as  demonstrated  by  the  emergence  of  approved  antibody-­‐drug  conjugates.      In  
common   with   the   broader   field   of   protein   modification,   the   selective   synthesis   of   these  
agents  represents  a  significant  chemical  challenge,  as  the  conjugation  reaction  must  modify  
the  targeted  residue  in  the  presence  of  other  competing  unprotected  amino  acid  side  chains.  
While  the  alkylation  of  cysteine  thiols  remains  the  most  commonly  utilized  method  for  the  
selective  modification  of  proteins,  there  remain  significant  issues  with  this  approach  in  terms  
of   controlling   cysteine   oxidation,   separation   of   any   unreacted   protein,   and   reagent  
compatibility.  
In  order  to  address  these  issues,  we  have  developed  a  novel  system  containing  a  thiol  reactive  
group  (iodoacetamide)  attached  to  the  standard  solid  support  (agarose)  via  a  linker  that  can  
be  readily  cleaved  under  mild  conditions.  Following  initial  studies  an  allyl  carbamate  linker  
was   selected   due   to   its   general   stability   and   relatively   straightforward   deprotection  with  
optimised  catalytic  Pd  systems.  Based  on  this  we  have  developed  a  synthesis  of  the  completed  
catch-­‐release  linker  system  in  7  steps  and  demonstrated  that  this  linker  can  be  immobilised  
on  agarose  and  cleaved  on  the  solid  phase.  
This  system  was  then  combined  with  a  second  solid  phase  reducing  agent  to  allow  the  direct  
reduction  and  alkylation/trapping  of  a  standard  protein  (BSA).  The  protein  was  successfully  
alkylated  and  separated  from  the  unreacted  protein  by  simple  filtration.  Unfortunately,  the  
release   of   alkylated   BSA   from   the   solid   support   by   using   catalytic   Pd   did   not   proceed   as  
expected  from  the  model  system  and  this  step  is  currently  under  investigation.   
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Chapter  1:  Introduction  
     
 2 
1.1  Chronic  myelomonocytic  leukemia  (CMML)  
Leukemia   is   a   blood   cancer   that   starts   in   the   bone  marrow   and   forms   high   numbers   of  
abnormal  blood  cells  called  blasts  or  leukemia  cells.    Leukemia  is  classified  according  to  the  
effected  blood  cells;   lymphoblastic  or  lymphocytic  leukemias  where  the  cancer  occurs  in  a  
cell  lineage  which  normally  forms  lymphocytic  cells,  or  the  myeloid  or  myelogenous  leukemia  
where   the   cancer   occurs   in   bone   marrow   cells   that   normally   forms   red   blood   cells,  
monocyte/granulocyte-­‐derived  cells,  and  platelets.  Each  type  of  leukemia  can  be  either  acute  
(where   levels  of   the   immature  blood  cells   increase   rapidly)  or   chronic   (sustained   levels  of  
elevates  but  typically  lower  levels  of  abnormal  white  blood  cells).1  
Chronic   myelomonocytic   leukemia   (CMML)   is   the   only   subtype   of   chronic   myelogenous  
leukemia.1  It  is  a  rare  hematopoietic  malignancy  characterised  by  an  increase  in  monocytes  
in  the  peripheral  blood  (monocytosis)  and  bone  marrow,  with  a  bone  marrow  dysplasia  in  at  
least  one   type  of  blood   cell.2  CMML   is   characterised  as  both  a  myelodysplastic   syndrome  
(MDS)   and   a   myeloproliferative   neoplasm   (MPN).3   It   was   grouped   with   myelodysplastic  
syndrome  (MDS)  until  2002  because  it  shared  several  clinical  and  biological  features,  including  
bone  marrow   and   cytopenia   failure,   risk   of   acute   (AML)   transformation   and   cytogenetic  
abnormality.4  The  first  significant-­‐size  cohort  of  CMML  was  only  identified  in  1975,  consisting  
of  18  elderly  patients  with  unexplained  monocytosis,  cytopenias  and  splenomegaly.5       The  
incidence  rate  of  CMML  is  estimated  to  be  0.3  -­‐  0.7  per  100000  person-­‐years  and  the  median  
age  of  CMML  is  70  year  at  diagnosis.6,7    
The  French-­‐American-­‐British  group  (FAB)  classified  the  CMML  into  two  subtypes  according  to  
the  white  blood  cell  (WBC)  count  at  patient  diagnosis;8  myelodysplastic  CMML  (MD-­‐CMML)  
for  patients  that  have  WBC  counts  of  ≤13  ×  109  L-­‐1,  or  myeloproliferative  CMML  (MP-­‐CMML)  
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for  patients  that  have  WBC  counts  of  >13  ×  109  L-­‐1.8  The  World  Health  Organization  (WHO)  
classifies   CMML   according   to   the   blast   percentage   in   the   peripheral   blood   (PB)   and   bone  
marrow  (BM).9  The  first  category  is  CMML-­‐1  for  patients  have  blast  percentage  fewer  than  
5%   in   PB   or   10%   in   BM,   while   the   second   category   is   CMML-­‐2   for   patients   have   blast  
percentage  with  5%-­‐19%  in  PB  or  10%-­‐19%  in  BM.9  
Selimoglu-­‐Buet   et   al.   differentiated   between   CMML   cases   and   other   hematologic  
malignancies   by   the   type   of  monocyte   that   accumulate   in   the   peripheral   blood   of   CMML  
patients   compared   to   both   healthy   controls   and   patients   with   other   hematologic  
malignancies.10  They  reported  the  accumulation  of  classical  monocyte  (MO1)  with  a  cut  off  
value  of  greater  than  94%  MO1s  in  comparison  with  intermediate  (MO2)  and  non-­‐classical  
monocytes  (MO3)  in  the  peripheral  blood  of  CMML  patients.10  The  increase  in  MO1%  caused  
by  the  increase  in  the  total  number  of  MO1s  and  a  decrease  in  the  number  of  MO3s  in  the  
peripheral  blood  of  CMML  patients  can  be  used  to  differentiate  between  CMML  cases  and  
MDS  or  MPN.10      
These  findings  were  supported  by  Hudson  et  al.  who  differentiated  between  CMML  cases  and  
non-­‐CMML  and  non-­‐atypical  chronic  myeloid  leukemia  (non-­‐aCML)  patients  by  quantification  
of   the   non-­‐classical   monocyte   (MO3)   percentage   in   both   blood   and   bone   marrow  
specimens.11  They  reported  a  significant  decrease  in  MO3%  in  peripheral  blood  specimens  in  
patients  with  CMML  in  comparison  with  non-­‐CMML  and  non-­‐aCML  patients  (0.5%  ±  0.3%  vs  
5.8%  ±  4.4%,  P  <  .001),11    while  the  percentage  of  the  MO3  in  the  bone  marrow  specimens  of  
CMML  patients   are   decreased   significantly   in   comparison  with   non-­‐CMML   and   non-­‐aCML  
patients  (1.1%  ±  0.5%  vs  10.7%  ±  8.6%,  P  =  .002).11  Moreover,  Hudson  reported  the  decrease  
of   the   intermediate  monocytes  MO2  percentage   in   peripheral   blood   specimens   in   CMML  
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patients  in  comparison  with  non-­‐CMML  and  non-­‐aCML  patients  (4.5%  ±  6.8%  vs  8.3%  ±  4.6%,  
P   =   .014),   while   in   the   bone   marrow   specimens   there   was   no   significant   difference   the  
intermediate  monocyte  MO2  percentage.11    
The  blast  count  is  one  of  the  most  important  prognostic  indicators  in  CMML.  CMML-­‐1  patients  
are  likely  to  live  longer  than  CMML-­‐2  patients  with  median  survival  time  of  20  months  and  
they  have  an  18%  risk  of  transforming  to  acute  myeloid  leukemia  (AML)  within  5  years  of  their  
CMML  diagnosis.12  The  median  survival  time  of  CMML-­‐2  patients  was  15  months  and  they  
have  an  63%  risk  of  transforming  to  AML  within  5  years.12  However,  some  CMML-­‐1  (about  
20%)  and  CMML-­‐2  (about  10%)  patients  survived  much  longer  than  5  years.12    
At   present,   the   intensive   chemotherapy   followed   by   allogeneic   hematopoietic   stem   cell  
transplantation  (alloHSCT)  is  the  only  known  curative  treatment  for  CMML.6  However,  HSCT  
is  limited  to  a  minority  of  CMML  patients,  generally  younger  patients  with  good  performance  
status,  due  to  the  toxicity  of  the  alloHSCT.6  Therefore,  for  the  majority  of  patients  there  is  no  
curative   treatment   for   CMML   and   the   therapeutic   options   are   cytotoxic   hypomethylating  
agents  (HMA)  (such  as  5-­‐azacitidine  (AZA)  or  decitabine  (DEC))  to  delay  progression  used  in  
combination  with  hydroxyurea  for  myeloproliferation  and  erythropoiesis-­‐stimulating  agents  
for  anemia.6  
There  are  relatively  few  on  going  clinical  studies  investigating  new  therapies  for  CMML,  with  
recent   commercial   trials   failing   to   deliver   improved   therapeutic   options.   For   example,      
Tefinostat  (CHR-­‐2845)  is  a  cell  permeant  ester  which  is  converted  into  an  active  acid  histone  
deacetylase  (HDAC)  inhibitor  (CHR-­‐2847)  by  the  human  carboxylesterase  1  (hCE-­‐1)  enzyme,  
which  is  highly  expressed  in  cells  of  monocyte  lineage.13  The  selective  toxicity  of  tefinostat  
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towards  monocytic  cells  and  tolerability  were  confirmed  in  pre-­‐clinical  and  phase  1  studies.13  
However,  the  minimum  number  of  clinical  responses  to  tefinostat  (CHR-­‐2845)  and  targeting  
monocyte  in  CMML  were  not  achieved  in  a  phase  2  study.13    
The  strongest  prognostic  factor  in  CMML  is  gene  mutation.  The  most  frequent  genetic  events  
in  CMML  are  TET2,  SRSF2  and  ASXL1  mutations.14    The  study  of  genetic  lesions  in  28  cases  of  
CMML   confirmed   the   gene   mutations   are   found   early   in   hematopoiesis,   during   myeloid  
differentiation   to   the   granulocyte/monocyte   progenitor   (GMP)   stage,   resulting   in  
accumulation  of  monocytes  and  decrease   in  erythrocytes   (figure  1  and  2).14  Therefore,   to  
improve  disease  control  there  is  a  need  to  find  therapeutic  strategies  that  target  the  disease  
at  the  earliest  hematopoiesis  stages  in  bone  marrow.14    
  
Figure  1:  Immature  CMP  and  MPP  in  CMML.  MPP:  multipotent  progenitor  (left  hand  side),  
CMP,  common  myeloid  progenitor  (right  hand  side).  Proportion  of  MPP  and  CMP  by  flow  
cytometry  among  total  BM  CD341  cells  from  patients  with  CMML  (n  =  33)  or  aged-­‐matched  





Figure  2:  Proposed  model  linking  early  clonal  dominance  with  granulomonocytic  skewing  of  
immature  progenitors  in  CMML  and  later  clonal  dominance  in  other  chronic  myeloid  
neoplasms,  dashed  lines  represent  the  mutated  cells,  green  represents  granulomonocytic  
differentiation  potential,  red  represents  erythroid  potential.14  
  
1.2  Monocytes  
All  blood  cells  originate  from  hematopoietic  stem  cells  (HSCs)  in  bone  marrow  in  a  process  
called   hematopoiesis.   Hematopoietic   stem   cells   (HSCs)   differentiate   into   multi-­‐potent  
progenitors   (MPP)  and  then  to  common  lymphoid  progenitors   (CLP)  and  common  myeloid  
progenitors  (CMP),  with  each  lineage  further  differentiating  to  produce  one  or  more  specific  
types   of   blood   cell.   The   common   myeloid   progenitors   (CMP)   differentiate   to   produce  
granulocyte-­‐macrophage   progenitors   (GMP)   and   megakaryocyte-­‐erythrocyte   progenitors  
(MEP)   which   further   differentiate   to   more   specific   types   of   blood   cells;   monocytes,  
granulocytes,  megakaryocytes  and  erythrocytes  (figure  3).15    
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Figure  3:  Differentiation  of  hematopoietic  stem  cells  (HSCs)  into  blood  cells  in  bone  marrow  
(hematopoiesis).16  
 
Monocytes   are   a   subset   of   the   white   blood   cells   (leukocytes),   which   typically   represent  
around   10%   of   the   circulating   white   blood   cells   in   humans.17   Monocytes   originate   from  
hematopoietic  stem  cells  (HSCs)  in  bone  marrow  then  are  released  to  the  bloodstream,18,19  
where   they   circulate   in   the   blood   for   up   to   a   few   days   before   differentiating   into  
macrophages,  dendritic  cells  and  osteoclasts.18,19  The  main  functions  of  the  monocytes  are  
homeostasis,  immune  defence  and  tissue  repair.20,19    
Human  peripheral-­‐blood  monocytes  are  variable  in  size,  receptor  expression,  trafficking  and  
ability   to   differentiate   after   stimulation   by   cytokines   or   microbial   molecules.21   The   CD14  
surface  receptor  is  used  to  mark  human  monocytes  due  to  its  abundant  expression  on  the  cell  
surface.22   Monocytes   are   divided   into   three   subsets   according   the   CD   and   chemokine  
receptor  expression,  which  are  classical,  intermediate  and  non-­‐classical  monocytes.19,22,23    
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The   classical   monocytes   MO1   (CD14++CD16-­‐)   are   the   most   abundant   subset   of   human  
monocytes.24  They  express  high  level  of  the  CCR2  receptor,  which  is  a  chemokine  receptor  
that  mediates  chemotaxis  of  the  monocytes  during  inflammation,  and  express  low  levels  of  
the  CX3CR1  receptor  which  is  a  chemokine  receptor  that  mediates  accumulation  of  tissue-­‐
resident   monocytes   (table   1).17   Phagocytosis   is   considered   to   be   the   major   function   of  
classical  monocytes  MO1  (CD14++CD16-­‐).22  In  addition  classical  monocytes  MO1  (CD14++CD16-­‐
)  are  pro-­‐inflammatory  in  part  due  to  expression  CD62L,  which  plays  role  in  migration  into  
lymph  nodes,  where  they  can  differentiate   into  macrophages  and  dendritic  cells   that  help  
control  the  adaptive  immune  response.22  
In  contrast,  the  intermediate  and  non-­‐classical  monocytes  (which  are  called  CD16+  monocytes  
due  to  co-­‐expression  of  CD16  with  CD14)  have  lower  phagocytic  capacity  and  express  more  
MHC  class  II  complex  for  antigen  presentation  (table  1).18  The  non-­‐classical  human  monocytes  
MO3  (CD14+CD16+)  produce   low   level  of   the  CCR2  receptors  and  high   level  of   the  CX3CR1  
receptors.22,23   The   intermediate   human   monocytes   MO2   (CD14++CD16+)   express   CCR2  
receptors   and   have   inflammatory   function   and   low   peroxidase   activity.22   During  
inflammation,  the  classical  monocytes  MO1  (CD14++CD16-­‐)  and  the  intermediate  monocytes  












Endothelium  patrolling   no   no   yes  
Phagocytose  beads   high   high   low  
ROS  production   high   none   none  
TNF-­‐æ   none   high   low  
IL-­‐1ß   low   high   high  
CCR2   high   med   low  
IL-­‐10   high med   none  
IL-­‐8   high med   low  
IL-­‐6   high high   low  
CCL3   high high   low  
IL-­‐1  receptor  antagonist   none   low   high  
  
Table  1:  Comparison  between  the  three  monocyte  subsets  in  production  of  
cytokines/chemokines.25  
 
The  differentiation  of  the  classical  human  monocyte  MO1  into  non-­‐classical  monocyte  is  now  
widely   accepted.26   CCR2  mediates  migration   of   the   classical   human  monocyte   from   bone  
marrow  to  the  blood  stream  after  maturation.  In  the  blood,  classical  human  monocytes  MO1  
differentiate   into   intermediate   monocytes   MO2   then   non-­‐classical   human   monocytes  
MO3.20,27  
1.3  Chemokines  and  their  receptors  
Chemokines  are  small  heparin-­‐binding  proteins  containing  60-­‐100  amino  acids  that  control  
cell  trafficking  (chemotaxis).  More  than  50  human  chemokines  and  20  chemokine  receptors  
have  been  discovered  since  1977.  The  molecular  mass  of  chemokines  is  about  8  -­‐  12  kDa  and  
they  contain  1–3  disulfide  bonds.  The  four  subfamilies  of  chemokines  are  classified  according  
to   the   number   and   location   of   the   cysteine   residues   at   the   N-­‐terminus   of   the  molecule,  
resulting  in  the  classification  CXC-­‐,  CC-­‐,  CX3C-­‐,  and  C-­‐.28,29    
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Despite  having  limited  secondary  structure  the  chemokines  contain  three  distinct  domains.  
The  first  domain  is  N-­‐terminal  region,  which  is  highly  flexible  and  is  the  region  that  binds  to  
and  activates  receptors.    The  disulfide  bond  between  the  N-­‐terminal  cysteine  constrains  the  
N-­‐terminal  region  in  place  relative  to  the  second  domain,  which  is  a  long  loop  that  enters  the  
triple-­‐stranded   antiparallel   β-­‐sheet.   The   final   domain   is   C-­‐terminal   α-­‐helix   region   which  
overlies  the  sheets  (figure  4).30,31,32    
  
Figure  4:  The  structure  of  chemokines.28  
 
The   chemokine   ligands   are   secreted   by   many   cell   types   in   response   to   signals   such   as  
proinflammatory   cytokines,  and   specifically   recruit   subsets  of  monocytes,  neutrophils  and  
lymphocytes.   As   a   result,   their   receptors   are   generally   found   only   on   the   surface   of  
leukocytes.    The  chemotaxis  process  is  induced  by  binding  of  the  chemokines  ligands  to  G-­‐
protein-­‐coupled  receptors   (GPCRs)  on  the  specific  cell  surface.      The   resulting  activation  of  




1.3.1  CCL2-­‐CCR2  Signalling  Axis    
CCL2,  also  called  monocyte  chemoattractant  protein-­‐1  (MCP-­‐1),  belongs  the  C-­‐C  chemokine  
family  and  is  composed  from  four  members  (MCP-­‐1,  -­‐2,  -­‐3,  and  -­‐4).  CCL2  contains  76  amino  
acids  and  the  molecular  mass  of  the  mature  protein  is  about  9  kDa.  The  principle  receptor  for  
CCL2  is  CCR2,  a  helical  seven-­‐transmembrane  G  protein-­‐coupled  receptor  (GPCR)  found  on  
the  cell  membrane  of  a  large  proportion  of  monocytic  cells.  CCL2  acts  as  a  chemoattractant  
chemokine  which  is  responsible  for  monocyte  recruitment  from  bone  marrow  into  peripheral  
blood   then   into   tissue;   CCL2   is   expressed   by  many   cells   in   response   to   pro-­‐inflammatory  
cytokines   or   microbial   molecules,   leading   to   increased   CCL2   concentration   in   serum   and  
within   inflamed   tissue   followed   by   migration   of   the   monocytes   to   the   site   of   the  
infection.28,33,34    
G  protein-­‐coupled  receptors  (GPCR)  consist  of  two  regions,  intracellular  and  extracellular.  The  
extracellular  region  is  composed  of  the  N-­‐terminus  and  three  extracellular  loops,  while  the  
intracellular  region  is  composed  of  C  terminus  and  three  intracellular  loops.  The  extracellular  
domain   is   important   for   binding   with   chemokines   ligand   and   the   intracellular   domain  
collaborate   to   transduce   the   chemokine   signal.   Changes   in   the   seven-­‐transmembrane  
conformation  lead  to  receptor  activation.32,33,35  
The  binding  of  the  chemokine   ligands  to  the  G  protein-­‐coupled   receptor   (GPCR)  enhances  
internalisation   and   trafficking   of   the   receptor.   There   are   two   different   mechanisms   for  
internalisation,   clathrin-­‐mediated   endocytosis   and   lipid   raft/caveolae-­‐dependent  
internalization.   Most   ligand-­‐induced   internalisation   of   the   receptors   occurs   through   the  
clathrin-­‐mediated   endocytosis   mechanism,   while   the   research   in   the   lipid   raft/caveolae-­‐
dependent  pathways  is  limited  with  only  CCR5  and  CXCR4  being  identified  in  lipid  rafts.  Lipid  
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rafts  are  glycosphingolipid-­‐enriched  microdomains  and  caveolae   is  a  protein   that   is  highly  
enriched  in  cholesterol  and  glycosphingolipids.    Once  internalised  GPCRs  enter  caveosomes,  
followed   by   fusing   with   early   endosomes   and   join   the   clathrin-­‐mediated   endocytosis  
pathway.36    
The  clathrin-­‐mediated  endocytosis  mechanism  starts  with  binding  of  chemokine  ligands  with  
GPCR,   causing   conformational   changes   that   result   in   phosphorylation   of   the   chemokine  
receptor  in  serine  and  threonine  residues  in  the  intracellular  loops  and  carboxyl-­‐terminus  by  
G  protein-­‐coupled  receptor  kinases  (GRKs).  Phosphorylation  of  the  chemokine  receptor  leads  
to  G  protein  subunits  uncoupling  from  the  receptor  and  migration  of  the  adaptor  molecules  
which  link  the  receptor  to  a  lattice  of  clathrin  to  facilitate  receptor  internalization.  Adaptin  2  
(AP-­‐2)   and   ß-­‐arrestin   are   adaptor   molecules   have   critical   role   in   internalization   of   the  
chemokine   receptor.   The   endocytosis   is   mediated   by   binding   of   ß-­‐arrestin   to   the  
phosphorylated   receptors   and   adaptin   2   (AP-­‐2)   then   binds   to   clathrin   to   form   a   clathrin-­‐
coated   pit.   This   is   followed   by   internalization   of   the   receptor   in   a   clathrin-­‐coated   vesicle  
through  cleavage  from  the  membrane  by  the  action  of  dynamin.  Following  uncoating  of  the  
clathrin-­‐coated  vesicle  the  receptor-­‐ligand  complex  progresses  into  an  early  endosome,  from  
which  the  chemokine  receptor  can  be  either  recycled  back  to  the  surface  for  further  ligand  
binding  or  degraded  by  entering  the  late  endosome  then  to  lysosomes  (figure  5).36,32      
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Figure  5.  Endocytosis  scheme.  CCP:  clathrin-­‐coated  pit,  CCV:  clathrin-­‐coated  vesicle,  EE:  
early  endosome,  LE:  late  endosome,  RE:  recycling  endosome,  RRP:  rapid  recycling  pathway,  
SRP:  slow  recycling  pathway,  EEA-­‐1:  early  endosomal  antigen-­‐1,  FIP-­‐2:  Rab11-­‐family  
interacting  protein-­‐2,  LAMP-­‐1:  lysosomal-­‐associated  membrane  protein-­‐1.36  
 
Although   CCL2   attracts   mature   monocyte/macrophages   to   migrate   to   the   area   of  
inflammation   and   injury   by   activation   of   CCR2,   it   has   been   demonstrated   that   CCR2   also  
mediates   hematopoietic   stem   and   progenitor   cells   trafficking   from   BM   to   areas   of  
inflammation   and   injury   in   mice   in   response   to   CCR2   ligands.37   While   the   role   of   the  
hematopoietic   stem   and   progenitor   cells   in   the   inflammation   site   is   unclear,   it   has   been  
suggested   to   contribute   in   the   repair   and   regeneration   of   damaged   tissue   by   in   situ  
hematopoiesis  and  differentiation.37  CCR2  expression  can  be  observed  on  the  surface  of  a  
portion  of  primitive  hematopoietic  cells  in  mice,  with  the  proportion  of  cells  expressing  CCR2  
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increasing  as  differentiation  proceeds  toewards  monocytes.37  The  expression  of  CCR2  in  the  
myeloid  lineages  (CMPs  and  GMPs)  is  more  than  self-­‐renewing  HSCs  and  MPPs  (figure  6)  and  
expression  increases  further  in  fully  differentiated  monocytes.37  
  
Figure  6:  CCR2  expression  on  cells.  HSC:  hematopoietic  stem  cells,  MPP:  multipotent  
progenitor,  CMP:  common  myeloid  progenitor,  GMP:  granulocyte-­‐macrophage  progenitor,  
MEP:  megakaryocyte-­‐erythroid  progenitor.37  
 
1.3.2  CCL2/CCR2  Therapies  and  CCL2  Conjugates    
Several  CCL2  conjugates  have  been  used  to  investigate  the  functional  behaviour  of  CCL2-­‐CCR2  
signalling  axis  or  towards  development  of  novel  therapeutics  agents.  Volpe  and  co-­‐workers  
developed  a  fluorescent  protein  tagged  CCL2  by  fusing  mCherry  fluorescent  protein  at  the  C-­‐
terminus  of  CCL2,1  which  they  used  to   investigate  the  migration  of  the  human  monocytes  
mediated  by  CCL2/CCR2.38  It  was  shown  that  the  potency  of  the  CCL2-­‐mCherry  conjugate  to  
initiate   chemotaxis   is   similar   to   the   wild-­‐type   CCL2.38   The   time-­‐lapse   video   microscopy  
showed   the  CCR2  meditated   the  efficient  and   selective   internalization  of   the  CCL2  during  
migration  and  the  rapid  processing  of  CCR2  from  the  plasma  membrane  to  the  endosomal  
structure  for  CCL2  degradation,  with  CCR2  recycled  to  the  surface  for  further  chemotaxis  and  
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ligand  internalisation.38  The  uptake  of  the  fluorescent  CCL2–mCherry  demonstrates  that  the  
CCR2  which  expressed  on  the  surface  of  monocytes  can  act  as  scavenger  for  CCL2.38      
CCL2  conjugates  have  also  been  used  to  deliver  therapeutics  inside  cells;  the  CCL2-­‐SA1  toxin  
was  prepared  as  a   fusion  protein   containing   the  Shigella  dysenteriae  holotoxin   (SA1)  with  
CCL2  through  recombinant  protein  expression.39  The  CCL2  binds  to  CCR2  that  is  expressed  on  
the  cell  surface,  where  the  fusion  protein  enters  the  cells  then  the  SA1  toxin  causes  cell  death  
by   inhibition   of   protein   synthesis.39   It   has   been   shown   that   the   CCR2   mediates   the  
internalization   of   CCL2-­‐SA1   conjugate   in   monocytes   that   caused   a   reduction   in   protein  
synthesis   and   subsequent   cell   death.39   In   the   kidney   nephropathy   model,   the   CCL2-­‐SA1  
conjugate   caused   decrease   in   infiltrating   monocytes/macrophages,   decrease   glomerular  
lesions  and  proteinuria.39  However,  no  chemotactic  migration  was  observed  when  non-­‐native  
CCL2  variant  was  used  this  was  in  line  with  previous  reports  that  CCL2-­‐variants  can  reduce  
the  chemotactic  potency  relative  to  wild-­‐type  CCL2.39    
In  the  previous  work  of  our  group,  novel  CCL2-­‐fluorophore  conjugates  have  been  prepared  to  
investigate   the   CCL2   uptake   by   primary   human   immune   cells   that   express   CCR2   and  
chemotactic   activity   of   CCL2   conjugate.   The   CCL2-­‐fluorophore   conjugate   is   prepared   by  
copper   catalysed   azide   alkyne   cycloaddition   reaction   (CuAAC)   between   an   azido-­‐bearing  
fluorophore  and  synthetic  CCL2  that  is  modified  by  propargyl  glycine  at  C-­‐terminus  (scheme  
1).    In  order  to  study  the  impact  of  changes  in  the  protein  the  conjugates  were  prepared  using  





Scheme  1:  Synthesis  CCL2  fluorophore  conjugates  by  CuAAC  reaction  between  azido-­‐bearing  
fluorophore  and  alkyne  modified  CCL2.  
  
The  transwell  Chemotaxis  assay  was  used  to  characterise  the  chemotactic  activity  of  the  CCL2-­‐
fluorophore  conjugates.  This  assay  is  composed  from  an  upper  chamber  where  the  immortal  
monocytic  THP-­‐1  cells  are  placed  and  a  lower  chamber  where  the  chemoattractant  is  placed.    
The  two  chambers  are  separated  by  a  porous  membrane  to  facilitate  cell  migration  from  the  
upper  chamber  towards  the  chemoattractant  in  the  lower  chamber.  The  chemotactic  activity  
of  the  conjugates  was  clearly  observed  with  maximum  migration  response  at  10  nM  (figure  
7).  However,  fewer  cells  migrated  at  higher  concentrations  because  the  highly  concentrated  
chemokine  saturates  the  receptors,  thus  blocking  the  cell’s  ability  to  detect  the  direction  of  
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concentration   gradient   (figure   7)   with   the   cells   movement   therefore   switched   from  
chemotaxis   to   chemokinesis,   where   cells   move   in   a   random   motion.   The   migrated   cells  
showed  a   concentration-­‐dependant   increase   in   fluorescence,  which  appears   to  plateau  at  
around  30  nM  which  would  be  consistent  with  this  being  a  saturating  concentration  in  this  
model.  
  
Figure  7:  Transwell  Chemotaxis  assay  for  CCL2  fluorophore  conjugate  and  THP1  cells.  The  
maximum  migration  response  at  10  nm  of  CCL2  fluorophore  conjugate,  few  cells  were  
migrated  at  higher  concentrations.  
  
Fluorescence   microscopy   was   used   to   determine   the   behaviour   of   the   CCL2   fluorophore  
conjugate  inside  cells.  Either  THP-­‐1  cells  or  peripheral  blood  mononuclear  cells  (PBMCs)  from  
healthy  volunteers  were  incubated  with  CCL2  fluorophore  conjugate  for  2  hours  then  4’,6-­‐
diamidino-­‐2-­‐phenylindole  (DAPI)  was  used  to  stain  the  nuclei.  The  Zeiss  Axio  Observer  was  
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then  used  to  capture  the  images  using  LED  illumination  at  405  and  495  nm  with  Apotome  
optical  sectioning  (figure  8).  The  images  demonstrate  that  the  PBMCs  internalise  the  CCL2  
fluorophore  conjugate,  with  the  fluorophore  distributed  throughout  the  cytosol  even  at  early  
time  points  (2  hr),  with  similar  results  observed  for  THP-­‐1  cells  and/or  WT  CCL2.  
  
    
Figure  8:  The  fluorescence  microscopy  of  PBMCs  incubated  with  P8A  CCL2  fluorophore  
conjugate  for  2  hours.  
 
1.3.3  CCL2-­‐NAMPTi  Conjugates    
FK866   is   an   experimental   anticancer   drug   that   acts   as   a   highly   specific   inhibitor   for  
nicotinamide  phosphoribosyltransferase  (NAMPT),  which   is  an  essential  enzyme  regulating  
the  biosynthesis  of  the  intracellular  coenzyme  NAD+  from  the  natural  precursor  nicotinamide  
(figure  9).41  FK866  effectively  inhibits  NAMPT  in  HepG2  human  liver  carcinoma  cells  in  an  IC50  
of  ~1  nM  leading  to  gradual  depletion  in  NAD+  that  results  in  cell  death  by  apoptosis.41  The  
metabolic   mechanism   of   action   makes   this   an   interesting   class   of   anticancer   drug   in  
comparison  to  the  traditional  cell-­‐cycle  cytotoxins,  however  unfortunately  to  date  there  have  
been   no   successful   late-­‐stage   clinical   trails   with   NAMPT   inhibitors   such   as   FK-­‐866,  
predominantly  due  to  their  poor  selectivity  for  cancerous  cells.  In  order  to  investigate  if  this  
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poor  selectivity  can  be  overcome  by  use  of  a  targeting  peptide,  our  group  have  prepared  a  
CCL2-­‐FK866   conjugate   and   evaluated   its   function   using   THP1   cells   that   express   CCR2   and  
Jurkat  cells  that  do  not  have  CCR2.  While  FK-­‐866  was  toxic  to  both  cell  types,  the  CCL2-­‐FK866  
conjugate  induced  cell  death  in  THP1  cells  with  an  IC50  of  2  nM,  while  Jurkat  cells  were  not  
affected  up  to  concentrations  of  100  nM  (figure  10).  
  
Figure  9:  Chemical  structure  of  FK866,  NADPRT  inhibitor.41  
 
  
Figure  10:  Investigation  of  CCR2-­‐cytotoxin  conjugates  in  THP1  cells  and  Jurkat  cells.  
 
  
We  have  successfully  confirmed  the  chemotactic  activity  of  the  CCL2  fluorophore  conjugate  
by   using   the   transwell   Chemotaxis   assay   and   cellular   internalising   the   CCL2   fluorophore  








has  been  confirmed  in  compare  with  control  cell.  However,  we  faced  issues  in  the  scaling  the  
CCL2  synthesis  as  just  a  few  milligrams  are  available,  therefore,  we  decided  to  move  to  the  
recombinant   system  by   targeting   a   nucleophilic   thiol   introduced   at   the   C-­‐terminus   of   the  
CCL2.    The  FK866  will  be  attached  to  a  thiol  alkylation  reagent  then  reacted  with  cysteine  in  
order  to  form  the  CCL2-­‐FK866  conjugate.    
  
1.4  Peptide  -­‐drug  conjugate  (PDCs)  
Antibody-­‐drug  conjugates  (ADCs)  and  peptide-­‐drug  conjugate  (PDCs)  are  targeted  therapies  
that   have   been   extensively   studied   in   recent   years.   They   contain   three   components;   a  
monoclonal  antibody  or  peptides,  one  or  more   (toxic)  payloads  and   linker   to   connect   the  
active  components  (figure  11).  PDCs  and  ADCs  are  generally  designed  to  reduce  the  adverse  
effects  of  typical  therapy  as  they  combined  the  advantages  of  both  cytotoxic  payloads  and  
highly  specific  monoclonal  antibodies/peptides  ligands.  ADCs  are  generally  more  stable  and  
selective  in  comparison  with  PDCs,  however  PDCs  composed  of  linear  or  cyclic  peptides  have  
lower   molecule   weight   than   ADCs,   which   can   allow   higher   drug   loading   and   enhanced  
penetration   into   solid   tissues.   Moreover,   the   short   peptide   nature   of   PDC   make   their  
structure   more   flexible   and   modification   and   conjugation   much   easier,   allowing   rational  




Figure  11:  The  basic  structure  of  PDCs.42  
  
While  there  are  several  approved  ADCs  and  a  much  larger  number  under  development,  there  
are  relatively  few  PDCs  in  late  stage  trials  and  only  approved  drug.  GHIH-­‐177Lu  conjugate  is  a  
peptide-­‐drug   conjugate   that   has   recently   been   approved   for   treatment   of  
gastroenteropancreatic  neuroendocrine  tumours.  The  GHIH-­‐177Lu  conjugate  is  a  conjugation  
of   a   somatostatin-­‐derived   peptide   with   beta-­‐emitter   177   Lu   that   acts   as   a   radioactive  
chemotherapeutic  agent  (figure  12).    Somatostatin  is  a  growth  hormone-­‐inhibiting  hormone  
(GHIH)   that   inhibits   secretion   of   different   hormones   such   as   growth   hormone,   thyroid  
stimulating   hormone,   and   other   pituitary-­‐derived   hormones.   Therefore,   Somatostatin  
analogues  are  used  clinically  to  treat  acromegaly  and  hormone-­‐dependent  tumours  such  as  
pancreatic   and   vasoactive   intestinal   peptide-­‐secreting   tumours.   Somatostatin   has   five  
receptors   subtypes   (SSTR1-­‐5)   that   are   expressed   by   many   cells,   with   SSTR2   in   particular  
expressed  by  many  tumour  cells.  Somatostatin  is  has  higher  affinity  for  SSTR2  (IC50  1.5  nM)  in  
comparison  with  other   receptor   such  as  SSTR5   (IC50  547  nM)  and  SSTR3   (IC50  >1000   nM),  
therefore,   GHIH-­‐177Lu   is   able   to   target   SSTR2   in   tumour   cells   to   selectively   induce  
internalization  of  the  cytotoxic  component.43  
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The  combination  of  the  anticancer  pharmacology  of  somatostatin  and  radioisotope  therapy  
leads   to   tumour   death   by   process   called   peptide   receptor   radionuclide   therapy   (PRRT).   A  
clinical   study   in  310  patients  with  gastroenteropancreatic   cancer   showed   the  GHIH-­‐177Lu  
conjugate  provided  28%  partial  tumour  remission  and  2%  complete  tumour  remission.43    
  
Figure  12:  chemical  structure  of  GHIH-­‐177Lu  conjugate.43  
  
1.5  Protein  modification  
1.5.1  Background  
Proteins  are  responsible  for  a  wide  range  of  critical  functions  in  living  organisms,  including  for  
example   DNA   replication,   catalysis   of   metabolic   reactions,   stimulation   response   (cell  
signalling)  and   transport  of  molecules.     Because  of   the  broad  array  of   roles   conducted  by  
proteins,  the  control  of  protein  behaviour  provides  a  huge  number  of  opportunities  to  study  
and  exploit  their  function  in  the  fields  of  biology,  medicine  and  enzymatic  catalysis.44  
Many  chemical  species  are  added  to  proteins  during  and  after  synthesis  on  the  ribosome  to  
modify  their  structure.  This  is  can  explain  the  complexity  of  the  human  proteome  over  the  
human  genome;  It  is  estimated  that  the  human  genome  comprises  about  20,000  to  25,000  
genes   but   the   human   proteome   is   estimated   to   comprise   over   1   million   proteins.45   This  
demonstrates  that  a  single  gene  can  encode  multiple  proteins,  as  a  single  gene  generates  
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different   mRNA   transcripts   due   to   transcription   initiation   at   alternative   promoters,  
differential   transcription   termination,   and   alternative   splicing   of   the   transcript.   The   Post-­‐
translational  modifications  (PTM)  play  a  key  role   in  further  increasing  the  complexity  from  
level  of  the  genome  to  the  proteome  (figure  13).46  
  
Figure  13:  The  role  of  post-­‐translation  modifications  in  increasing  proteomic  diversity.46  
  
  Post-­‐translational   modifications   (PTM)   are   the   natural   modification   of   proteins   after  
synthesis  in  the  ribosome.  A  large  set  of  reactions  have  been  developed  by  chemists  to  mimic  
natural  protein  modification  in  order  to  determine  the  exact  biological  roles  of  PTMs.47  Such  
protein   modifications   have   many   applications   in   biology   and   therapeutic   discovery.   For  
example   as   previously   discussed   protein   conjugation   with   fluorophores   allows   optical  
measurement   of   physiological   parameters   of   cells   and   tissues,   while   the   conjugation   of  
cytotoxic  medicines  to  antibodies  can  improve  the  efficacy  and  reduce  the  side  effects  of  anti-­‐
cancer  drugs.48,49,50  
The  ideal  chemical  modification  of  protein  should  be  chemoselective  to  one  amino  acid  side  
chain  among  other  reactive  amino  acid  side  chains  on  the  protein  surface.  While  nature  can  













modification   typically   relies   on   targeting   amino  acids  with   low   abundance   on   the   protein  
surface,   such   as   cysteine.   Another   method   for   site-­‐selective   protein   modification   is  
incorporation  of  unnatural  amino  acids  (UAAs)  to  form  proteins  that  have  functional  groups  
that   are   normally   not   present   in   living   cells,   such   as   an   azide,   alkyne,   ketone,   alkene   or  
tetrazine.  The  reactions  with  these  functional  groups  are  highly  chemoselective  over  all  other  
amino  acid  side  chains  that  are  present  in  cells.51,52  
1.5.2  Natural  post-­‐translation  modification  
The  post-­‐translational  modification  of  proteins  (PTMs)  can  lead  to  changes  in  the  structure,  
localisation  and  activity  of  proteins  and  plays  a  critical  role  in  the  vast  biodiversity  of  proteins  
found  in  nature.46,53  In  addition,  PTMs  play  an  important  role  in  many  cellular  processes  such  
as  protein  degradation,  cellular  differentiation,  cellular  signaling,  protein-­‐protein  interactions  
and  gene  expression  regulation.46,53,47  These  modifications  can  cause  very  simple  chemical  
changes  of  proteins   such  as   phosphate  and  acetate  addition  or  more   significant   chemical  
changes  such  as  proteoglycans.53  
PTMs  occur  at  any  step   in  the  protein   life  cycle.  For   instance,  some  proteins  are  modified  
directly   after   completion   of   translation   in   order   to   provide   a   proper   protein   folding   or  
stability,  such  as  in  proteins  glycosylation  and  lipidation.  Other  proteins  are  modified  after  
completion  of  folding  and  localisation  in  order  to  activate  or  inactivate  their  biological  activity,  
such   as   phosphorylation   of   proteins   and   methylation.46   PTMs   can   be   classified   into   four  
categories,   which   are   addition   of   proteins   or   peptides,   an   addition   of   functional   groups,  
changes   protein   structure   and   changes   to   the   chemical   nature   of   an   amino   acid,   some  
common  PTMs  are  listed  in  table  2  and  some  of  common  PTMs  are  discussed  briefly  below.  
Proteins  can  have  single  modification  or  combinations  of  these  modifications.54  
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Modification   Function   Residue  
Phosphorylation   Control  of  cellular  function  and  signalling   Ser,  Thr,  Tyr,  Asp,  His,  Cys  
N-­‐Acetylation  
N-­‐Methylation  
Transcriptional  regulation   Arg,  Lys,  His  
Glycosylation   Cellular  differentiation,  fertilization,  Immune  
response  
Ser,  Thr,  Asn,  Trp  
Oxidation   Protein  stability,  Redox  regulation   Cys,  Met  
Polyprenylation   Membrane  localisation,  Protein-­‐protein  interaction   Cys  
Hydroxylation   Oxygen  sensing,  Collagen  maturation   Lys,  Pro,  Asn  
Sulfation   Control  of  protein-­‐protein  interactions   Tyr  
  
Table  2:  Examples  of  post-­‐translational  protein  modifications  (PTM).54  
 
1.5.2.1  Glycosylated  proteins  
The  most  common  PTM  in  eukaryotic  cells  is  glycosylation,  it  is  estimated  that  50%  to  70%  of  
human   proteins   are   glycosylated.55      Glycosylated   proteins   are   the   most   clinically   useful  
proteins,  which  include  in  over  40%  of  the  approved  protein  therapeutics  such  as  activase  
(thrombolytic),  avastin  (antibody)  and  gonal  F  (hormone).56,57  The  glycosylation  pathway  is  an  
important   pathway   for   proteins,   as   defects   in   a   number   of   genes   in   this   pathway   cause  
congenital   disorders   with   serious   medical   consequences   and   the   change   of   glycosylation  
profiles  of  specific  proteins  is  recognized  as  disease  marker.55  For  example,  the  alteration  of  
glycosylation  is  among  the  best  methods  for  characterisation  of  cancer,58  and  can  aid  in  the  
understanding,   diagnosis   and   treatment   of   several   disease   such   as   heart   disease,   cancer,  
diabetes  and  immune  disorders.55    
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Glycoproteins  are  categorized  according  to  the  type  of  the  linkage  between  protein  and  the  
complex  oligosaccharide  chains  (glycans)  such  as  N-­‐linked  glycoprotein,  O-­‐linked  glycoprotein  
or  glycosylphosphatidylinositol  (GPI)  anchored.59,60  However,  some  glycoproteins  have  more  
than   one   type   of   saccharide   side   chain.61   The   attachment   of   glycans   to   the   polypeptide  
backbone  highly  influences  the  physicochemical  properties  of  protein,  such  as  protein  folding,  
solubilize  and  sorting  of  protein  within  the  cell.62  Glycan  can  be  very  large  and  bulky  that  can  
affect  protein-­‐protein  interactions  by  either  facilitating  or  preventing  proteins  from  binding  
to  cognate  interaction  domains.  In  addition,  the  hydrophilic  property  of  sugar  can  also  change  
the  solubility  of  a  protein.63  
N-­‐glycosylation  is  the  covalent  attachment  of  glycans  to  the  amide  nitrogen  on  the  side  chain  
of  asparagine  (Asn)  residues,  which  presents  as  a  part  of  Asn-­‐X-­‐Ser/Thr  consensus  sequence  
(X   is   any   amino   acid   except   proline   (Pro))   (figure   14).63   N-­‐glycosylation   can   change   the  
essential  biological  functions,  such  as  the  immunogenicity,  clearance  rate,  specific  activity  and  
ligand–receptor   interactions.63   O-­‐glycosylation   is   the   attachment   of   oligosaccharide   to  
oxygen   atom   at   serine   or   threonine   residues   (figure   14).59,63   It   is   started   by   protein  
mannosyltransferases,   which   transfer   mannose   to   serine   or   threonine   residues   in   the  
endoplasmic  reticulum,  then  completed  in  the  Golgi  by  mannosyltransferases.63,64  
A  glycosylphosphatidylinositol  (GPI)-­‐anchor  is  the  attachment  of  phosphatidylinositol  to  the  
tri-­‐amannosyl  core  attached  to  a  non-­‐acetylated  glucosamine  through  a  glycosidic  linkage.65  
During   transfer   GPIs   to   the   rough   endoplasmic   reticulum,   GPIs   are   attached   to   the  
polypeptide   chain   with   cleavage   and   removing   of   a   hydrophobic   carboxy-­‐terminal   signal  




Figure  14:  The  attachment  of  N-­‐acetylglucosamine  to  protein  through  N-­‐  linked  
glycosylation  and  O-­‐  linked  glycosylation.  
 
1.5.2.2  Protein  Lipidation  
Lipids  are  covalently  attached  to  protein  for  regulation  of  protein  functions  and  localisation.  
The  most  common  outcome  of  lipid  attachment  is  an  increased  affinity  for  membranes  and  
enabling   of   protein-­‐protein   interactions.   However,   the   study   of   protein   lipidation   is  
considered  challenging  due  to  hydrophobic  character  of  lipid  modifications.66,67,68    
  In   cells,   five   types   of   lipids   are   used   to  modify   about   1000   proteins;   sterols,   fatty   acids,  
isoprenoids   and   glycosylphosphatidyl   inositol   (GPI)   anchors.   These   lipids   are   attached   to  
proteins  covalently  and  more  than  one  type  of  lipid  can  bind  with  protein  such  as  palmitate  +  
myristate,  palmitate  +  cholesterol  or  palmitate  +  farnesyl.  Different  lipid  transferases  are  used  
to  attach  different  lipid  with  proteins  and  each  type  of  lipid  provide  different  properties  to  

























The  major   classes   of   lipid  modification   of   protein   are   N-­‐myristylation,   palmitoylation   and  
prenylation,  which  occur  in  the  cytoplasm.  Palmitoylation  is  the  attachment  of  the  saturated  
long  chain   fatty  acid   to   the  cysteine   residue   through   thioester  bond   (figure  15).   In   the  N-­‐
myristylated  protein,  the  saturated  fatty  acid  myristate  is  attached  to  an  N-­‐terminal  glycine  
residue  by  a  stable  amide  bond.  In  the  prenylated  protein,  the  15-­‐carbon  isoprenes  farnesyl  
and   20-­‐carbon   geranylgeranyl   are   attached   to   the   C-­‐terminal   end   of   cysteine   residue   by  
thioether  bond.  The  attachment  glycosylphosphatidylinositol  (GPI)  anchors  is  another  type  of  
lipid   modification,   which   occur   in   the   lumen   of   the   secretory   pathway.   In   this   lipid  
modification,   the   phosphatidylinositol   attached   to   the   protein   through   a   carbohydrate  
linker.71,72    
  




















1.5.2.3  Protein  Phosphorylation  
Protein   phosphorylation   is   one   of   the   most   important   and   well-­‐studied   areas   of   post-­‐
translational   modification.   It   is   estimated   that   one-­‐third   of   mammalian   proteins   are  
substrates   for   phosphorylation.   Protein   phosphorylation   plays   a   significant   role   in   the  
regulation  of  many  cellular  processes  such  as  cell  cycle,  growth,  apoptosis,  differentiation,  
transformation,   development,   peptide   hormone   response,   adaptation   and   signal  
transduction   pathways.73   It   is   considered   the  most   common  mechanism   for   regulation   of  
transmission   of   signals   throughout   the   cell,   where   kinase-­‐catalysed   phosphorylation   of  
downstream   proteins   results   in   conformational   changes   that   can   regulate,   for   example,  
catalytic  activity.74,75    
Although  protein  phosphorylation   is   the  most   common  post-­‐translational  modification   for  
regulating  protein  function,  only  three  amino  acid  side  chains  (in  eukaryotic  cells)  are  stably  
phosphorylated,  which  are  serine,  threonine  and  tyrosine.  It  is  a  reversible  modification  that  
is   mediated   by   kinases   for   phosphorylation   of   substrates   and   phosphatases   for  
dephosphorylation  of  substrates.  During  phosphorylation  the  nucleophilic  hydroxyl  groups  of  
these   three   amino   acids   attack   the   terminal   phosphate   group   (γ-­‐PO32-­‐)   on   the   universal  
phosphoryl   donor   adenosine   triphosphate   (ATP)   causing   transfer   phosphate   group   to   the  
amino  acid  side  chain  (figure  16).  Magnesium  (Mg2+)  facilitates  this  transfer  by    chelating  the  









1.5.2.4  Protein  Tyrosine  Sulfation  
The  sulfation  of  tyrosine  residues  is  a  common  post-­‐translational  modification  that  was  first  
discovered  in  bovine  fibrinogen,  with  the  estimated  level  of  tyrosine  sulfation  in  eukaryotic  
proteins  being  about  1%  of  total  tyrosines.77,78  The  sulfation  of  tyrosine  residues  is  catalyzed  
by   tyrosylprotein   sulfotransferase   (TPST)   and   takes   place   in   the   Golgi   apparatus.   The  
tyrosylprotein  sulfotransferase  (TPST)  catalyses  protein  tyrosine  sulfation  by  transfer  of  an  
activated  sulfate  from  3'-­‐phosphoadenosine-­‐5'-­‐phosphosulfate  (PAPS)  to  the  hydroxyl  group  
of   tyrosine   residues   in   proteins   or   peptides   to   form   a   tyrosine   O-­‐sulfate   ester   and   3ʹ′-­‐
phosphoadenosine-­‐5ʹ′-­‐phosphate  (PAP)  (figure  17).  There  are  two  TPST  isoforms  in  human,  














































Figure  17:  Protein  tyrosine  sulfation,  catalyzed  by  tyrosylprotein  sulfotransferase  (TPST).80  
 
The  sulfation  of  tyrosine  residues  often  occurs  in  secreted  and  transmembrane  proteins  that  
and   plays   important   roles   in   the   regulation   of   intracellular   trafficking   and   proteolytic  
processing  of   secreted  proteins.   It   is   a   key  modulator  of   protein-­‐protein   interactions   that  
plays  important  roles  in  some  biological  process  include  hemostasis,  inflammation,  viral  entry  
into   cells,  leukocyte  rolling   on   endothelial   cells,     visual   functions,   and   binding   of   several  
chemokine  receptors  with  the  chemokine  ligands  by  recognising  sulfated  proteins.83,84,85  As  a  
result   protein   tyrosine   sulfation   plays   important   roles   in   several   diseases   such   as   HIV  
infection,   lung   diseases,   autoimmune   response,   multiple   sclerosis   and   cellular   enzyme  
regulation.86   For   example,      tyrosine   sulfation   of   chemokine   receptor  CCR5   leads   to   viral  
attachment  and  invasion  in  HIV-­‐1  infection  of  T  cells,  therefore  it  suggested  that  the  inhibition  













































1.5.3  Synthetic  approaches  to  protein  post-­‐translation  modification  
The   usage   of   both   genetic   and   chemical   methods   allows   the   preparation   of   an   almost  
unlimited  number  of  protein  constructs  with  either  natural  or  synthetically  modified  residues.  
The  natural  modifications  of  proteins  (by  introducing  natural  PTMs)  are  highly  efficient  and  
controlled,  which  allow  studying  the  specific  protein  functions,  however  they  are  generally  
undertaken   by   enzymes   with   high   substrate   specificity,   limiting   the   application   of   these  
biological  processes  to  a  broader  range  of  systems.  The  synthetic  modification  of  proteins  
provides  a  key  tool  to  study  the  specific  proteins  functions  and  intervening  biological  systems  
both  in  vitro  and  in  vivo.  The  introduction  of  bio-­‐orthogonal  unnatural  amino  acids  improves  
the  properties  of  unnatural  PTMs  during  isolation,  analysis,  and  processing  and  provides  site-­‐
selective  modification  of  proteins.87    
  
The   different   methods   of   chemical   modification   provide   an   opportunity   to   decide   which  
residue   to   target   and   which   type   of   modification,   in   order   to   provide   a   desired   protein  
properties  and  functions  such  as  affinity  probes,  fluorophores,  reactive  tags.24  For  instance,  
the  attachment  of   single   chain  or  branched  chains  of  polyethylene  glycol   (PEG)  groups   to  
therapeutic  proteins  in  process  called  pegylation  leads  to  increased  circulation  half-­‐life  of  a  
therapeutic  protein.  However,   there  are  still  many  challenges  in  the  chemical  modification  
field  including  synthesis,  processing,  manufacturing,  stability  and  safety.54,88  
  
The   selective   synthetic  modification  of   complex  proteins   represents  a   significant   chemical  
challenge  because  the  reaction  must  modify  the  targeted  residue  selectively  in  the  presence  
of  other  competing  unprotected  polypeptide  side  chains  (carboxylic  acids,  amides,  amines,  
alcohols  and  thiols).  This  selectivity  needs  to  occur  under  specific  conditions  (aqueous  media,  
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low   temperature   and   neutral   pH)   in   order   to   prevent   denaturation   of   the   protein.  
Furthermore,  salts  and  surfactants  must  be  tolerated  during  the  reaction  in  order  to  maintain  
the  stability  of  the  protein.  In  addition,  the  reactions  have  to  be  rapid  in  order  to  achieve  full  
conversion  of  protein  due  to  the  likely  low  concentration  of  protein.54,88,89    
1.5.4  Selective  modification  of  natural  amino  acids  and  unnatural  amino  acids  
The  abundance  of  functional  groups  in  natural  amino  acids  play  a  critical  role  in  determination  
selectivity   and   hence   precision.   Strategies   of   site-­‐selective   reaction   may   be   possible   by  
targeting  functional  groups  with  low  abundance  on  the  protein  surface.  Nucleophilic  amino  
acids  (mainly  cysteine  (Cys)  or  lysine  (Lys)  residues)  are  usually  targeted  by  classical  protein  
bioconjugation   methods   (figure   18).54   However,   the   selectivity   in   natural   amino   acids   is  
limited  because  many  of  the  functional  groups  in  proteins  are  nucleophilic.  In  addition,  the  
high  abundance  of  functional  groups  can  generate  mixtures  of  many  products.90  
  
Figure  18:  Cysteine  and  lysine  structures.  
  
Limitations  of  selective  modification  of  natural  amino  acids  can  be  addressed  via  inclusion  of  
unnatural  amino  acids  into  the  peptide  sequence.  This  approach  can  solve  the  selectivity  issue  
because   it   can   allow   the   introduction   of   unique   bio-­‐orthogonal   functional   groups,   for  
example,   azide-­‐,   arylhalide-­‐,   alkyne-­‐,   and   alkene-­‐containing   amino   acids,   which   can   be  
modified   selectively   under   biocompatible   reaction   conditions.   These   reactions   typically  
depend  on  metal  catalysts  such  as  copper  catalysed  alkyne-­‐azide  cycloaddition  (CuAAC),  Ru-­‐











modification   is   limited   by   methods   of   the   installation   of   these   bio-­‐orthogonal   functional  
groups.91,92  
1.5.5  Cysteine  modification    
Despite  the  growing  body  of  methods  for  modification  of  a  range  of  natural  amino  acid  side  
chains  including  tyrosine,93  tryptophan,94,95  lysine96  and  methionine,97  cysteine  remains  the  
most  commonly  targeted  residue  for  selective  modification.87,98  This  is  due  to  the  presence  
of  the  sulfhydryl  side  chain,  which  is  a  strong  nucleophile,  and  because  of  the  low  abundance  
of   cysteine   on   peptide   surfaces   in   comparison   with   other   reactive   amino   acids   such   as  
lysine.99,100   There   are   different   reactions   of   cysteine   that   are   widely   used   for   protein  
modification,  which  are  alkylation,  oxidation,  disulphide  formation,  desulfurization,  oxidative  
elimination  and  metal-­‐mediated  modification  at  cysteine,  which  generally  exploit  the  ‘soft’  
nucelophilic  nature  of  thiols  to  enhance  selectivity  over  ’hard’  nucleophiles  such  as  the  amine  
side  chain  of  lysine.54  A  nucleophile  is  a  chemical  moiety  that  donates  a  pair  of  electrons  to  
form  a  new  covalent  bond  with  its  reaction  partner  (the  electrophile).  They  are  molecules  like  
NH3  or   ions   like  OH-­‐  that  have  at   least  one   lone  pair  of  electrons  or  one  σ-­‐bond.  Because  
nucleophilicity  is  defined  as  the  affinity  of  nucleophile  to  nuclei,  they  are  regarded  as  Lewies  
bases.   Therefore,   nucleophilicity   represents   the   capacity   of   Lewis   base   to   take   part   in   a  
nucleophilic  substitution  reaction  and  differs  from  basicity  which  is  measured  by  monitoring  
the  position  of  an  equilibrium  reaction  with  a  proton  donor  (usually  water).  Nucleophilicity  
describes  rates  of  substitution  reaction  trends  that  are  ascribed  to  nucleophile  properties,  
however  there  is  no  unified  scale  to  measure  nucleophilicity  as  the  relative  nucleophilicity  of  
any   species  varies   toward   different   electrophiles.  However,   some   indication   can   be   given  
about   the   structural   features   that   control   nucleophilicity   and   the   relationship   between  
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nucleophilicity  and  basicity   to  get  a  better  understanding  about  how   the   structure   of   the  
nucleophile  (base)  and  reactant  affect  the  two  competing  reactions.101,102  The  most  important  
factors  influencing  nucleophilicity  are  those  measured  regarding  an  SN2  mechanism  in  which  
the  properties  of  the  nucleophile  are  very  important,  as  the  rate  of  an  SN2  reaction  is  directly  
linked   to   the   nucleophilic   displacement   of   the   leaving   group,   whereas   the   rate   of   an  
SN1reaction  is  not  affected  by  relative  nucleophilicity.103  There  are  many  factors  that  influence  
the  behaviour  of  nucleophiles,  the  most  significant  factors  amoung  these  are  listed  below.104    
(1)  nucleophile  solvation  energy:  Nucleophiles  with  strong  solvation  means  the  anionic  
nucleophile  have  lower  energy  compared  to  the  TS,  in  which  the  Ea  is  increased  due  
to  greater  diffusion  of  the  charge.  The  two  different  obtained  trends  depend  on  the  
type  of  solvent.  In  polar  protic  solvents   (table  3)  nucleophilicity   increases  as  we  go  
down   the   periodic   table   (table   3).   This,   because   at   the   top   of   periodic   table   the  
capacity  of  hydrogen  bonding  is  the  highest  hence  the  nucleophile  is  more  hindered  
during  solvation.105    
  
Table  3:  Strength  of  some  nucleophiles  in  polar  protic  solvents.  
 
 
In   polar   aprotic   solvents   (table   4),   hydrogen   bond   formation   with   the   nucleophile   is  
insignificant.   As   a   result,   nucleophiles   have   more   freedom   to   attack   and   nucleophilicity  
increases  up  the  periodic  table  (table  4).106    
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Table  4:  Strength  of  some  nucleophiles  in  polar  aprotic  solvents.  
 
 
(2)  The  strength  of  the  bond  formed  with  carbon:  Since  SN2  is  regarded  more  important,  the  
strength  of  the  partially  formed  new  bond  with  carbon  results  in  lower  Ea  and  more  stable  
TS.101    
(3)  Electronegativity  of  the  attacking  atom:  High  electronegativity  is  unfavorable  because  the  
SN2   process   requires   donation   of   electrons   to   an   antibonding   orbital   of   the   electrophile  
(figure  19).101  
  
Figure  19:  Strength  of  some  nucleophiles  according  to  their  electronegativity.  
 
 
(4)  Polarizability  of  the  attacking  atom:  Polarizability  explains  how  the  electron  density  of  the  
nucleophile  is  easily  distorted.  Since  bond  formation  by  an  electron  pair  from  the  nucleophile  
is  required  by  SN2  reaction,  therefore  better  nucleophilicity  is  achieved  by  easier  distorted  the  
attacking  atom.  This  means  nucleophilicity  increases  with  increasing  electron  density  on  the  
attacking  atom  (figure  20).101  
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Figure  20:  Strength  of  some  nucleophiles  according  to  electron  density.  
 
 
(5)  Steric  bulk  of  the  nucleophile:  less  hindered  nucleophile  is  more  reactive  than  sterically  
congested  one  because  in  the  TS  nonbonded  repulsions  are  developed.  In  the  TS  the  trigonal  
bipyramidal  geometry  is  sterically  more  demanding  than  the  tetrahedral  reactant  in  SN2.  The  
bulkier  the  nucleophile  is  the  slower  the  rate  of  the  reaction  (figure  21).101  
  
Figure  21:  strength  of  nucleophiles  according  to  their  bulkiness.  
  
While   this   aids   understanding   of   relative   reactivity   and   demonstrates   some   contrasting  
properties  that  can  result  in  increased  or  decreased  reactivity,  as  mentioned  above  the  nature  
of   the   relative   nucleophiles   and   electrophiles   also   influence   the   rate,   and   therefore   the  
selectivity,  of  such  reactions.  The  most  effective  qualitative  method  for  making  predictions  
about   reactivity   is   based   on   the   observation   that   reactions   occurs  most   readily   between  
species  that  have  equivalent  strength  of  ‘hardness’  and  ‘softness’,  although  these  terms  are  
not  firmly  defined  (see  table  5).  Hard  nucleophiles  have  their  reactive  electron  pair  in  smaller  
orbitals  in  the  lower  shells  of  more  electronegative  atoms,  and  are  often  highly  charged  or  
more  basic   in  nature.  These  nucleophiles   interact  most  readily  with  smaller  and  are  more  
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reactive  towards  more  positively  charged  electrophiles,   for  example  smaller  metal   ions  or  
highly  d-­‐positive  carbon  electrophiles.  Soft  nucleophiles  have  their  reactive  electron  pair  in  
larger   orbitals   in   the   higher   shells   of   less  electronegative   atoms,   and   are   likely   to   be   less  
charged  charged  or  less  basic  in  nature.  Soft  nucleophiles  interact  most  readily  with  larger  
metal  ions  and  favourably  react  with  less d-­‐positive  carbon  electrophiles  and  p  systems.101,107  
  
Strength   Nucleophiles  (Bases)   Electrophiles  (Acids)  
Soft  
  
CO,  C2H4,  R2S,  RSH,  CN-­‐,  I-­‐,  (CH3CH2)3P,  
RCH=CHR,  benzene  
I2,  Br2,  RS-­‐X,  RSe-­‐X,  RCH2-­‐X  
Cu(I),  Ag(I),  Pd(II),  Hg(II)  
Zero  valent  metal  complexes  
  
Intermediate  
ArNH2,  C5N5N,  NO2,  Br-­‐,  N3-­‐,  Pyridine   Cu(II),  Zn(II),  Sn(II)  
R3C+,  R3B+  
Hard   H2O,  RNH2,  OH-­‐,  SO4-­‐2,  R2O,  F-­‐,  Cl-­‐,  RO-­‐
,  RCO2-­‐,  NH3,  NO3-­‐  
H-­‐X,  Li+,  Na+,  R3Si-­‐X  
Mg(II),  Ca(II),  Al(III),  Sn(IV)  
Ti(IV),  H+  
  




1.5.6  Cysteine  alkylation  
The   most   common   technique   for   cysteine   modification   is   the   direct   alkylation   of   its  
nucleophilic   thiol   with   suitable   electrophiles.   The   selective   reaction   of   cysteine   with  
electrophiles  such  as  α-­‐halocarbonyls  (e.g.,  iodoacetamide  or  chloroacetamide)  and  Michael  
acceptors   (e.g.,   maleimides   or   vinyl   sulfones)   has   been   known   for   almost   a   century.88   If  
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surface  cysteines  are  not  present  in  the  natural  protein  or  are  not  found  in  the  region  of  the  
protein  that  is  to  be  labelled  they  can  be  readily  introduced  via  expression  of  recombinant  
DNA  in  standard  expressions  systems.54,  44  
1.5.6.1  α-­‐halocarbonyls  
The  alkylation  of  cysteine  with  iodoacetamide  (  scheme  2)  has  been  widely  used  in  protein  
analysis   by  mass   spectrum,   peptide  mapping   of   cysteine   containing   proteins   and   protein  
modification.108,109,110,111,112  Although   iodoacetamide   reacts  more   rapidly  with   the  cysteine  
thiol  than  lysine  amine,  undesired  reaction  with  lysine  has  been  noticed  when  the  pH  >7-­‐8,  
which   can   be   resolved   by   adjusting   the   pH   and   reaction   time   or   using   less   reactive  
chloroacetamide.108  The  undesired  reaction  with  lysine  N  terminal  can  be  avoided  by  reducing  
the  reaction  pH  to  less  than  7-­‐8  in  order  to  protonate  the  nucleophilic  amine.108,110    
  
Scheme  2:  Alkylation  of  cysteine  using  iodoacetamides.  
 
  
Robinson   and   his   co-­‐workers   compared   the   selectively   of   iodoacetamide   and  
chloroacetamide  to  alkylate  cysteine  in  the  presence  of  another  nucleophilic  amino  acids.113  
They   demonstrated   that   both   iodoacetamide   and   chloroacetamide   are   able   to   alkylate  
cysteine,  however  chloroacetamide  is  more  specific  than  iodoacetamide,  which  showed  low  
level  of  off-­‐target  modifications  to  the  N-­‐terminus  along,  Asp,  Glu,  His,  Lys,  Ser,  Thr,  and  Tyr  

















N-­‐terminus  alone  is  about  0.05%  while  the  off-­‐target  modification  of  the  iodoacetamide  at  
the  N-­‐terminus  is  about  0.5  %.  However,  the  average  overall  level  of  off-­‐target  alkylation  with  
both  alkylation  reagents  was  <0.5%  which   is  relatively  low.113  Although  there  was  a  minor  
difference   between   the   two   alkylation   reagent   in   the   off-­‐target   alkylation,   there   was   a    
significant      differences   in      levels   of   oxidation   between   the   two   alkylation   reagents.      The  
oxidation  level  of  the  methionine  and  tryptophan  was  greatly  increased  with  chloroacetamide  
in   comparison  with   iodoacetamide   (figure   23).   For   example,   the   average   of   the   oxidised  
methionine  in  all  peptides  containing  methionine  in  the  presence  of  chloroacetamide  is  about  
28.7  %,  while  the  average  of  the  oxidised  methionine   in  the  presence  of   iodoacetamide   is  
about  3.4  %.113  
  
  





Figure  23:  The  comparison  between  iodoacetamide  (IOA)  and  chloroacetamide  (CA)  
oxidation  level.  (A)  the  percent  of  oxidised  methionine  (MSO).  (B)  the  percent  of  singly  
oxidised  Tryptophan  (Wox),  and  the  dioxidised  form  of  Tryptophan  (DiWox).113  
 
  
Carbohydrate-­‐tethered   iodoacetamides   can   be   used   to   glycosylate   protein   selectively   by  
reaction  with  cysteine  side  chains  to  offer  the  cysteine-­‐sugar  linkages,  which  mimics  to  the  
natural  asparagine-­‐linked  glycoproteins.114  This  methodology  has  been  used  to   investigate  
the  glycosylation  effect  on  the  thermal  stability  of  dihydrofolate  reductase  (DHFR)  which  is  
naturally  non-­‐glycosylated  enzyme.115   In  addition,  ß-­‐N-­‐glycosyl   iodoacetamides  have  been  
used   to   glycosylate   human   erythropoietin   to   study   the   effect   of   the   glycosylation   on   the  
structure  and  function  of  the  human  erythropoietin.116  
Sunbul  and  co-­‐workers  alkylated  proteins  with  a  chloroacetamide-­‐appended  fluorophore  in  
order  to  study  the  target  proteins  role  in  biological  systems  by  fluorescence  microscopy.117  
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The  TR512  peptide  attached  to  two  cysteine  residues  to  offer  a  Reactive  Texas  Red  binding  
(ReacTR)  tag  was  conjugated  to  the  maltose  binding  protein  (MBP),117  using  fluoresence  to  
quantify   the   formation   of   a   covalent   bond   between   the   N-­‐α-­‐chloroacetamide-­‐Texas   Red  
fluorophore  and  cysteine  of  MBP-­‐ReacTR.117    
Cysteine   alkylation   with   α-­‐halocarbonyl   electrophiles   has   been   used   to   introduce   ester  
carbonyls  as  infrared  (IR)  probes  in  peptides  and  BSA  to  study  peptide  structure  integrity  and  
ligand  binding  that  induce  changes  in  the  local  hydration  status  of  BSA.118  Although  the  ester  
moiety  can  be  introduced  simply  in  the  protein  by  using  solid-­‐phase  synthesis,  the  cysteine  
alkylation   methodology   used   to   introduce   ester   moiety   in   the   specific   site   of   the   large  
protein.118  Therefore,  methyl  bromoacetate  was  used   to  alkylate   cysteine   in  peptides  and  
proteins  under  mild  conditions  to  introduce  methyl  ester  in  high  yield  (scheme  3).118    
  
  
Scheme  3:  Installation  the  ester  carbonyl  (IR  probe)  into  proteins  at  cysteine.118  
 
1.5.6.2  Michael  Acceptors    
The  chemoselective   cysteine  alkylation  by  Michael  acceptors  has  been   used  widely.54  The  
most  used  Michael  acceptors  used  for  cysteine  alkylation  are  maleimides  and  vinyl  sulfones.  
Maleimide  reagents  are  used  in  protein  analysis  by  blocking  the  sulfhydryl  groups,  peptide  
mapping   of   cysteine   containing   proteins   and   protein  modification   in   various   applications,  
including  the  preparation  of  approved  ADCs.119,120  Maleimide  reagents  are  used  in  chemical  
 43 
protein  modification  because  they  are  highly  selective  towards  thiol  groups  with  lack  of  side  
products  (scheme  4).  Moreover,  the  nitrogen  atom  of  maleimide  moiety  can  be  functionalised  
with   different   groups   such   as   fluorophores,   polymer   moieties   and   lipids.   Some   of   the  
antibody-­‐containing  therapeutics  that  are  already  on  the  market  are  formed  by  maleimide–
thiol  conjugation.  For  example,  certolizumab  pegol  (Cimzia)  is  an  anti-­‐TNF  antibody  fragment  
which  is  conjugated  to  polyethylene  glycol    through  succinamide  thioether  linkages  to  extend  
in  vivo  half-­‐life.121  Cimzia  has  been  approved   by  FDA   for  Crohn’s  disease  and   rheumatoid  
arthritis  treatment.121    
  
Scheme  4:  Alkylation  of  cysteine  using  maleimides.  
 
Although   the   succinimide   thioethers   are   stable,   they   are   sensitive   to   oxidative/reductive  
environments   under   near-­‐physiological   conditions.   The   potential   for   cleavage   by   retro-­‐
Michael   addition   is   the  main   disadvantage   of   the   succinimide   thioethers,   which   leads   to  
formation   of   the   free   maleimide   in   solution   (scheme   5)   followed   by   thiol   exchange   by  
endogenous  thiol  in  blood  plasma  (GSH).122  Hydrolysis  is  another  side  reaction  that  can  occur  
to   the   succinimide   thioethers,   leading   to   ring   opening.   However,   the   ring   opening   after  
conjugation   is   in   fact  a  preferred  outcome   in   therapeutic  applications  because   it  provides  


















thioethers,   the   electron-­‐withdrawing   N   substituents   increase   the   hydrolysis,   while   the  
electron-­‐donating  N  substituents  minimise  the  hydrolysis  process.99  
  
  




Another  limitation  of  maleimides  in  protein  modification  is  that  while  conjugation  is  partly  
reversible,  regeneration  of  the  unmodified  protein  by  controlled  disassembly  of  the  conjugate  
is  impossible.123  That  can  be  solved  by  using  of  bromomaleimide  derivatives  which  provide  
selective   and   reversible   conjugation   with   cysteine.123   They   allow   formation   of   stable  
conjugates  of  thiolates,  which  can  be  easily  cleaved  upon  reaction  with  phosphines  (e.g.  TCEP)  
or  a  large  excess  of  a  thiol  (scheme  6).123  In  addition,  further  attachment  of  functional  groups  
to  the  protein-­‐maleimide  adducts  is  possible  by  using  (di-­‐)bromomaleimide  derivatives,  the  











































R” = basic amino group




  hydrolysis retro-Michael
GSHhydrolysis accelerated by local positive charge, 
electron-withdrawing R
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(scheme  6).123  In  addition  to  the  N  substituents  on  the  maleimide  ring,  the  bromomaleimide  
derivatives  provide  three  points  of  protein  conjugation.123    
     
Scheme  6:  Conjugation  of  bromomaleimide  with  cysteine.  
 
The  first  example  of  using  maleimide  for  cysteine  alkylation  in  proteins  was  introduced  by  
Moore  and  Ward  where  the  disulfide  bonds  were  reduced  then  bis-­‐maleimides  were  used  to  
cross-­‐link   cysteine   in   proteins.124   The   chemoselective   cysteine   alkylation  with  maleimides  
have  been  used  to  glycosylate  hemoglobin  (Hb)  which  provide  higher  oxygen  affinity.125  In  
addition,  the  maleimide  conjugation  was  used  in  synthesis  of  cancer  vaccines.126  Haralampiev  
et   al.   recruited   sulfhydryl-­‐containing   biomolecules   to   membranes   by   using   palmitic   acid  
functionalized   with   a   maleimide   moiety   (PAEM)   and   applied   to   recruit   proteins   to   lipid  
vesicles  and  biological  membranes.127  Inclusion  of  a  rhodamine-­‐label  allowed  detection  and  






































Figure  24:  Recruitment  of  rhodamine-­‐labeled  peptide  RLP  to  membranes  using  palmitic  acid  
functionalized  with  a  maleimide  moiety  (PAEM).  The  lipid  membrane  was  prepared  to  
contain  a  donor  fluorophore  then  the  Forster  Resonance  Energy  Transfer  (FRET)  between  
two  fluorophores  used  to  determine  the  binding  of  PAEM  and  RLP.99  
  
Oxytocin  is  a  peptide  hormone  that  is  used  to  prevent  postpartum  haemorrhaging  (PPH)  after  
childbirth.128  Oxytocin   prevent   blood   loss   post-­‐birth   by   causing   contraction   of   the   uterus,  
however,   it   is   degraded   at   higher   temperature,   causing   a   loss   of   drug   activity.128      The  
degradation  of  oxytocin  occurs  through  several  processes,   the  most  significant  of  which   is  
cleavage  of  its  disulfide  bond.128  It  has  been  found  that  reduction  of  the    disulfide  bond  in  
oxytocin  followed  by  disulphide  ‘re-­‐bridging’  using  dithiophenol  maleimide,  (that  was  further  
functionalised  with  a  polymer)  significantly  increased  the  stability  of  the  oxytocin  at  elevated  





Scheme  7:  The  reduction  and  conjugation  of  the  therapeutic  oxytocin  peptide  with  
maleimide  functional  polymer.128  
 
 
1.5.6.3  Aminoethylation    
Cysteine   aminoethylation   can   be   used   to   convert   cysteine   to   lysine   mimics,   allowing  
controlled  investigation  of  the  role  of  lysine  in  protein  function.129  Mecinovic  and  co-­‐workers  
installed   trimethyl   lysine   analogs   into   histone   proteins   by   cysteine   alkylation,   leading   to  










The  cysteine  alkylation  can  also  be  used  to  install  acetyl-­‐Lys  mimics  at  specific  sites  of  peptides  
and   proteins   as   a   model   of   protein   acylation.131,132   Methylthiocarbonyl-­‐aziridine   (MTCA)  
reacts  selectively  with  the  cysteine  thiol  to  offer  methylthiocarbonyl-­‐thiaLys  (MTCTK)  which  
close  to  natural  acylated  lysine  (scheme  9).131  The  mass  spectrometric  analysis  confirmed  that  
six  different   cysteine-­‐containing  peptides  were  completely   converted   to  MTCTK,  while  no  
modification  was  observed   in   the  Cysteine   free  peptide  control  which  confirmed   the  high  
selectivity  of  MTCA  to  the  cysteine  thiol.131    
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Scheme  9:  Alkylation  of  cysteine  with  methylthiocarbonyl-­‐aziridine  (MTCA)  to  form  
methylthiocarbonyl-­‐thiaLys  (MTCTK).131  
 
1.5.7  Other  Cysteine  modification    
1.5.7.1  Site-­‐Selective  formation  of  disulfides    
Disulfides  are  essential  in  structure  and  stability  of  proteins  and  disulfide  formation  is  one  of  
the  most  common  natural  cysteine  modifications.  Due  to  the  critical  role  of  glycoproteins  in  
mediating   a   variety   of   cellular   processes,   disulfide-­‐linked   glycoproteins   provide   an  
opportunity  to  assess  glycoprotein  function.  Although  a  mixed  disulfide  can  be  formed  by  air  
oxidation  of  a  mixture  of  a  thiol  and  a  cysteine-­‐tagged  protein,  the  reaction  will  also  form  
unwanted   symmetrical   disulfides.133   However,   cysteine   reacts   with  methanethiosulfonate  
(MTS),  phenylthiosulfonate  (PTS),  or  phenylselenenylsulfide  (SeS)  rapidly  and  specifically  to  
form  mixed  disulfides  (or  more  stable  SeS-­‐  linked  conjugates)  (figure  25).134,135,136  
  



















These  reactions  are  used  widely  for  the  synthesis  of  glycoproteins  due  to  highly  efficiency  of  
these   reactions,   which   do   not   need   a   large   excess   of   reagent.   For   example,  
glycodendriproteins   and   delicate   trisulfide-­‐linked   glycoproteins   are   synthesised   by   this  
chemistry.137,138   In   addition,   the   selenenylsulfide  method   can   be   used   to   conjugate   up   to  
seven  saccharide  units  in  size  at  protein,  which  is  a  synthetic  glycan  attached  to  a  protein.136    
1.5.7.2  Formation  of  Stable  Thioethers  
Although  disulfides  are  often  stable  in  vivo,  they  are  typically  labile  under  reducing  conditions.  
The  conversion  of  the  disulfide   into  stable  thioether  derivative  facilitates  the  combination  
between   the   convenience   of   the   disulfide   modification   and   the   benefit   of   the   thioether  
stability.   The   reaction   of   electron-­‐rich   phosphines   (e.g   hexamethylphosphorus   triamide  
(HMPT))  with  disulfide  glycoconjugates  provides  stable  thioether  derivatives   (figure  26  A).  
The  mechanism  of  the  transformation  of  the  disulfide  to  the  stable  thioethers  proceeds  by  
attack   of   the   cysteine   sulfur   onto   the   aminophosphine,   followed   by   elimination   of   the  
thiophosphonium   ion   to   produce   dehydroalanine.   The   liberated   thiol   can   then   add   to  






Figure  26:  A-­‐  Disulfide  conversion  to  the  thioether-­‐linked  glycoprotein.  B-­‐  A  model  for  the  
transformation  mechanism  of  the  the  disulfide  into  stable  thioether  derivative.133  
 
  
Dehydroalanine  also  can  be  rapidly  formed  by  treatment  of  cysteine  with  the  electrophilic  
nitrogen   source   O-­‐mesitylsulfonylhydroxylamine   (MSH)   (figure   27).139   The   use   of  
dehydroalanine   tag   provides   rapid   and   selective   incorporation   of   a   high   range   of   post-­‐
translational  modifications  and  their  mimics,  for  example  these  methods  can  also  be  applied  
to   introduce  
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F-­‐fluorosugars   as   potential   imaging   labels.140   In   addition,   these   methods  
allowed   preparation   of   PEGylated   proteins,   homogeneous   glycoconjugate   vaccine  
candidates,  and  histone  mimetics.141,142,143  On  the  other  hand,  the  potential  racemization  at  




Figure  27:  A-­‐  Conversion  of  cysteine  to  dehydroalanine  by  treatment  of  cysteine  with  O-­‐
mesitylsulfonylhydroxylamine  (MSH)  and  use  in  synthesis  of  post-­‐translational  modifications  
and  their  mimics.    B-­‐  different  thiol  groups  for  post-­‐translational  modifications.133  
  
1.5.7.3  Metal-­‐mediated  natural  modification  at  cysteine    
One  of  the  critical  advances  in  synthetic  protein  modification  allowed  use  of  organometallic  
transformations   in   site-­‐selective   protein   modification.   These   new   approaches   attracted  
synthetic  chemist  interest  in  protein  modification  because  these  reactions  provide  excellent  
functional  group  tolerance  and  high  yields  under  mild  conditions.  On  the  other  hand,  there  
are  several  limitations  of  using  these  reactions  for  site-­‐specific  protein  modification.    It  should  
be   suitable   for   protein   reaction   conditions   (aqueous   media,   high   efficiency,   and  
chemoselectivity  at  or  near  room  temperature  and  over  a  narrow  pH  range).  In  addition,  it  
should   tolerate   potential   nonspecific   binding   to   the   Lewis-­‐basic   residues   on   protein  
surfaces.90  
The  gold-­‐mediated  oxidative  allene–thiol  coupling  reaction  is  a  new  approach  for  selective  
cysteine  modification  in  aqueous  media,  which  is  the  first  gold-­‐mediated  reaction  use  allenes  
for  cysteine  modification  of  peptides.  In  this  reaction,  gold  complexes  are  used  to  activate  
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allenes  diversity   followed  by  coupling  with  the  thiol  group  of  cysteine-­‐containing  peptides  
that  provides  a  novel  hydroxy  vinyl  thioethers  instead  of  1,2/1,3-­‐adducts,  which  is  commonly  
observed  (scheme  10).  The  highest  conversion  of  allene  is  achieved  by  using  AuCl/AgOTf  as  a  
catalytic  system  at  room  temperature.  This  method  provides  a  direct  functionalization  of  N-­‐
terminal,  internal  and  C-­‐terminal  cysteine  residues.145  
  
  
Scheme  10:  Nucleophilic  addition  to  allenes  and  Gold-­‐mediated  selective  cysteine  































1.5.8  Cysteine  modification  in  the  preparation  of  therapeutic  protein  conjugates    
The   conjugation   of   cytotoxic   drugs   to   antibodies   in   ADC  preparation   is   typically   achieved  
through  modification   of   lysine   side-­‐chain   amines   or   cysteine   thiols,   that   are   activated   by  
reduction  of  interchain  disulfide  bonds.146  However,  these  procedures  leading  to  formation  
of  heterogenous  ADCs  that  contain  a  mixture  of  drug  to  antibody  ratio  (DAR)  with  linkages  at  
different   sites,   which   may   impact   on   the   efficacy   and   stability   of   ADCs   profile.146   The  
incorporation  of  engineered  cysteine  residues  into  specific  site  in  the  antibody  can  be  used  
to  produce  a  new  ADC  format  with  precise  DAR.147  Potent  cytotoxic  drugs  can  be  attached  to  
recombinant   antibodies   engineered   with   cysteine   residues   by   using   strategies   of   site-­‐
selective   modification,   typically   based   on   those   developed   for   the   selective   reduction   of  
disulfides  present  in  the  natural  antibody  structure.147  N-­‐substituted  maleimide  linkers  with  
a  cleavable  site  for  drug  release  are  usually  used  to  build  antibody−drug  conjugates  (ADCs).147  
however,  these  methods  are  limited  by  the  high  cost  and  low  expression  yield.148  
Chudasama   and   co-­‐workers   demonstrated   that   the   insertion   of   the   next   generation  
maleimides   NGMs   (dithiomaleimide)   into   antibody   disulfide   bonds   provide   site-­‐selective  
conjugation  (figure  28).148    In  a  comparison  between  the  stability  of  the  classical  maleimide  
conjugate  and  NGM  conjugates,  neither  were  stable  in  blood  serum  due  to  the  retro-­‐Michael  
reaction   that   lead   to   transfer   the   payloads   to   serum  albumin   (figure  28).148  However,   the  
hydrolysis   of   the   NGM   conjugate   to   form   a     maleamic   acid   conjugate   provides   complete  
stability  in  blood  serum  (figure  28).148    
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Figure  28:  A-­‐  Classical  maleimide  with  payload  conjugate  to  antibody.  B-­‐  NGM  with  payload  
conjugate  to  antibody.  C-­‐  maleamic  acid  with  payload  conjugate  to  antibody.148  
  
Spring   and   co-­‐workers   developed   a   novel   divinylpyrimidine   (DVP)   linker   to   conjugate  
cytotoxics  drugs  to  the  native  antibody  by  reduction  of  the  disulfide  bond  followed  by  re-­‐
bridge  of  the  cysteine  residue  (figure  29).149  DVP  conjugates  provide  highly  stable  ADCs  with  
precise  DAR  and  drug  distribution  at  native  antibody.149    
  
  


























1.6  Disulfide  reduction  
The  alkylation  of  cysteine  thiols  is  complicated  by  the  fact  that  free  cysteines  are  isolated  as  
mixtures  of  the  reactive  thiol  alongside  disulfides  (as  dimers  or  conjugates  with  other  native  
thiols  such  as  cysteine)  and  sulfinic/sulfonic  acids  (figure  30).150  Therefore,  reducing  agents  
are  used  to  selectively  reduce  these  mixtures  to  the  thiol  form  for  alkylation.  Reducing  agents  
can   be   phosphines,   such   as   tris(2-­‐carboxyethyl)phosphine   (TCEP)   and   tris(3-­‐
hydroxypropyl)phosphine   (THPP)   or   thiols,   such   as   dithiothreitol   (DTT),   dithiobutylamine  
(DTBA)  and  2-­‐mercaptoethanol  (2-­‐ME)  (Figure  31).151,91  The  disulfide  bonds  are  reduced  by  
thiol–disulfide  exchange  in  the  thiol-­‐containing  reagent,  while  the  phosphine  reagent  forms  
phosphine  oxide  after  disulfide  reduction  (Figure  31).  
  

























































Figure  31:  Structure  of  some  thiol  and  phosphine  reducing  agents.  
  
Suttapitugsakul  and  coworkers  evaluated  the  reduction  step  of  the  cysteine  disulfide  with  
commonly  used  reducing  agents;  DTT,  2-­‐ME,  TCEP  and  THPP.111  Peptides  were  incubated  with  
the  same  concentration  of  each  of  these  reducing  reagents  at  56  °C  for  25  minutes,  under  
these  somewhat  harsh  conditions  all  four  reducing  reagents  have  the  same  efficacy  to  reduce  
disulfide  bonds.111      
The  majority  of  thiol-­‐reducing  agents  contain  either  nucleophilic  phosphines  or   free  thiols  
(DTT  and  DTBA),  which  can  compete  directly  with  the  cysteine  thiol  for  attachment  of  thiol-­‐
reactive   labels  such  as  maleimide  and   iodoacetamide  derivatives.      In  addition,  as  they  are  
used   in   excess   this   completing   reaction   will   degrade   both   the   alkylation   agent   and   the  
reducing  agent.152  Although  DTT  is  the  standard  reagent  for  reducing  disulfide  bonds  between  
























reactive.  On  the  other  hand,  the  pKa  value  of  DTBA  thiol  is  lower  than  DTT  by  about  1  unit,  
and  this  resides  as  the  reactive  thiolate  at  pH  7.0.  As  a  result  DTBA  reduces  disulfide  bonds  
3.5-­‐  fold  faster  than  DTT  in  oxidised  β-­‐mercaptoethanol  (βME)  and  14-­‐  fold  faster  than  does  
DTT  in  papain  at  pH  7.0.151    
The  trialkylphosphines  derivatives  reduce  the  disulfide  bonds  irreversibly  due  to  the  strength  
of  the  phosphorus-­‐oxygen  bond.153  The  low  solubility  of  some  of  simple  trialkylphosphines  in  
water  limited  their  usage,  however,  TCEP  is  a  water-­‐soluble  phosphine  agent  that  efficiently  
cleaves  the  disulfide  linkage.153  TCEP  has  been  used  extensively  for  disulfide  reduction  before  
cysteine  alkylation  for  example  Getz  and  his  co-­‐workers  reported  the  using  of  TCEP   in  the  
attachment   of   maleimide   to   mysin.154   In   addition,   TCEP   has   been   used   to   study   protein  
structure,  for  example,  TCEP  has  been  used  to  break  the  disulfide  bond  in  the  hen  egg-­‐white  
lysozyme  (HEWL)  model  in  order  to  study  the  folding  and  unfolding  mechanism  of  protein.155    
Although  TCEP  is  normal  used  to  break  the  disulfide  bonds  for  protein  analysis,  the  excess  of  
TCEP  can  interfere  with  these  methods.  In  addition,  there  are  several  reports  proved  that  the  
presence  of  TCEP  in  the  reaction  medium  can  prevent  the  labelling  of  cysteine  thiol  because  
it   can   react   with   maleimide   and   iodoacetamide   derivatives.156   It   has   been   reported   the  
exposure   to   TCEP   over   prolonged   time   can   cause   cleavage   in   the   protein   backbone.157  
Therefore,  TCEP  is  normally  removed  before  any  modification  reaction,  by  using  dialysis  or  
gel   filtration  but  these  are  time-­‐consuming  and  can  result   in  re-­‐oxidation  of  the  protein   if  
oxygen  cannot  be  excluded  during  this  process.  There  are  different  alternative  methods  to  
separate  TCEP  such  as  immobilisation  of  TCEP  on  polyethylene  glycol  (PEG)  beads,  but  it  is  
effective  just  for  small  peptides.156  Zwyssig  and  his  co-­‐workers  developed  a  novel  method  to  
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separate  TCEP  by  immobilization  of  the  phosphine  on  magnetic  nanoparticles  with  reduction  
capacity  of  70  mmol  per  gram  of  particles.156  
  
1.7  The  aim  of  project  
The  aim  of  this  project   is   to  develop  a  robust  system  to  reliably  provide  clean  products  of  
nucleophilic   cysteine   thiol   alkylation,   to   allow  us   to   synthesise   CCL2-­‐FK866   conjugates   by  
utilising  a  recombinant  CCL2-­‐Cys  construct.  Alkylation  of  protein  thiols  is  complicated  by  the  
free  cysteine  typically  being  isolated  as  mixtures  of  the  reactive  thiol  alongside  disulfides.150  
Therefore,  reducing  agents  are  used  to  selectively  reduce  these  mixtures  to  the  thiol  form  for  
alkylation,  however  prolonged  exposure  of  CCL2  to  phosphines  such  as  TCEP  will   result   in  
reduction  of  the  functionally  essential  disulfides  in  CCL2.  
Thiol-­‐based  reducing  reagents  are  mild  but  must  be  removed  before  selective  alkylation  of  
cysteine  otherwise  they  will  compete  with  the  target  thiols  in  proteins.  Unfortunately,  this  
process  is  complicated  by  difficulties  in  monitoring  the  progress  of  reduction  and  the  fact  that  
the  cysteine  unless  the  reaction  is  conducted  in  oxygen-­‐free  conditions  the  cysteine  will  begin  
to  re-­‐oxidise  as  soon  as  the  reducing  agent  is  removed.  Consequently,  the  alkylation  is  likely  
to  be  conducted  on  a  mixture  of  free  and  oxidised  thiol,  resulting  in  mixtures  of  alkylated  and  
non-­‐reactive  proteins  that  are  hard  to  separate.  This   is  an   issue  for  the  purity  of  the  final  
alkylated  protein  as  in  most  instances  the  difference  between  the  species  is  too  small  to  allow  
further  purification  and  both  of  them  are  in  the  solution  phase  (figure  32).158  
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Figure  32:  Issues  in  cysteine  alkylation.  Iodoacetamide  is  used  as  alkylation  agent,  SOx  are  
undefined  oxidised  thiol  species.  
 
Developing   a   solid   phase   catch-­‐release   alkylation   system   can   help   to   address   both   the  
incompatibly  of  the  reducing  and  alkylation  agents  and  the  purification  of  alkylated  protein.  
In  this  approach  the  cysteine  oxidation  that  occurs   in  the  solution  phase  approach  can  be  
avoided  in  the  solid-­‐phase  system  by  attaching  the  reducing  and  alkylation  agents  to  separate  
solid   phases.159   The   protein   should   therefore   be   able   to   access   the   reducing   agent   and  
alkylation   agent   in   situ,   in   order   to   overcome   the   re-­‐oxidation   of   cysteine   residue,   while  
avoiding  reaction  of  the  alkylation  agent  with  the  reducing  agent  (DTBA)  as  shown  in  figure  
33.   In   comparison   to   the   solution-­‐phase   approach,   the   solid-­‐phase   purification   of   the  
immobilsed   S-­‐alkylated   protein   should   then   be   easily   and   quickly   performed   by   simple  
filtration.   Finally,   following   cleavage   from   the   solid   phase   the   protein   should   be   readily  





















Figure  33:  Proposed  reaction  utilising  solid  phase  alkylation  and  reducing  agents.  
  
The  aims  of  the  project  are  therefore  as  follows:    
1-­‐   Synthesise  azide-­‐containing  alkylation   linkers  and   immobilize  onto  solid  phase  by  
copper  (I)-­‐catalysed  alkyne-­‐azide  cycloaddition  (CuAAC)  reaction.  
2-­‐   Prepare  a  solid  phase  alkylation  linker  containing  a  cleavable  group  that  can  release  
the  alkylated  protein  after  purification.  
3-­‐   Investigate  the  cleavage  reaction  in  solution  phase.  
4-­‐   Investigate  the  CuAAC  reaction  in  solution  phase.  
5-­‐     Investigate  the  selectivity  of  the  alkylation  reagent  toward  thiol  in  solution  phase.  
6-­‐   Evaluate   the  use  of   catch-­‐release  methodology   to   selectively  alkylate   cysteine   in  
combination  with  a  second  solid  phase  by  using  BSA  (which  is  well  studied  in  the  
context  of  cysteine  alkylation  methodology  and  readily  available).  


























Chapter  2:  Result  and  Discussion  
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2.1  First  generation  solid  phase  alkylation  system  with  a  cleavable  linker  
This   project   has   focused   on   the   synthesis   of   a   solid   phase   protein-­‐alkylation   system,  
containing  a   cleavable   linker   that  will   allow   liberation  of   the  alkylated  protein  under  mild  
conditions.  The  alkylation  linker  1  was  initially  designed  to  include  an  azide  group  to  allow  
immobilisation  onto  the  solid  phase  through  a  copper  (I)-­‐catalysed  alkyne-­‐azide  cycloaddition  
(CuAAC)  reaction  between  the  azide  and  alkyne  groups  immobilised  onto  agarose  gel  (figure  
34).   An   allyl   ester   was   included   as   a   cleavable   group   and   a   chloroacetamide   as   the   thiol  
alkylation  agent  (figure  34).  In  this  first  model  system  we  plan  to  use  a  simple  glycine  linker  
as  the  modifying  agent  (figure  34).  This  will  allow  us  to  minimise  the  complexity  of  the  system  
but   could   be   replaced   by   alternative   amino   acids   or   related   systems   with   increased  
functionality  once  the  basic  aims  of  the  project  have  been  achieved.  
  
Figure  34:  The  thiol  alkylation  system  containing  an  allyl  cleavable  linker  and  azide  to  
immobilise  onto  solid  support.  
 
Although   the  maleimide   is  more   selective   towards   cysteine,   the   iodoacetamide   has   been  
selected  as  the  alkylation  agent  in  our  project  due  to  its  easy  chemical  synthesis  and  the  fact  
it   can   be   carried   through   the   synthetic   sequence   as   a   less-­‐reactive   chloroacetamide   and  
activated   by   SN2   displacement  with   excess   iodide   once   immobilised.   The   allyl   group  was  
selected  to  be  used  as  the  linker  due  to  its  general  stability  and  straightforward  deprotection  









utilising   water-­‐soluble   phosphine   ligands.   The   biocompatibility   of   this   process   has   been  
highlighted  by  the  use  of  this  system  in  cells  by  Chen  et  al.,160  who  demonstrated  that  allyl  
group  is  biocompatible  with  cell  integrity.    
Aldehyde-­‐modified   agarose   gel   2   was   selected   as   the   solid   phase   because   it   is   readily  
available,  and  agarose  gel  has  been  used  extensively  in  the  immobilisation,  purification  and  
transformation   of   proteins.  The  aldehyde-­‐modified  agarose  gel  2   can  be  used   to  attach  a  
commercially   available   alkyne   3   to   the   solid   phase   via   well-­‐establish   reductive   amination  
conditions  in  aqueous  media,  to  provide  the  alkyne  immobilised  onto  solid  phase  4  (scheme  
11).  We  tried  to  attach  a  long  chain  alkyne  to  the  agarose  in  order  to  minimise  any  impact  
that   could   result   when   the   protein   interacted   with   the   solid   phase   (agarose   gel).161   The  
preparation  of  the  target  solid  phase  alkylation  agent  system  with  a  cleavable  linker  5  should  
be  achievable  by  CuAAC  reaction  of  azide  1  with  alkyne  4  (scheme  11)  
  
Scheme  11:  Proposed  synthetic  route  for  the  solid  phase  alkylation  linker  with  allyl  ester  as  




































2.1.1  Synthesis  of  the  alkylation  linker  
Alkylation   linker   1   was   prepared   by   acylation   of   compound   6   (figure   35),   compound   6  
prepared  by  using  a  commercially  available  allyl  compound  8  followed  by  selective  activation  
of  the  primary  alcohol  with  a  tosyl  group  9  (scheme  12).162,163  The  p-­‐toluenesulfonyl  chloride  
selectively  activates  the  primary  alcohol  due  to  the  higher  steric  hinderance  of  the  secondary  
alcohol,   and   it   is   a   good   leaving   group   that   facilitates   the   next   substitution   reaction.163  
Although  the  selective  activation  of  the  primary  alcohol  with  a  p-­‐toluenesulfonyl  chloride  was  
a   straightforward   step,   it   took   several  days   to   complete   the   reaction,   yielding  68%  of   the  
desired  compound  9,  as  confirmed  by  mass  spectrometry,  13C  NMR  and  1H  NMR.    
  
Figure  35:  Retrosynthesis  of  the  alkylation  linker  with  azide  to  use  in  CuAAC  reaction.  
 
  











































It  has  been  demonstrated  that  the  Sn-­‐derivative-­‐catalysed  diol  tosylation  reaction  provides  
higher   yield   and   better   selectivity   than   the   uncatalysed   diol   tosylation   reaction.162   in   our  
hands   using   the   catalytic   dibutyl   tin   oxide   (Bu2SnO)   helped   improve   the   tosylation   of   the  
primary  alcohol,  thus  providing  a  better  yield  (71%  of  compound  9)  in  24  hours.  The  Bu2SnO  
is  thought  to  accelerate  the  tosylation  reaction  due  to  the  formation  of  the  reactive  tin  acetal  
intermediate   12   followed   by   the   fast   selective   addition   of   TsCl   and   the   metal   exchange  
(scheme  13).162  
  
Scheme  13:  Bu2SnO-­‐catalysed  monotosylation  of  a  diol  8.162  
 
  
After  the  successful  synthesis  of  compound  9,  this  intermediate  subjected  to  the  published  
synthetic   procedure   for   protecting   a   secondary   alcohol   with   silyl   ether   before   azide  
displacement,   followed   by   a   deprotection   step   to   yield   compound   6   (scheme   12).164   The  
published   synthetic   procedure   showed   the   protection   of   the   secondary   alcohol  with   tert-­‐
butyldimethylsilyl  chloride  (TBDMSCl)  using  imidazole  and  dichloromethane,  however  these  
conditions  did  not  protect  the  secondary  alcohol  even  when  the  equiv.s  of  TBDMSCl  were  
increased.164   In  order   to   optimise   the   reaction  conditions,  dimethylformamide   (DMF)  was  
used  instead  of  dichloromethane  in  order  to  improve  the  solubility  of  the  reagents,  and  the  



























However,  changing  the  reaction  solvent  and  heating  the  reaction  did  not  help  improve  the  
protection   step.      Therefore,   we   tried   to   determine   the   effect   that   the   base   had   on   the  
reaction,  so  we  used  pyridine  instead  of  imidazole.    The  reaction  with  pyridine  took  seven  
days   to   complete,  and   it   yielded  68%  of   the  desired  compound  10,   as  confirmed  by  mass  
spectrometry,  1H  NMR  and  13C  NMR.    
A  simpler  form  of  silyl  ether  (trimethylsilyl  chloride,  TMSCl)  was  also  used  instead  of  TBDMSCl  
to  help   speed  up   the  protection   reaction   (scheme  14).165   In   this   silylation,  all   the   starting  
material   was   consumed   in   just   24   hours,   and   yielded   78%   of   the   desired   compound   13.  
Although  this  silylation  reaction  was  rapid  and  provided  a  better  yield  in  comparison  to  the  
reaction   that   used   TBDMSCl,   compound   13   was   not   stable   in   the   next   step   (azide  
displacement)   due   to   the   cleavage   of   the   bond   between   silicon   and   oxygen,   presumably  
resulting  from  nucleophilic  attack  at  the  unhindered  TMS  (scheme  14).      
  
Scheme  14:  Use  of  TMSCl  for  secondary  alcohol  protection  of  compound  9.  
  
  
After  the  disappointing  result  for  TMSCl  protection,  we  decided  to  return  to  TBDMSCl  and  use  
a  base  that  is  stronger  than  pyridine,  such  as  triethylamine.  We  found  that  triethylamine  was  
very  helpful  in  accelerating  the  protection  reaction  in  12  hours  at  room  temperature  to  yield  
82%  of  the  desired  compound  10.  This  effect  appears  to  relate  to  difference   in  the  pKa  of  
these  three  bases  as  shown  in  table  6,  although  the  exact  role  of  the  base  in  this  reaction  is  
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   78%
 68 
should  be  sufficiently  basic  to  neutralise  the  HCl  formed.  
Base   pKa  
Triethylamine   10.75  
Imidazole   7.05  
Pyridine   5.5  
Alcohol   16  
  
Table  6:  The  pKa  values  of  different  bases  used  in  the  protection  of  compound  9.  
 
  
The  next  step   in  the  synthesis  of  compound   6   is   the  displacement  of  the  tosyl  group  with  
azide.166  Initially  the  reaction  was  carried  out  using  NaN3  and  DMF  at  room  temperature,  but  
it  took  a  long  time  (more  than  7  days).  Therefore,  the  reaction  temperature  was  increased  to  
75  °C   in  order  to  speed  up  the  reaction;  however,   it   took  seven  days  until  all   the  starting  
material  was  consumed,  and  the  yield  was  very  low.  Surprisingly,  the  1H  NMR  did  not  show  
any   signals   for   the   desired   compound   11   or   even   the   starting   material   10.   In   order   to  
understand   this   situation   and   to   optimise   this   displacement   reaction   condition,   different  
conditions  were  investigated  (table  7).    
Towards  that  end,  DMF  is  the  best  solvent  for  this  reaction,  and  tetrabutylammonium  iodide  
(TBAI)  accelerates  the  displacement  reaction,  because  iodine  is  able  to  displace  the  OTs  and  
then  act  as  a  better  leaving  group  than  tosyl.150  The  displacement  reaction  was  carried  out  
using  NaN3,  TBAI  and  DMF  at  75  °C  and  all  the  staring  material  was  consumed  within  24  hours.  
However,  the  1H  NMR  did  not  show  any  signals  for  the  desired  compound  11  or  the  starting  
material  10.  The  low  recovery  after  simple  extraction  led  us  to  suspect  that  the  product  was  
volatile,  and  therefore  lost  by  evaporation  when  concentrating  the  solvent.167  This  is  in  line  
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with  previous  report,  where  compound  6  was  lost  during  the  work  up  due  to  its  low  boiling  
point.167      
  
Solvent   Catalyst   Temperature   Comment  
DMF   TBAI   RT   Reaction  completed  within  three  days.  
DMF   TBAI   75  °C   Reaction  completed  within  24  hours.  
DMF   -­‐   RT   No  reaction  
DMF   -­‐   75  °C   Reaction  completed  within  seven  days.  
DMF  and  H2O   TBAI   RT   No  reaction  
DMF  and  H2O   TBAI   75  °C   Reaction  completed  within  three  days.  
DMF  and  H2O   -­‐   RT   No  reaction  
DMF  and  H2O   -­‐   75  °C   No  reaction  
DMF  and  H2O   NaI   RT   No  reaction  
DMF  and  H2O   NaI   75  °C   No  reaction  
Methanol   TBAI   60  °C   No  reaction  
Wet  Methanol   TBAI   60  °C   No  reaction  
  
Table  7:  Summary  of  different  reaction  conditions  to  synthesis  compound  11.  
 
  
Consequently,  deuterated  dimethyl  sulfoxide  (DMSO)  was  used  to  check  the  reaction  mixture  
by  1H  NMR  before  doing  the  extraction  and  concentration.  Proof  of  a  successful  reaction  was  
provided   by   the   NMR   of   compound   11,   this   is   confirmed   the   volatility   of   compound   11.  
Keeping  the  volatility  of  compound  11  in  mind  we  prepared  it  by  using  DMF,  which  is  easier  
to  remove  than  DMSO  and,  this  time,  we  avoided  using  high  vacuum.  However,  only  37%  of  
the   desired   compound   11   was   recovered   (accounting   for   residual   DMF   not   removed   by  
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extraction,  which  was  quantified  by  relative  peak  integrals  in  the  NMR  spectra).  Moreover,  
after  conducting  the  deprotection  step  using  tetra-­‐n-­‐butylammonium  fluoride  (TBAF),  only  
57%  of  compound  6  was  isolated.  Our  conclusion  from  these  studies  was  that  the  published  
route  did  not  describe  an  optimal  synthesis  of  compound  6.168  
In  order  to  resolve  the  volatility  issue,  we  used  the  bulkier  silyl  ether  (tert-­‐butyldiphenylsilyl,  
TBDPS)  for  secondary  alcohol  protection  instead  of  TBDMSCl  (scheme  15).  When  using  this  
bulkier  group,  the  protection  reaction  took  longer  until  the  reaction  reached  completion  and  
yielded  just  28%  of  the  desired  compound  14.  Moreover,  the  azide  displacement  was  more  
difficult  because  TBDPS  makes  the  molecule  less  reactive.    
  
Scheme  15:  Protection  of  compound  9  with  tert-­‐Butyldiphenylsilyl  (TBDPS).  
  
After  understanding  that  following  the  published  routes  for  the  synthesis  of  compound  6  does  
not   provide   a   good   yield,   and   after   finding   the   best   reaction   conditions,  we   decided   to  
attempt  the  synthesis  of  the  azide  allyl  alcohol  by  direct  azide  displacement  of  compound  9,  
as   this  approach  allowed   to   synthesise   compound   6   in  one   step   instead  of   three   steps   in  
previous  procedure  (scheme  16).  The  displacement  reaction  was  carried  out  using  NaN3,  TBAI  
and  DMF  at  75  °C  and  under  these  conditions  all  starting  material  was  consumed  within  24  
hours   to   yield   compound   6   (scheme   16).   The   higher   aqueous   solubility   of   compound   6  
necessitated  extracting  the  product  eight  times  with  diethyl  ether  to  take  it  from  the  aqueous  
phase  to  the  organic  phase.  After  optimisation  it  was  found  that,  compound  6  can  be  isolated  












was  quantified  by   relative  peak   integrals   in  the  NMR  spectra);   in  contrast  when  DMF  was  
completely  removed,  the  yield  decreased  to  26%.  Therefore,   this  product  was  used   in  the  
next  step  (acylation)  without  fully  removing  DMF,  and  after  the  acylation  reaction  we  could  
easily  purify  the  product  of  interest.    
  
Scheme  16:  Synthesis  of  compound  6  by  direct  azide  displacement  of  compound  9.  
 
  
With   compound  6   in  hand,   compound   7  was  prepared   in  order   to   carry  out   the  acylation  
reaction  to  afford  compound  1.  Although  compound   7   is  commercially  available,  we  were  
interested   in   preparing   it.169,170   compound   7   was   prepared   by   following   the   published  
preparation  (scheme  17).169  Although  this  reaction  was  expected  to  be  extremely  rapid  due  
to   the  high   reactivity  of   chlorine,   it   took   three   days   to  yield  only  40%  of   compound   7,   as  
confirmed  by  mass  spectrometry,  13C  NMR  and  1H  NMR.    
  
  
Scheme  17:  Preparation  of  compound  7.  
  
The   acylation   reaction   (scheme   18)   was   first   carried   out   using      4-­‐dimethylaminopyridine  
(DMAP),   1-­‐ethyl-­‐3-­‐(3-­‐dimethylaminopropyl   (EDC)   and   DMF   (DMF   was   used   as   a   reaction  
solvent  because  compound  6  was  isolated  with  some  DMF)  at  room  temperature  to  afford  
NaN3, TBAI
DMF, 75 °C





















only  12%  of  compound  1.171  This  low  yield  might  be  due  to  the  possibility  of  the  nucleophilic  
attack  from  DMAP  lone  pair  on  compound  7  as  shown  in  figure  36.    
  
  
Scheme  18:  Optimised  acylation  reaction  to  form  compound  1.  
  
  
Figure  36:  Mechanism  of  the  DMAP  nucleophilic  attack.  
 
  
To   investigate   this   possibility,   we   conducted   an   acylation   reaction   with   a   commercially  
available  acetylglycine  17,  which  does  not  contain  a  chlorine  atom  (scheme  19).    This  acylation  
reaction  produces  a  low  yield  (12%),  similar  to  the  previous  reaction.  This  low  yield  invalidates  
our  expectation  that  chlorine  would  have  an  effect  on  the  reaction  yield.    
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In   terms  of  optimising   the   reaction  conditions   (table  8),   it   is  not  enough   to  use  an  equiv.  
amount   of   amino   acid;   rather,   an   excess   amount   of   amino   acid   should   be   used.   Using  
dichloromethane   as   a   reaction   solvent   increased   the   reaction   yield   from   12%   to   86%  
(compound  18)  and  83%  (compound  1)  at  room  temperature  in  24  hours,  while  the  reaction  
that  used  DMF  needed  to  be  heated,  and  it  took  three  days  to  yield  70%.  In  addition,  it   is  
necessary   to   use   an   equiv.   amount   of   DMAP   for   the   base,   while   triethylamine   does   not  
improve  the  reaction.  Proof  of  the  successful  preparation  of  compound  1  and  compound  18  
was  provided  by  the  NMR  of  the  compounds.  
  
Solvent   Base   Catalyst   Temperature   Equiv.  amino  acid   Yield,  Time  
DMF   DMAP      RT   1  equiv.   12%,  48  hours  
DMF   DMAP      RT   6  equiv.   39%,  7  days  
DMF   DMAP      65  °C   6  equiv.   70%,  72  hours  
DMF   Et3N      65  °C   6  equiv.   10%,  72  hours  
DMF   Et3N   DMAP   6  5  °C   6  equiv.   39%,  72  hours  
CH2Cl2   DMAP      RT   4  equiv.   86%,  24  hours  
CH2Cl2   DMAP      RT   2  equiv.   50%,  72  hours  
  
Table  8:  Different  acylation  reaction  conditions.  
 
2.1.2  Investigation  CuAAC  reactions  in  the  solution  phase  
      
After  the  successful  synthesis  of  the  alkylation  agent  containing  an  allyl  ester  cleavable  linker  
(compound  1),  we  were  interested  in  investigating  the  CuAAC  reaction  and  the  Pd  catalysed  
allyl  deprotection  in  the  solution  phase  in  order  to  find  efficient  reactions  conditions  before  
going   to   the   solid   phase.   Moreover,   we   were   interested   in   investigating   the   iodine  
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displacement  reaction  and  the  thiol  alkylation  by  the  alkylation   linker  that  we  prepared   in  
solution  phase.    
For  the  CuAAC  reaction  in  solution  phase,  the  commercially  available  simple  alkyne  19  was  
coupled  to  compound  18  (Scheme  20).172  A  CuAAC  reaction  can  be  conducted  under  aqueous  
conditions  at  room  temperature,  and  it  should  specifically  yield  the  1,4-­‐disubstituted  1,2,3-­‐
triazoles   regioisomer,   in   contrast   to   the   Huisgen   1,3-­‐dipolar   cycloaddition   (uncatalysed),  
which   requires   an   elevated   temperature   and   provides   a  mixture   of   1,4-­‐triazoles   and   1,5-­‐
triazoles  regioisomers  (figure  37).173    
  
  





Figure  37:  Azide-­‐Alkyne  cycloaddition  reaction,  (A)  uncatalysed  thermal  Azide-­‐Alkyne  











































The  CuAAC  reaction  mechanism  is  complicated  due  to  the  number  of  copper  ions  that  are  
involved  in  the  reaction.174  It  is  started  by  the  reduction  of  the  copper  (II)  salt  into  copper  (I)  
followed   by   coordination   of   the   terminal   alkyne   to   the   copper   to   form   π   alkyne-­‐copper  
intermediate.  This  coordination  increases  the  acidity  of  the  terminal  alkyne  hydrogen  leading  
to  deprotonation  of  the  terminal  alkyne  to  form  copper  (I)  acetylide.175  After  formation  of  the  
copper  (I)  acetylide  intermediate,  the  azide  could  attack  the  same  copper  centre  that  binds  
to  alkyne,  which  is  the  oldest  proposed  mechanism  of  the  CuAAC  reaction  called  the  mono-­‐
copper  pathway  (figure  38).176,  177,178    In  the  reviewed  mechanism  of  the  CuAAC  reaction,  the  
copper   (I)   acetylide   intermediate   binds   to   a   second   copper   ion   to   form   bis-­‐Cu   acetylide  
complex,  and  then  the  azide  can  attack  the  second  copper  centre,  which   is  called  the  bis-­‐
copper  pathway  (figure  39).176,  177,178    
Regardless  of  the  mono/bis  mechanism,  the  azide  binds  to  the  copper  (I)  acetylide  through  
the   proximal   nitrogen   to   the   carbon   to   form   azide-­‐copper   intermediate.179,180      The   distal  
nitrogen  of  the  azide  then  attacks  the  C2  carbon  of  the  acetylide  to  form  a  six-­‐membered  
copper   containing   intermediate,179   followed   by   reductive   elimination   and   formation   the  
second  C-­‐N  bound  to  form  the  1,4-­‐disubstituted  1,2,3-­‐triazoles.  Finally,  the  1,4-­‐disubstituted  
1,2,3-­‐triazole  product  is  released  and  the  active  copper  species  catalyst  regenerated  by  fast  










































Figure  39:  Bis-­‐  copper  mechanism  for  the  copper  (I)-­‐catalysed  alkyne-­‐azide  cycloaddition  
(CuAAC).  
  
Tris(3-­‐hydroxypropyltriazolylmethyl)amine   (THPTA)   is   a  water   soluble   amine   ligand   that   is  
used   to   avoid   the   oxidation   of   catalytic   Cu(I)   by   dissolved   oxygen   and   to   accelerate   the  
reaction  rate  by  facilitating  the  coordination  of  the  azide  to  the  copper  center.175,183  It   is  a  
water-­‐soluble  ligand  that  provides  further  simplification  for  the  click  chemistry  by  allowing  
the  entire  reaction  to  be  run   in  water,   thereby  affording  biological  compatibility   for  these  










































Figure  40:  The  tris(3-­‐hydroxypropyltriazolylmethyl)amine  (THPTA)  structure.  
 
 
Although   the  CuAAC   is  a   click   reaction   that   should  provide  a  high  yield,   in  our   hands   the  
reaction  only  provided  a  low  yield  of  the  triazole  compound  20  (Scheme  20).182  The  product  
identity   was   confirmed   by  mass   spectrometry   and   1H   NMR,   however,   1H   NMR   showed   a  
mixture  of  product  and  impurities  that  was  hard  to  purify,  in  part  due  to  the  low  yield  of  the  
reaction.    
In  order  to  investigate  the  low  yield  of  CuAAC,  alkyne  21  was  used  for  the  CuAAC  reaction  
(Scheme  21).    Using  alkyne  21  with  compound  18  yielded  86%  of  the  desired  product  22,  as  
confirmed  by  mass  spectrometry,  1H  NMR  and  13C  NMR,  suggesting  that  the  poor  reaction  
profile  observed  when  using  propargyl  alcohol  19  is  due  to  some  specific  side  reactions  with  
this  compound.      
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2.1.3  Investigation  of  the  cleavage  reactions  in  the  solution  phase  
To   investigate   the   Pd-­‐catalysed   allyl   deprotection   in   solution   phase,   different   allyl   esters  
(compounds  1,  18,  22)  were  used   to   investigate  the  cleavage  of   the   linker   in   the  solution  
phase  based  on  the  reported  strategy  of  the  mild  deprotection  of  allyl  ethers  in  the  presence  
of  Pd(0)  catalyst  (1  mol%  )  under  basic  conditions.185  These  studies  showed  the  deprotection  
of  allyl  aryl  ethers  with  1  mol%  of  tetrakis(triphenylphosphine)Pd(0)  (Pd(PPh3)4)  and  3  equiv.  
of  potassium  carbonate  (K2CO3)  in  methanol  was  faster  than  deprotection  of  the  allyl  alkyl  
ether   in   the   same   reaction   conditions.185   Here   we   were   interested   in   the   allyl   ester  
deprotection,  where  the  pKa  value  of  the  acid  is  lower  than  phenolic  OH,  which  makes  it  much  
less  basic  and  better  leaving  group  than  allyl  aryl  ether.  Therefore,  the  compounds  1,  18  and  
22  were  treated  with  Pd  (PPh3)4  in  methanol  in  order  to  investigate  the  ability  of  Pd  to  undergo  
deallylation  in  the  presence  of  azide  (compounds  1,  18)  and  triazole  (compound  22).  If  this  
chemistry   worked,   we   planned   to   investigate   allyl   deprotection   using   water-­‐soluble  
phosphine  ligands.  
The  mechanism  of  allyl  deprotection  is  closely  related  to  the  more  studied  Pd-­‐catalysed  allyl  
alkylation,  which  was  first  introduced  by  Tsuji  1965  then  further  developed  by  Trost  in  1973  
through   inclusion   of   phosphine   ligands.186,187   The   Pd-­‐catalysed   deallylation   occurs   in   two  
steps;  the  first  step  is  the  coordination  of  the  Pd(0)-­‐catalyst  to  the  double  bond,  to  give  the  
η2  π-­‐allyl  complex,  followed  by  expelling  the  leaving  group  (with  inversion)  to  give  the  η3  π-­‐
allyl  complex.  The  Pd(0)  is  oxidised  to  Pd(II)  in  this  process,  which  is  also  called  the  ionization  
step  (Figure  41,  Path  A).  The  second  step  is  the  nucleophilic  substitution  step,  which  results  
in  reduction  to  Pd(0),  followed  by  decomplexation  of  the  η2  π-­‐allyl  complex  to  produce  the  
allylation   product   and   recover   the   active   Pd(0)   species      (Figure   41,   Path  





Figure  41:  Pd  catalysed  the  reactions  of  allylic  compounds  (the  nucleophilic  pathway  and  the  
b-­‐hydride  elimination  pathway).  
 
The  addition  of  the  nucleophile  can  occur  through  two  different  pathways  depending  on  the  
nature   of   the   nucleophile.   Soft   nucleophiles   attack   directly   the   allylic   moiety   on   carbon,  
opposite  from  the  face  where  the  Pd  resides  (leading  to  net  retention  of  stereochemistry  from  
the   leaving   group).192,190,193,188   The   nucleophile   can   attack   either   terminal   allyl   carbon   to  




















































increases   the   regioselectivity   of   the   reaction   (Figure   42,   Type   A).192   In   contrast,   hard  
nucleophiles  attack  the  metal  center  first,  with  the  allylation  product  produced  by  reductive  
elimination   (Figure   42,   Type   B).192,190,193,188,194   In   line  with   this   hard/soft   principle   carbon  
nucleophiles  prefer  to  attack  the  η3  π-­‐allyl  complex  directly,  while  heteroatom  nucleophiles  
attack  the  Pd  center  followed  by  migration  to  the  allyl  unit.188,193    
  
Figure  42:  Soft  (type  A)  and  hard  (type  B)  nucleophile  addition  to  the  η3  π-­‐allyl  Pd  complex.  
  
On  the  other  hand,   if   the   ligand  has  hydrogens  on  b-­‐carbon  of  the  alkyl,  an  alternative  b-­‐
hydride  elimination  reaction  pathway  can  theoretically  occur.  The  hydride  on  b-­‐carbon  of  the  
η3  π-­‐allyl  complex  is  transferred  to  the  Pd  center,  followed  by  the  reductive  elimination  to  
regenerate  the  Pd(0)  in  the  presence  of  a  base.    Based  on  other  Pd-­‐catalysed  reactions  it  was  
expected  that  the  b-­‐hydride  elimination  pathway  is  rapid  in  comparison  to  the  nucleophilic  
pathway  (Figure  41,  Path  B).197,198      
  
The  allyl  ester  was  cleaved  in  all  compounds  (1,  18  and  22)  when  the  reaction  was  carried  out  
in   deuterated   methanol   (CD3OD)   in   the   presence   of   Pd(0)   catalyst   (1   mol%)   under   basic  
conditions  (3  equiv.  of  K2CO3)  (scheme  22).  This  was  confirmed  by  1H  NMR,  which  showed  the  

































(Figure  43)  and  appearance  of  a  proton  peak  at  4.20  ppm,  which  is  similar  to  the  signal  of  the  
C-­‐H  adjacent  to  the  alcohol  in  compound  6  (Figure  43).    The  peak  of  the  methylene  protons  
that  are  adjacent   to  amine  are  also   completely   lost  under   these  conditions,  which  can  be  
attributed  to  exchange  with  deuterium.    Although  this  result  was  initially  promising,  control  
experiments  demonstrated  that  the  allyl  ester  is  unstable  in  the  basic  conditions  leading  to  
direct   hydrolysis   of   the   molecule   independently   of   the   Pd   deprotection   pathway.   This  
hypothesis  was  confirmed  by  1H  NMR  when  the  reaction  was  carried  out  in  CD3OD  and  K2CO3  
in   the   absence   of   the   Pd(0)   catalyst.   Again,   the   disappearance   of   the   adjacent   amine  
methylene  protons  is  most  likely  due  to  the  use  of  base  in  deuterated  methanol  leading  to  
exchange  of  these  acidic  protons  (Figure  44).    
  
  
Scheme  22:  The  cleavage  reaction  of  compound  18  by  catalyst  Pd(0)  in  the  presence  of  base,  









































Figure  43:  Comparison  between  1H  NMR  spectrum  for:  1-­‐  compound  18  in  CD3OD,  2-­‐  
compound  6  in  CD3OD,  3-­‐  compound  18  with  potassium  carbonate  in  CD3OD  without  Pd(0)  















































































































































































Figure  44:  Hydrolysis  and  Pd  deallylation  pathways  of  compound  18.  
 
  
We  optimised  the  reaction  conditions  and  found  that  the  allyl  ester  compounds  (1,  18  
and  22)  were  hydrolyzed  under  basic  conditions  even  when  deuterated  water  (D2O)  is  
used   instead   of   CD3OD   (Table   9).   Also,   we   note   that   no   deprotection   product   was  
observed  when  the  reaction  was  carried  out  in  CD3OD  in  the  presence  of  Pd(0)  catalyst  
but   without   base,   consistent   with   literature   reports   that   the   absence   of   the   base  
slowed  the  reaction  process  in  the  deprotection  of  allyl  ether  in  CD3OD  in  the  presence  
of  a  Pd(0)  catalyst.185  However,  the  deprotection  of  the  allyl  ester  was  achieved  when  


























































without   base   (Table   9).   We   therefore   conclude   that   the   failure   of   catalytic   Pd  
deprotection   under   neutral   conditions   is   due   to   trapping   of   a   stable   catalytic  
intermediate  that  forms  following  the  oxidative  addition.  This  could  be  the  Pd  hydride  
species  (Figure  41,  path  B),  as  base  is  generally  required  to  recycle  Pd(0)  during  e.g.  
Heck   reactions,   it   is   also   possible   that   the   η3   π-­‐allyl   complex   itself   is   stable   in   the  
absence   of   a   good   nucleophile.   It   was   also   noted   that   the   presence   of   agarose  
prevented  the  cleavage  when  the  reaction  was  carried  out  in  DMSO,  however  there  
was  no  effect  when  the  reactions  were  carried  out  in  D2O  and  CD3OD.    
Solvents   Pd(0)  catalyst  (5  mol%)   Pd(0)  (100  mol%)  
CD3OD  +  K2CO3   Hydrolysis   NA  
CD3OD   No  reaction   Complete  conversion  at  3  hours  
CD3OD  +  Agarose   No  reaction   Complete  conversion  at  3  hours  
D2O  +  K2CO3   Hydrolysis   NA  
D2O   No  reaction   Complete  conversion  at  3  hours  
D2O  +  Agarose   NA   Complete  conversion  at  3  hours  
DMSO   No  reaction   Complete  conversion  at  3  hours  
DMSO  +  Agarose   NA   No  reaction  
    
Table  9:  Different  reaction  conditions  to  optimise  the  deallylation  of  the  allyl  ester.  
 
2.1.4  Investigation  of  the  iodine  displacement  and  the  thiol  alkylation  reactions  in  the  
solution  phase  
To  investigate  the  iodine  displacement  reaction  in  solution  phase,  compound  1  was  treated  
with  sodium  iodide  (NaI)   in  acetone  for  24  hours  to  provide  compound  24   in  76%  yield  as  
confirmed  by  mass  spectrometry,  13C  NMR  and  1H  NMR  (scheme  23).  To  investigate  the  thiol  
alkylation   reaction   in   solution   phase,   compound  27  was   prepared   by   the   CuAAC   reaction  
between  compound  1  and  a  commercially  available  N-­‐Boc  propargylamine  25  followed  by  Boc  
deprotection  under  acidic  conditions  (scheme  24).    Compound  27  was  designed  to  be  close  
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to   our   thiol   alkylation   linker   which   has   chloroacetamide,   allyl   ester   and   triazole   group.  
Compound  27  was  treated  with  different  amounts  of  cysteamine  28  (4,  2,  1  and  0.5  equiv.)  in  
PBS  at  room  temperature  and  60  °C  with  and  without  sodium  iodide  (NaI)  in  order  to  find  
efficient  reaction  conditions.    
  
  
Scheme  23:  Iodine  displacement  to  chlorine  of  compound  1.  
 
  
Scheme  24:  Preparation  of  the  compound  27.  
 
  
The  thiol  alkylation  reaction  of  the  cysteamine  28  resulted  in  a  mixture  of  products  in  the  1H  
NMR  spectra  and  ES+MS  (scheme  25).  As  expected  the  1H  NMR  showed  a  shift  of   the  two  
protons  that  were  next  to  chlorine  from  4.1  ppm  into  3.4  ppm,  however  we  also  observed  
loss  of  the  signal  of  the  methylene  proton  that  was  adjacent  to  the  ester  at  5.75  ppm  and  
appearance  of  a  new  proton  peak  at  4.60  ppm.  One  hypothesis  for  this  side  reaction  was  that  
the  cystemine  28  caused  an  increase  in  the  pH  of  the  reaction  mixture  that  led  to  hydrolysis  
1 24
NaI
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of  the  ester,  although  this  occurred  even  when  small  amount  of  cysteamine  28  was  added  
(0.5  equiv.).  Therefore,  we  used  thioglycolic  acid  30  instead  of  cysteamine  28  and  found  that  
the  ester  of  compound  27  was  still  hydrolysed.  
  
  
Scheme  25:  alkylation  of  Cysteamine  28  by  compound  27.  
 
  
By  this  stage  it  was  clear  that  the  ester  system  was  unlikely  to  be  sufficiently  stable  for  longer-­‐
term  use  in  the  project,  therefore,  we  attempted  to  investigate  the  thiol  alkylation  by  using  
simple   molecules   that   do   not   have   ester,   in   order   to   avoid   hydrolysis.   The   (2-­‐
chloroacetyl)glycine   7   was   treated   with   cysteamine   28,   thioglycolic   acid   30   or  
mercaptoethanol  31  (figure  45)  in  PBS  for  24  hours  in  presence  or  absence  of  NaI  (table  10).  
We   also   prepared   (2-­‐iodoacetyl)glycine   32   to   investigate   the   efficiency   of   thiol   alkylation  
reaction  by  using  iodine  instead  of  chlorine  (table  10).  When  the  (2-­‐chloroacetyl)glycine  7  was  
treated  with  different  thiol  molecules  in  PBS  for  24  hours,  no  change  was  observed  in  the  1H  
NMR.  However,  the  presence  of  NaI  in  the  reaction  mixture  provided  ~100%  alkylation  when  
thiol  was   used   in   excess.   The   iodine   is   a   good   leaving  group   due   to   the  weakness   of   the  
carbon-­‐iodine  bond  in  comparison  with  other  carbon-­‐halogen  bonds.  The  bond  dissociation  
energy  of  carbon-­‐iodine  bond  is  57.6  kcal/mol  while  the  bond  dissociation  energy  of  carbon-­‐
chlorine  bond  is  83.7  kcal/mol.  The  large  atomic  radius  of  the  iodine  and  the  long  carbon-­‐
























Figure  45:  Cysteamine  28,  thioglycolic  acid  30  and  mercaptoethanol  31.  
  
  




Temp.   Comments  
1   (2-­‐chloroacetyl)glycine  7   Cysteamine  28   2   -­‐   RT   0%  conversion  
2   (2-­‐chloroacetyl)glycine  7   Cysteamine  28   4   4   60  °C   100%  conversion  
3   (2-­‐chloroacetyl)glycine  7   Thioglycolic  acid  30   2   -­‐   40  °C   0%  conversion  
4   (2-­‐chloroacetyl)glycine  7   Thioglycolic  acid  30   2   2   40  °C   100%  conversion  
5   (2-­‐chloroacetyl)glycine  7   Mercaptoethanol  31   2   -­‐   40  °C   0%  conversion  
6   (2-­‐chloroacetyl)glycine  7   mercaptoethanol31   2   2   40  °C   59%  conversion  
7   (2-­‐iodoacetyl)glycine  32   Thioglycolic  acid  30   2   -­‐   60  °C   100%  conversion  
  
Table  10:  Different  reaction  conditions  for  thiol  alkylation.  
 
2.1.5  Investigation  of  the  immobilisation  of  the  alkylation  linker  onto  agarose  and  
cleavage  reaction  in  the  solid  phase  
Investigation  of  the  loading  of  the  alkylation  linker  into  agarose  and  cleavage  efficiency  of  the  
allyl  ester  from  the  solid  phase  was  expected  to  be  complicated  by  challenges  with  directly  
quantifying  the  degree  of  loading  on  the  solid  phase.  To  address  this  question,  we  therefore  
focussed  our  efforts  on  accurately  quantifying  the  amount  of  recovered  linker  following  the  
immobilisation   step   and   considering   the   mass   balance   when   the   immobilised   material   is  
isolated  following  cleavage.  In  order  to  facilitate  these  studies  a  model  system  was  developed  































rhodamine   azide  34  was   prepared   by   the   acylation   of   compound   6  with   a   commercially  
available  rhodamine  B  33  (scheme  26).  Then,  the  rhodamine  azide  34  was  immobilised  onto  
agarose  by  the  copper  (I)-­‐catalysed  alkyne-­‐azide  cycloaddition  (CuAAC)  reaction  of  azide  34  
with  alkyne  4  (scheme  26).  The  extent  of  labelling  of  the  commercial  aldehyde-­‐agarose  gel  2  
is  approximately  45  µmole/mL,  though  the  precise  amount  of  gel  used  in  reactions  (scheme  
27).  None  the  less  by  varying  equiv.  the  recovery  of  free  rhodamine  33  following  the  CuAAC  
reaction  to   form   the   solid  model   system  35  can  be  used  estimate  both   the   loading  of   the  
agarose  with  alkyne  and  efficiency  of  the  CuAAC  reaction.    
  
Scheme  26:  The  loading  of  the  fluorophore  Rhodamine  Azide  35  on  the  resin  4  and  the  
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In   order   to   find   the   best   condition   for   the   CuAAC   reaction,   varying   equiv.   of   the  
rhodamine  azide  34  were  reacted  with  the  solid  phase  alkyne  4  (table  11).  The  data  
supports   an   alkyne   loading   close   to   that   expected,   with   high   loading   efficiency   for  
the  rhodamine  azide  34  when  excess  azide  is  used.  However,  only  55%  of  rhodamine  
azide  34  was  recovered  after  using  4  equiv.  of  the  azide  relative  to  the  alkyne,  which  
theoretically  should  be  75%.  This  suggests  that  either  the  alkyne  loading  is  higher  than  
expected,   or   we   are   seeing   incomplete   recovery   of  the  free   Rhodamine  
following  the  CuAAC  reaction.    
  
Amount  of  Rhodamine  Azide   Loading  Efficiency  
0.25  equiv.   11%  
1  equiv.   77%  
4  equiv.   164%  
  
Table  11:  The  loading  efficiency  of  the  Rhodamine  azide  34  on  the  resin.  
  
Unfortunately,  the  cleavage  conditions  developed  off-­‐agarose  gave  very  poor  recovery  
of   the   rhodamine  B  33   in   the   solid  model  system  35   (0.4  %)  when  the  reaction  was  
carried   out   in   CD3OD   in   the   presence   of   100   mol%   Pd(0)   (scheme   26).   It   became  
apparent  at  this  stage  that  the  low  yield  of  the  cleavage  reaction  of  the  solid  model  











during  the  CuAAC  reaction.200  It  has  been  reported  that,  the  Cu(I)  decreased  the  MW  
of  polysaccharides,  likely  through  formation  of  reactive  intermediates,     and  changed  
the  colour  of  the  agarose  from  colourless  to  dark  brown.200  We  could  not  notice  these  
effects   of   the   Cu(I)   during   the   ligand   immobilisation   due   to   the   purple   colour   of  
rhodamine  azide  34.  It  is  therefore  possible  that  the  agarose  products  and/or  retained  
copper  leads  to  degradation  of  the  rhodamine  at  this  stage.  The  Cu(I)  side  effects  on  
the  agarose  may  be  avoided  by  doing  the  CuAAC  reaction  before  the  attachment  to  
the  agarose,  however  given  the  concerns  about  the  stability  of  the  allyl  ester  in  the  
actual   linker   system  we   instead   chose   to   redesign   the   linker   system   in   full   to   allow  
alternative  immobilisation  approaches.  
  
In  the  first  attempt  toward  the  solid  phase  alkylation  linker,  the  alkylation  linker  1  had  
been  successfully  synthesised  and  the  CuAAC  reaction  in  the  solution  phase  and  solid  
phase  confirmed  the  formation  of  the  triazole  product  in  good  yield  when  the  reaction  
was   carried   out   under   aqueous   conditions   at   room   temperature.   In   addition,   the  
deprotection  of  the  allyl  ester  was  achieved  when  the  reaction  was  carried  out  in  the  
presence   of   100   mol%   Pd(0),   without   base.   However,   the   cleavage   reaction   of   the  
rhodamine  solid  model  system  gave  very  low  yield  when  the  reaction  was  carried  out  
in  the  presence  of  100  mol%  Pd(0).  Moreover,  the  allyl  ester  linker  was  unstable  under  
basic   conditions,   leading   to   direct   hydrolysis   of   the   allyl   ester   system   which  
complicates  understanding  of  the  cleavage  reaction.  In  a  comparison  between  a  simple  
iodoacetamide   molecule   and   the   chloroacetamide,   it   was   demonstrated   that   the  
iodoacetamide  molecule  is  more  efficient  for  thiol  alkylation  than  the  chloroacetamide  
molecule.  
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2.2  Development  of  the  cleavable  linker  and  cleavage  conditions  
2.2.1  Optimisation  of  linker  Stability  
It  is  essential  that  the  solid  phase  alkylation  linker  is  stable  under  the  conditions  needed  to  
prepare   the   solid   phase   system   and   conduct   the   immobilisation   reactions.   After   the  
disappointing  finding  that  hydrolysis  of  the  allyl  ester  linker  occurs  under  basic  conditions,  we  
turned  our  attention  to  improve  the  stability  of  the  linker.  We  expected  that  changing  this  
component   of   the   linker   to   a   carbamate   or   carbonate  would   improve   the   stability   as   the  
carbonyl   group   in   the   carbamate   and   carbonate   is   conjugated   to   two   electron   donating  
groups  (amine  and  oxygen  in  carbamates,  oxygen  and  oxygen  in  carbonates)  therefore  the  
carbonyl  group  is  more  electron  rich  and  thereby  protected  from  nucleophilic  attack.    
Changing  the  allyl  ester  into  allyl  carbamate  or  allyl  carbonate  should  not  affect  the  cleavage  
of  the  linker  as  it  is  still  good  leaving  group  (their  pKa  are  close  to  the  carboxylic  acid  of  the  
ester)  (figure  46).201,202  This  approach  has  been  used  by  other  groups  looking  at  biocompatible  
Pd  activated  prodrugs,  for  example  Unciti-­‐Broceta  and  co-­‐workers  showed  the  gemcitabine  
carbamate   prodrugs   are  more   stable   than   the   gemcitabine   carbonate   prodrugs   in   human  




Figure  46:  Ester,  carbamate  and  carbonate  leaving  group.  
 
2.2.2  Carbamate  to  improve  the  linker  stability  
Bearing  in  mind  the  importance  of  the  stability  of  linkers  in  basic  conditions,  two  different  
allyl   carbamate   derivatives   37   and   39  were   prepared   by   the   reaction   of      commercially  
available   1-­‐bromo-­‐4-­‐isocyanatobenzene   36   and   (isocyanatomethyl)benzene   38   with  
compound  6  (scheme  28).204  These  derivatives  were  synthesised  to  make  the  carbonyl  group  
more  resistant  to  nucleophilic  attack,  therefore,  the  stability  these  derivatives  were  studied  
under  basic  conditions.      
  
  


















































Allyl  carbamate  37  was  found  to  undergo  hydrolysis  in  methanol  under  basic  conditions  using  
3  equiv.  of  K2CO3.  The  instability  of  allyl  carbamate  37  in  basic  conditions  is  most  likely  due  to  
the  amine  lone  pair  being  delocalised  into  the  phenyl  ring,  reducing  the  stabilisation  of  the  
carbonyl  group.  However,  the  1H  NMR  confirmed  that  the  carbamate  molecule  39  was  stable  
under  basic  conditions.  The  deallylation  reaction  of  the  carbamate  molecule  39  resulted  in  a  
complex  mixture  of  products   in  the  1H  NMR  spectra  when  the  reaction  was  carried  out   in  
methanol  in  the  presence  of  Pd(PPh3)4  catalyst  under  basic  conditions.  This  could  be  due  to  
the   high   reactivity   of   azide   towards   phosphines,   as   seen   in   the   Staudinger   reaction.    
Therefore,  the  allyl  carbamate  molecule  39  was  not  used  for  further  investigation  in  order  to  
avoid  any  unwanted  reactivity  between  the  azide  and  phosphine  ligands.      
  2.2.3  Propargyl  carbamate  as  a  cleavable  group    
After  Optimisation  of  the  linker  stability  by  using  carbamates  instead  of  esters,  we  turned  our  
attention  to  investigating  a  wider  range  of  functional  groups  that  can  be  cleaved  by  catalytic  
Pd  under  mild  conditions.  It  has  been  reported  that  the  Pd  catalyses  the  depropargylation  
reactions  more  efficiently  than   the  deallylation   reactions  without  any  additional   reagents,  
potentially  because  the  depropargylation  reactions  can  be  catalysed  by  Pd(0)  or  Pd(II)  forms  
with  little  dependence  on  phosphine  ligands,  while  the  deallylation  reaction  needs  a  Pd(0)-­‐
active   species   and   is   greatly   accelerated   by   phosphine   ligands.203,160,205,206   Therefore,  
depropargylation  can  reduce  the  need  for  strong  reducing  agents  and  phosphine  ligands  and  
may  therefore  prove  more  compatible  with  peptides.207    
Chen   and   co-­‐workers   investigated   propargyl/allyl   carbamate   lysine   protecting/blocking  
groups  and  the  Pd  complexes  that  can  catalyse  uncaging  reactions  under   living  conditions  
(figure  47).    They  found  allyl2Pd2Cl2  and  Pd(dba)2  were  the  most  efficient  simple  Pd  complexes  
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that   catalysed   the   uncaging   reactions.160   They   reported   the   cleavage   reaction   of   the  
propargyloxycarbonyl  (Proc)-­‐caged  rhodamine  was  more  efficient  than  the  allyloxycarbonyl  
(Aloc)-­‐caged   rhodamine.160   Moreover,   neither   of   the   simple   Pd   species   catalyse   the  
deallyation  reaction  of  the  Alloc-­‐protected   lysine  amino  acid   in  the  absence  of  a  reducing  
agent.160  However,  they  showed  the  addition  of  the  water-­‐soluble  phosphine  ligand  (TPPS)  
increased  the  deallyation  reaction  of  the  allyloxycarbonyl   (Aloc)-­‐caged  rhodamine  without  
any  noticeable  effect  on  the  depropargylation  reaction  of  the  propargyloxycarbonyl  (Proc)-­‐




Figure  47:  A  chemical  decaging  strategy  for  protein  activation  in  living  cells.  a,  a  lysine  
residue  caged  on  a  protein  of  interest,  showing  how  a  biocompatible  catalyst  triggers  the  
decaging  reaction  to  activate  protein  inside  living  cells.  b,  decaging  conditions  for  propargyl  
and  allyl  group.  c,  Structures  of  lysine  (Lys,  1),  pyrrolysine  (Pyl,  2),  N-­‐  propargyloxycarbonyl-­‐
L-­‐lysine  (Proc-­‐Lys,  3)  and  N-­‐allyloxycarbonyl-­‐L-­‐lysine  (Aloc-­‐Lys,  4).  
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Unciti-­‐Broceta  and  co-­‐workers  tested  Pd  catalysed  deprotection  reactions  under  biological  
conditions,   with   HPLC   used   to   analyse   the   deprotection   reactions   at   different   time  
points.203,205    They  reported  that  Pd(0)-­‐resin  mediated  the  activation  of  5-­‐fluoro-­‐1-­‐propargyl-­‐
uracil  (Pro-­‐5FU)  to  release  the  cytotoxic  5-­‐fluorouracil  (5FU),and  that  this  reaction  was  more  
efficient  and   faster   than   the  activation  of   the   5-­‐fluoro-­‐1-­‐allyl-­‐uracil   (All-­‐5FU).205  The   same  
authors  reported  the  activation  of  gemcitabine  prodrugs  was  faster  when  the  proc-­‐protected  
gemcitabine  was  treated  with  Pd(0)-­‐resin  at  37  °C  (reaction  half-­‐life  <  6  hours)  than  the  Alloc-­‐
protected  gemcitabine.203    
In   contrast,   Weissleder   and   co-­‐workers   tested   different   Pd(0)   and   Pd(II)   catalysts   under  
biological  conditions.  They  reported  the  deallylation  reaction  of  the  Alloc-­‐caged  rhodamine  
was  37%  more  efficient  than  the  deproprargylation  reaction  of  the  Proc-­‐caged  rhodamine.  
The   addition   of   the   electron   deficient   ligands   (tri-­‐2-­‐furylphosphine   (TFP))   increased   the  
efficiency   of   the   deprotection   reaction   due   to   the   generation   of   a   more   reactive   Pd(0)  
species.208    
Wood  and  his  co-­‐workers  investigated  the  cleavage  of  allyl  carbamate  attached  to  a  Halo  Tag  
labelled  with  tetramethylrhodamine  (TAMRA)  fluorophore  to  monitor  the  cleavage  efficiency  
by   loss   of   fluorescence.   They   screened   a   set   of   water-­‐soluble   phosphine   ligands   in  
combination   with   various   nucleophiles   and   showed   that   the   allyl   carbamate   cleavage  
conducted   using   sodium   tetrachloropalladate   (Na2PdCl4)   in   combination  with   o-­‐DANPHOS  
(which  is  an  electron-­‐deficient  sulfonated  phosphine  ligand)  and  the  nucleophilic  morpholine  
in   amine-­‐based   buffer   MOPS   was   nearly   complete   within   30   minutes   in   a   protein-­‐rich  
environment.209    
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Interestingly,  despite  the  commonly  observed  poisoning  of  Pd(0)   catalysts  by  thiols   it  was  
reported   that   the   presence   of   glutathione   increased   the   efficiency   of   the   deallylation  
reaction.  In  this  context  glutathione  was  hypothesised  to  act  as  both  nucleophile  (to  recycle  
Pd   from   the  π-­‐allyl   complex)   and   reducing   agent   for   the   Pd.210,211   In   agreement  with   this  
finding,   Bradley   and   his   co-­‐workers   reported   that   Pd(0)   microspheres   catalysed   the  
deallylation  reactions  of  the  Aloc-­‐caged-­‐rhodamine  and  that  catalytic  activity  was  increased  
7  fold  in  the  presence  of  5  mM  glutathione.211    
2.2.4  Pd  catalysed  depropargylation    
The  Pd-­‐catalysed  reactions  of  allylic  compounds  have  been  extensively  studied  as  discussed  
earlier  in  this  chapter,  while  the  reactions  of  propargylic  compounds  are  more  complex  and  
less  studied,  although  the    propargylic  carbonates  are  highly  reactive.212    
The  Pd  catalysed  depropargylation  reactions  begin  with  oxidative  addition  of  the  Pd(0)  to  the  
propargyl   compound   to   give   the   η1-­‐s-­‐propargyl   Pd(II)   intermediate   complex,   which   is   in  
equilibrium  with  η1-­‐s-­‐allenyl  Pd(II)  complex    and  η3-­‐π-­‐propargyl  Pd(II)  cation  complex  (figure  
48).   The   η3-­‐π-­‐propargyl   Pd(II)   cation   complex   displays   different   reactivity   towards  
nucleophiles,  dependant  on  the  nature  of  the  nucleophile.  Hard  nucleophiles  typically  prefer  
to  attack  the  C1  to  form  allenylated  product  or  attack  C3  to  form  the  propargylated  product  
(figure  48).212,213,214  
In  contrast,  two  equiv.  of  soft  nucleophiles  typically  react  with  the  η3-­‐π-­‐propargyl  Pd  (II)  cation  
complex   in   different   mechanism.   One   equiv.   of   nucleophile   undergoes   the   alkenylation  
reaction  and  another  nucleophile  undergoes  the  allyl  alkylation  reaction.  The  first  equiv.  of  
the  nucleophile  attacks  the  central  position  (C2)  of  the  η3-­‐π-­‐propargyl  Pd  (II)  cation  complex  
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followed  by  immediate  protonation  by  the  second  equiv.  of  the  nucleophile  to  produce  η3-­‐π-­‐
allyl  Pd  (II)  intermediate.  This  is  followed  by  addition  of  the  nucleophile  to  the  η3-­‐π-­‐allyl  Pd  
(II)   intermediate   at   one   of   the   terminal   positions   to   produce   the   alkene   product   (figure  
48).212,213,214,215,216    
  
Figure  48:  Pd  catalysed  reactions  of  propargyl  compounds.  
 
2.2.5  Design  of  a  second  cleavable  group  and  Pd  catalyst  system  
In   order   to   investigate   the   Pd   catalysed   cleavage   reaction   under   mild   conditions,   we  
synthesised  a  set  of  allyl  and  propargyl  carbamates  (scheme  29).204  Different  Pd(0)  and  Pd(II)  
catalysts  were  used  to  study  the  reactivity  of  these  systems,  including  Pd(PPh3)4  and  simple  
air  stable  Pd  species  (figure  49)  that  had  been  reported  as  useful  catalysts  for  deprotection  
reactions  at  mild  temperature.160  The  efficiency  of  the  cleavage  catalysed  by  each  Pd  species  
was  evaluated  by  1H  NMR  and  mass  spectrometry.  The  stability  of  the  carbamate  derivatives  
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in  CD3OD  for  24  hours,  with  1H  NMR  confirming  that  all  carbamates  41,  43,  45,  47  and  49  were  
stable.      
  
Scheme  29:  Synthesis  of  the  allyl  and  propargyl  carbamate  as  model  linkers  that  undergoes  
























































Figure  49:  Pd  species  structures  and  formula.  
  
The   Pd   tetrakis   complex   (Pd(PPh3)4)   was   the   most   efficient   catalyst   for   the   deallylation  
reactions.   In   contrast,   none   of   the   four   simple   Pd   species   catalysed   the   allyl   carbamate  
cleavage  (table  12).    This  result  is  broadly  in  line  with  the  previous  reports,  where  Pd  catalysed  
deallyation  reactions  requires  strong  reducing  agents  or  phosphine  ligands  to  reduce  the  Pd  





























     
K2CO3,  CD3OD   Stable   Stable  
5  mol%  Pd(PPh3)4,  K2CO3,  
CD3OD  
Complete  conversion  at  24  hours   Complete  conversion  at  24  hours  
50  mol%  Pd(PPh3)4,  CD3OD   Complete  conversion  at  24  hours   Complete  conversion  at  24  hours  
5  mol%  [PdCl(allyl)]2,  K2CO3,  
CD3OD  
No  Reaction   No  Reaction  
5  mol%  Pd  (dba)2,  K2CO3,  
CD3OD  
No  Reaction   No  Reaction  
5  mol%  Pd  (NO3)2,  K2CO3,  
CD3OD  
No  Reaction   No  Reaction  
5  mol%  PdCl2,  K2CO3,  CD3OD   No  Reaction   No  Reaction  
  
Table  12:  The  cleavage  of  the  allyl  carbamate  derivatives  by  different  Pd(0)  and  Pd(II)  in  the  
presence  of  base.  
 
However  the  poor  activity  of  Pd(dba)2  suggests  a  more  complex  role  for  the  phosphine  ligands  
in   activating   the   Pd   species.217,218,219,220   The   use   of   the   Pd(dba)2   in   the   presence   of   the  
phosphine  ligand  is  based  on  the  dba  being  a  poor    ligand  for  the  reaction,  that  therefore  
needs  to  be  replaced  by  phosphine  ligands  to  produce  the  active  complex  Pd(0)(PPh3)2  before  
the   oxidative   addition   step   (figure   50).221,218,222   Adding   2   equiv.   of   PPh3   affords   a   major  
complex  Pd(0)(dba)(PPh3)2  which  is  unreactive  and  a  minor  complex  Pd(0)(PPh3)2  which  is  the  
reactive   complex   that   catalyses   the   oxidative   addition.221,223   The   catalytic   activity   is  
dependent  on  the  concentration  of  the  Pd(0)(PPh3)2  in  the  solution,  and  therefore  the  dba  










Figure  50:  The  ligands  exchange  between  Pd(dba)2  and  triphenylphosphine.223,221,217  
  
As   the   allyl   carbamate   compounds   41   and   43   have   b-­‐hydrogens,   we   suspected   the   Pd  
recovery  from  the  η3  π-­‐allyl  complex  could  proceed  through  a  b-­‐hydride  elimination  pathway  
to  provide  diene  derivatives,  as  this  process  is  suspected  to  be  faster  than  the  nucleophile  
pathway  (figure  41,  path  B).197,198  The  external  allyl  carbamate  43  was  successfully  cleaved  
when  the  reaction  was  carried  out  in  CD3OD  in  the  presence  of  Pd(PPh3)4  catalyst  (5  mol%)  
under  basic  conditions,  as  well  as  the  presence  of  50  mol%  Pd(PPh3)4  under  neutral  conditions,  
but  not  with  lower  Pd  loadings.      
From   the   poor   reactivity   of   these   systems   under   neutral   conditions   and   the   presence   of  
alkene  and  methyl  peaks  corresponding  to  the  methoxy  allyl  produced  under  basic  conditions,  
we  concluded  that  the  b-­‐hydride  elimination  didn’t  occur;   therefore,   the  Pd  catalyst  cycle  
needed  a  nucleophile  to  recover  the  Pd  from  the  η3  π-­‐allyl  complex  and  release  the  allylated  
nucleophile  (figure  51).    The  addition  of  the  nucleophile  can  occur  at  two  different  sites  to  
produce  compound  51  or  compound  52  (figure  52).  The  1H  NMR  showed  the  appearance  of  
compound  52  and  compound  51  in  a  1:3  ratio  (figure  51,  third  spectrum).  More  compound  
51  formed  in  comparison  to  compound  52,  which  we  expect  is  a  result  of  the  secondary  alkane  
cation  being  more  stable  than  the  primary  alkane,  therefore  it  is  attacked  more  by  nucleophile  
(figure  52).    
  











Figure  51:  Comparison  of  1H  NMR  spectra  for;  1-­‐  external  allyl  carbamate  43  in  CD3OD,  2-­‐  
benzyl  amine  50  suspected  cleavage  product  in  CD3OD,  3-­‐  Pd  catalysed  cleavage  of  external  
allyl  carbamate  43  in  presence  of  potassium  carbonate  in  CD3OD  and  4-­‐  direct  reaction  
between  potassium  carbonate  and  benzyl  amine  50  in  CD3OD.  
CD3OD




























Figure  52:  Pd  catalysed  cleavage  of  external  allyl  carbamate  43  provides  mixture  of  the  
compound  51  and  compound  52.  
 
However,   the   1H  NMR  showed  appearance  of  a   peak  at  4.25   ppm  which   is   similar   to   the  
protons  between  benzyl  and  carbamate  in  the  starting  material  43,  the  absence  of  the  CH-­‐
CH-­‐CH2  allyl  proton  at  5.25  ppm  confirms  the  starting  material  43  is  no  longer  present  in  the  
reaction  (figure  51).  While  the  EI+  MS  showed  appearance  of  molecular  weight  168,  which  
corresponds  to  methyl-­‐D3  benzylcarbamate  53   (figure  53).      To  better  understand  how  this  
compound  forms  in  the  reaction  mixture,  benzyl  amine  50  was  mixed  with  K2CO3  in  CD3OD  
for   24   hours,   the   1H   NMR   showed   appearance   of   protons   at   4.25   ppm   (figure   51,   fourth  
spectrum),  which  is  consistent  with  formation  of  methyl-­‐D3  benzylcarbamate  53.    
  
Figure  53:  The  possible  formation  of  the  methyl-­‐d3  benzylcarbamate  53  by  direct  methoxide  












































The  internal  allyl  carbamate  41  also  was  successfully  cleaved  when  the  reaction  was  carried  
out  in  CD3OD  in  the  presence  of  Pd(PPh3)4  catalyst  (5  mol%)  under  basic  conditions,  as  well  as  
under  neutral  conditions   in  the  presence  of  50  mol%  Pd(PPh3)4.  This  was  confirmed  by  1H  
NMR,  which  showed  the  same  benzyl  amine  50  and  mixture  of  internal  52  and  external  allyl  
51  products  in  a  1:1.5  ratio  (figure  54).  This  result  was  interesting  as  it  suggests  that  while  the  
Pd-­‐allyl  species  retains  the  same  reactivity,   there   is  some  contribution  from  a  more  direct  
reaction  pathway  where  the  regioselectivity  remains  controlled  by  the  starting  material.224  
Also,  the  1H  NMR  and  EI+  MS  again  showed  the  appearance  of  the  methyl-­‐D3  benzylcarbamate  
53  (figure  55).    
  
Figure  54:  Mechanism  of  Pd  catalysed  internal  allyl  carbamate  41  cleavage,  providing  a  

















































Figure  55:  Comparison  of  1H  NMR  spectra  for;  1-­‐  external  allyl  carbamate  43  in  CD3OD,  2-­‐  
internal  allyl  carbamate  41  in  CD3OD,  3-­‐  Pd  catalysed  cleavage  of  the  external  allyl  
carbamate  43  in  presence  of  potassium  carbonate  in  CD3OD,  4-­‐  Pd  catalysed  cleavage  of  the  
internal  allyl  carbamate  41  in  presence  of  potassium  carbonate  in  CD3OD.  
External  propargyl  carbamates  45  and  49  were  stable  in  basic  conditions,  however  in  contrast  
to   the   allyl   system   these   compounds   are   stable   to   Pd(PPh3)4,   which   didn’t      catalyse   the  
depropargyltion  reaction  when  the  reaction  was  carried  out  with    5  mol%  Pd(PPh3)4  in  the  
CD3OD










































presence  of  base  or  50  mol%  Pd(PPh3)4  in  neutral  conditions  (table  13).  Interestingly  these  
compounds   are   also   stable   (or   poorly   reactive)   to   the   simple   Pd   reagents   under   neutral  
conditions,  however  under  basic  conditions  these  molecules  are  efficiently  cleaved  by  the  
four  simple  Pd  species.  We  found  that  the  most  efficient  catalyst  for  the  depropargylation  
reaction  was  [PdCl(allyl)]2,  which  provided  100%  cleavage  within  24  hours  followed  by  the  Pd  
dba)2,  which  provided  50%  cleavage  within  24  hours.  That  is  in  line  with  the  previous  report  
which  found  the  most  efficient  depropargylation  reaction  of  the  Proc-­‐caged  rhodamine  was  
obtained   when   [PdCl(allyl)]2   and   Pd   (dba)2      were   used   in   the   absence   of   any   additional  
reagents.160    
Pd  source  








Complete  conversion  at  24  
hours,  37  °C  
Complete  exchange  of  
alcohols  at  48  hours,  60  °C  
Complete  conversion  at  2  
hours,  37  °C  
5  mol%  
Pd  (dba)2,  K2CO3,  
CD3OD  
Starting  Material  +  Products  
at  24  hours,  37  °C  
Starting  Material  +  exchange  
product  at  48  hours,  60  °C  
Complete  conversion  at  24  




Starting  Material  +  Products  
at  24  hours,  37  °C  
Starting  Material  +  exchange  
product  at  2  hours,  60  °C  
Complete  conversion  at  24  
hours,  37  °C  
5  mol%  PdCl2,  
K2CO3,  CD3OD  
Starting  Material  +  Products  
at  24  hours,  37  °C  
Starting  Material  +  exchange  
product  at  2  hours,  60  °C  
Complete  conversion  at  24  
hours,  37  °C  
  
Table  13:  The  cleavage  of  the  propargyl  carbamate  derivatives  by  different  Pd(0)  and  Pd(II)  












External  alkyne  carbamate  45  was  successfully  cleaved  when  the  reaction  was  carried  out  in  
CD3OD  in  the  presence  of  5  mol%  [PdCl(allyl)]2  catalyst  under  basic  conditions.  The  success  of  
the  cleavage  reaction  was  confirmed  by  1H  NMR  and  EI+  MS.  However,  the  peak  at  4.35  ppm,  
corresponding  to  the  environment  next  to  the  alkyne  55  is  smaller  than  expected,  which  may  
be  due  to  the  exchange  with  deuterium  in  the  presence  of  Pd.  Once  again,  the  1H  NMR  and  
the  EI+  MS  confirmed  that  the  methyl-­‐d3  benzylcarbamate  53  was  formed  under  the  reaction  
conditions  (figure  56).  To  confirm  that  the  peaks  at  3.75  ppm  and  4.25  correspond  to  product  
formation   additional   benzylamine   was   added   to   the   reaction   mixture   after   cleavage  
completion,  resulting  in  an  increase  in  the  CH2  of  the  benzylamine  50  protons,  with  no  new  















Figure  56:  Comparisons  of  1H  NMR  spectra  for;  1-­‐  external  propargyl  carbamate  45  in  
CD3OD,  2-­‐  Pd  catalysed  cleavage  of  the  external  propargyl  carbamate  45  in  presence  of  
potassium  carbonate  in  CD3OD,  3-­‐  Pd  catalysed  cleavage  of  the  external  propargyl  
carbamate  45  in  presence  of  potassium  carbonate  in  CD3OD  (3)  followed  by  addition  of  
benzylamine.  
 
External  propargyl  carbamates  49  were  successfully  cleaved  when  the  reaction  was  carried  
out  in  CD3OD  in  the  presence  of  5  mol%  [PdCl(allyl)]2  catalyst  under  basic  conditions.  This  was  
confirmed   by   1H   NMR   and   the   EI+   MS   (figure   57).   Surprisingly,   the   methyl   protons   of  
compound  56  are  almost  absent  in  the  reaction  mixture.  This  cannot  be  due  to  formation  of  
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a  stable  Pd  complex  because  it  is  present  at  catalytic  levels  (compared  to  using  100  mol%  Pd  
on  allyl  ester  above),  and  is  not  likely  to  be  deuterium  exchange.  One  alternative  is  that  the  
results   from   a   change   in   the   reaction   pathway,   as   some   studies   have   demonstrated   the  
formation  of  different  molecules  resulting  from  allenylated  products.225,226  
The  internal  propargyl  carbamate  47  was  stable  under  the  basic  conditions  at  37  °C,  however  
in  contrast  to  45  and  49  neither  of  the  Pd  species  catalysed  the  depropargylation  reaction  
when  the  reaction  was  carried  out  in  presence  or  absence  of  base  in  CD3OD  at  37  °C  for  24  
hours.  To  optimise  the  depropargylation  reaction  of  the  internal  propargyl  carbamate  47,  the  
reaction  temperature  was   increased  to  60  °C,  which  resulted   in  a  reaction  that  exclusively  
formed  the  methyl-­‐d3  benzylcarbamate  53.  While  it  is  possible  that  the  benzylamine  50  forms  
in  this  reaction  and  then  is  more  fully  converted  to  the  carbamate  at  the  higher  temperature,  
it  is  more  likely  that  direct  nucleophilic  attack  by  methoxide  results  in  this  change  in  product  
profile  (scheme  30).    
Based  on  these  findings  we  decided  to  progress  assessing  all  these  systems  under  the  more  
mild  aqueous  conditions  that  would  be  required  should  this  chemistry  be  conducted  on  the  










Figure  57:  Comparison  of  1H  NMR  spectra  for;  1-­‐  external  propargyl  carbamate  49  in  CD3OD,  
2-­‐  Pd  catalysed  cleavage  of  the  external  propargyl  carbamate  49  in  presence  of  potassium  





Scheme  30:  Direct  methoxide  attack  to  provide  methyl-­‐d3  benzylcarbamate  53.  
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In  order  to  address  this,  we  prepared  water  soluble  molecules  63,  67,  71  and  75  in  three  steps  
(scheme  31).  The  commercially  available  allyl  and  propargyl  molecules  58,  64,  68  and  72  were  
treated  with  carbonyldiimidazole  (CDI)  59  to  offer  the  amine-­‐reactive  imidazolide  derivatives  
60,  65,  69  and  73.227  The  commercially  available  N-­‐Boc-­‐ethylenediamine  61  was  added  to  the  
imidazolide  to  offer  the  carbamate  derivatives  62,  66,  70  and  74  in  good  yields.228  This  was  
followed  by  Boc  deprotection  under  acidic  conditions  to  offer  the  final  water  soluble  model  
linker  molecules  63,  67,  71  and  75.229  These  water-­‐soluble  carbamate  derivatives  were  mixed  
with  K2CO3  in  D2O  for  24  hours  to  test  their  stability.    Unfortunately,  the  propargyl  carbamates  
71  and  75  were  not  stable  and  given  we  already  had  concerns  about  the  aqueous  solubility  of  
allyl  Pd  (II)  chloride  dimer  we  conducted  no  further  work  on  this  linker  system.    
In  contrast,  the  allyl  carbamates  63  and  67  were  stable  in  the  basic  conditions,  however  they  
did  not  cleave  when  the  reaction  was  carried  out  in  D2O  in  the  presence  of  Pd(PPh3)4  catalyst.  
That  was   unsurprising   as   the   Pd(PPh3)4   has   poor   aqueous   solubility   and   previous   reports  
mention  the  importance  of  the  nucleophile  in  the  deallylation  reaction,  which  is  likely  to  be  




Scheme  31:  The  synthesis  of  water-­‐soluble  allyl  and  propargyl  carbamates  63,  67,  71  and  75  
as  water  soluble  model  linkers.  
  
To  optimise  the  deallylation  reaction  in  the  aqueous  conditions,  we  carried  out  the  reaction  
with  a  water  soluble  Pd  species  in  the  presence  of  an  external  nucleophile  (scheme  32).  We  
were  encouraged  by  literature  demonstrating  that  combining  the  electron-­‐deficient  water-­‐
soluble  phosphine  o-­‐DANPHOS  with  the  barbituric  acid  anion  76   (pKa  4)  as  a  water-­‐soluble  
soft  nucleophile  resulted  in  efficient  uncaging  of  allyl  species  in  aqueous  conditions,  where  it  
was  found  that  the  carbon  based  nucleophilic  dimethylbarbituric  acid  with  PBS  provided  90%  
cleavage  of  the  allyl  carbamate  when  used  with  the  o-­‐DANPHOS-­‐derived  Pd  catalyst.209  The  
electron-­‐deficient   ligand   is   thought   to   provide   the   catalytically   active   coordinatively  
unsaturated   Pd   species   Pd0L4-­‐n,   whereas   more   electron-­‐rich   ligands   stabilise   the  
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CH2Cl2, 30 °C, 72 h
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Scheme  32:  Pd-­‐o-­‐DANPHOS  complex  catalysed  cleavage  of  the  allyl  carbamates  63  and  67  in  
the  presence  of  the  external  nucleophile  (barbituric  acid  anion)  76.  
This   system   proved   to   offer   superior   reactivity   to   our   previous   efforts   in   non-­‐aqueous  
conditions,  with   allyl   carbamates  63   and  67   successfully   cleaved  within   2   hours.   The   allyl  
carbamates  63  successfully  cleaved  to  form  a  clearly  defined  mixture  of  reaction  products  78  
and  79.   This  was   confirmed  by   1H  NMR,  which   showed  shift  of   the  CH2-­‐CH=CH-­‐CH3  allylic  
protons  from  4.50  ppm  to  2.90  ppm  and  the  NH2-­‐CH2-­‐CH2-­‐NHCO2  protons  next  to  carbamate  
from  3.1  ppm  to  3.3  ppm  (figure  58).  Mass  spectrometry  showed  the  presence  of  the  1,3-­‐
dimethylbarbituric  allyl  molecule  79  when  its  acidic  CH  proton  is  exchanged  with  deuterium.  
This  demonstrates  the  complexity  of  using  aqueous  NMR  to  monitor  these  reactions,  as  the  
chemical   shifts   of   the   NH2-­‐CH2   environments   in   both   starting   material   and   product   are  
influenced   by   ionisation   of   the   amine.   In   the   case   of   the   ethylene   diamine   product   we  
anticipate  these  peaks  will  be  especially  as  the  second  pKa  of  this  molecule  is  7.5,  meaning  
small  pH  changes  around  the  initial  pH  of  7.4  are  likely  to  significantly  impact  on  ionisation.  
To   confirm   the   desired   product   had   formed   we   added  more   ethylenediamine   78   to   the  
reaction   after   cleavage   completion,   this   presumably   raises   the   pH/reduces   ionisation  
H2N NH2
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resulting  in  the  ethylenediamine  4  protons  at  3.3  ppm  shifting  into  2.75  ppm,  however  no  
new  signals  were  observed  (figure  58).  
  
  
Figure  58:  Comparison  of  1H  NMR  spectra  for;  1-­‐  allyl  carbamate  63  in  PBS,  2-­‐  
ethylenediamine  78  cleavage  product  in  PBS,  3-­‐  Pd-­‐o-­‐DANPHOS  catalysed  cleavage  of  the  
allyl  carbamate  63  In  presence  of  barbituric  acid  anion  76  in  PBS,  4-­‐  Pd-­‐o-­‐DANPHOS  
catalysed  cleavage  of  the  allyl  carbamate  63  In  presence  of  barbituric  acid  anion  76  in  PBS  



































To  confirm  that  allyl  cleavage  was  due  to  the  Pd  catalyst  control  reactions  were  performed  
(table  14).  The  o-­‐DANPHOS-­‐derived  Pd  catalyst  provided  45%  cleavage  of  the  allyl  carbamate  
63   in   the  absence  of   the  dimethylbarbituric  acid  76,  however   in   the  absence  of   the  Pd-­‐o-­‐
DANPHOS   no   cleavage   was   observed.   We   are   therefore   satisfied   that   these   cleavage  
conditions  should  be  suitable  for  use  in  the  solid  phase  system.    
  
O-­‐DANPHOS  (0.4  equiv.)   Dimethylbarbituric  acid  76  (1  equiv.)   Time   Cleavage  %  
A   X   X   2  H   100%  
B   X  
  
2  H   45%  
C  
  
X   2  H   0  
D  
     
2  H   0  
  
Table  14:  Different  reaction  condition  for  deallylation  of  63.  
  
2.3  Second  generation  solid  phase  alkylation  agent  system  with  allyl  
carbamate  as  a  cleavable  linker  
With  the  allyl  carbamate  linker  in  hand,  we  turned  our  attention  to  immobilisation  onto  the  
solid  support.  To  avoid  the  issues  with  agarose  stability  under  the  CuAAC  chemistry  conditions  
which  we  faced  during  the  immobilisation  of  the  allyl  ester  linker  onto  the  aldehyde-­‐modified  
agarose  gel,  the  NHS-­‐activated  agarose  was  selected  to  provide  the  activated  solid  support  
for  the  alkylation   linker.  The  NHS-­‐activated  agarose  provides  a   long  spacer  arm  that  could  
help   in  simplifying  the  synthesis  of  the  alkylation   linker,  as  the  long  chain   linker   is  hard  to  
purify   and   this   long   spacer   arm   is   expected   to   be   necessary   to   allow   sufficient   reactivity  
between  the  protein  and  agarose.    
  
 118 
The  NHS-­‐activated  agarose   is  an  amine-­‐reactive  solid  support  that  can  be  used  for  a  rapid  
immobilisation   of   species   containing   a   primary   or   secondary   amines   in   a   simple   one-­‐step  
reaction  to  form  a  chemically  stable  amide  linkage.  Given  the  unreacted  primary  amine  can  
be  detected  by  several  primary  amine  detection  assays,  we  anticipated  that  we  should  be  
able  to  detect  the  concentration  of  the  unreacted  linker  without  needing  to  the  fluorophore  
model   system  previously   used.   The   alkylation   linker  was   redesigned   to   include   a   primary  
amine   to   immobilise   onto   the   NHS-­‐activated   agarose,   retaining   the   allyl   carbamate   as   a  
cleavable  group.  The  chloroacetamide  was   included  as   the   thiol   alkylation  agent,  with  no  
secondary  functionality  in  the  model  system  (figure  59).  
  




Several  assays  can  be  used  to  detect  the  free  primary  amine  in  order  to  estimate  the  coupling  
efficiency.   The   fluorescamine   assay   can   be   used   for   quantitative   and   qualitative   primary  
amine   detection   as   fluorescamine   is   a   powerful   fluorogenic   reagent   that   generates   a    
fluorescent   product   when   reacted   with   primary   amino   compounds.230   At   basic   pH,  
fluorescamine  reacts  stoichiometrically  with  primary  amines  at  room  temperature  within  a  
fraction  of  a  second  to  give  fluorophores  which  are  stable  for  several  hours,231  The  excess  of  
the   reagents   is   hydrolysed   in   few   seconds   to   give   non-­‐fluorescent   products,   therefore    
concentration  of  primary  amine  is  proportional  to  the  resulting  fluorescence.231  This  negates  












following  incubation  with  the  NHS-­‐activated  agarose  can  be  treated  with  fluorescamine,  with  
the   emission   at   479   nm  proportional   to   the   amount   of   the   unreacted   amine   based   on   a  
standard  curve  generated  with  the  amine  sample  used  in  the  reaction  (scheme  33).  
  
  
Scheme  33:  Analysis  of  the  immobilised  alkylation  linker  onto  agarose  by  fluorescamine  
detection  of  unreacted  amine.  
2.3.1  Synthesis  of  the  alkylation  linker  with  allyl  carbamate    
The  alkylation   linker  80  was  prepared   in  5   steps  by  using   compound  6   that  was  prepared  
before   in   the   alkylation   linker   1   (scheme   34).   Compound   6   was   treated   with  
carbonyldiimidazole  (CDI)  59   in  dichloromethane  at  room  temperature  to  offer  67%  of  the  
amine-­‐reactive  imidazolide  81  as  confirmed  by  mass  spectrometry,  13C  NMR  and  1H  NMR.227  
Then,  the  commercially  available  N-­‐Boc-­‐ethylenediamine  61  was  added  to  the  imidazole  81  
in  dichloromethane  at   room  temperature   to   offer   compound  82   in  86%  yield.228  This  was  















































Scheme  34:  Synthesis  of  the  alkylation  linker  with  allyl  carbamate  80.  
 
  
The  next  step  was  the  preparation  of  the  chloroacetamide,  which  was  achieved    by  treatment  
of   compound   83   with   the   commercially   available   chloroacetyl   chloride   (ClCH2COCl)   in  
dichloromethane  in  the  presence  of  triethylamine  for  24  hours  to  provide  compound  84  in  
45%  yield.232  The  final  step  in  the  synthesis  of  the  alkylation  linker  80  was  the  azide  reduction  
to  primary  amine.    This  could  not  be  achieved  by  hydrogenation  due  to  the  high  reactivity  of  
the  alkene  and  chloride  under  these  conditions,  and  we  were  also  concerned  about  potential  
reactivity  of  the  chloride  using  typical  Staudinger-­‐type  azide  reduction  conditions.  Therefore,  
compound  84  was  treated  with  tin  chloride  (SnCl2)  in  methanol  at  room  temperature  for  24  
hours  to  offer  the  final  alkylation  linker  80,  IR  confirmed  the  disappearance  of  azide  group  at  
2100  cm-­‐1.233  However,  after  purification  very  low  yield  (18%)  was  obtained  and  it  was  not  
complete  pure.    
In  order  to  facilitate  the  purification  of  the  alkylation  linker  80  by  silica  chromatography,  the  










































CH2Cl2, 12 h, RT, 86%
CH2Cl2, (-50 °C, RT)







CH2Cl2, 12 h, RT, 67%
 121 
alkylation  linker  80  again  (scheme  35).234,235  However,  1H  NMR  showed  similar  impurities  in  
the  alkylation  linker  80  in  compound  85.  Therefore,  we  tried  to  reduce  the  azide  by  using  iron  
instead  of  tin  chloride  using  a  model  azide  compound  39  to  preserve  our  supply  of  compound  
84   (scheme   36).   However,   when   compound   39   was   treated  with   iron   in   the   presence   of  
hydrogen   chloride   in   ethanol   for   24   hours   at   room   temperature,   no   primary   amine   was  
observed.236    
  





Scheme  36:  Investigation  of  the  efficiency  of  the  iron  to  reduce  azide  39.236  
 
 
In   order   to   optimise   the   synthesis   of   the   alkylation   linker   80,   we   decided   to   change   the  
sequence  of  the  synthesis  pathway,  conducting  the  azide  reduction  in  the  first  step  to  offer  
the  primary  amine  followed  by  amine  protection  reaction,  which  will  add  two  more  steps  but  
allow  to  investigate  more  reduction  conditions  such  as  triphenylphosphine  that  we  can  not  
















































triphenylphosphine   in  THF  and  H2O  at  room  temperature,  after  48  hours  we  obtained  the  
primary  amine  in  very  low  yield.237,238  
  




To  optimise  the  azide  reduction,  a  model  compound  82  was  used  to  investigate  to  preserve  
our  supply  of  starting  material  (scheme  38).  Therefore,  azide  compound  82  was  treated  with  
different  reducing  agents  in  different  conditions  (table  15).  The  mixture  of  tin  chloride  (SnCl2)  
with  thiophenol  (PhSH)  was  the  most  efficient  azide  reduction  condition  trialled,  yielding  82%  
of  primary  amine  92  in  1  hour  at  room  temperature.239,240,241  IR  confirmed  the  disappearance  
of   azide   group   at   2100   cm-­‐1.   In   contrast,   the   using   tin   chloride   (SnCl2)   alone   without  
thiophenol  and  base  provided  low  yield  (22%)  of  primary  amine  92  in  24  hours.  Moreover,  






























































CH2Cl2, 24 h, RT
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 123 
  
Scheme  38:  Model  azide  compound  to  investigate  the  azide  reduction  reaction.  
 
Reducing  agent   Additive   Time   Yield  
PPh3,  THF,  H2O      24  hours   20%  
PPh3,  CH2Cl2,  H2O      24  hours   28%  
PPh3,  CH2Cl2,  H2O   Na2CO3   24  hours   16%  
SnCl2,  CH3OH      24  hours   22%  
SnCl2,  CH3CN   PhSH,  Et3N   1  hour   82%  
  
Table  15:  different  reaction  condition  for  azide  reduction  into  primary  amine.  
 
  
After  finding  an  efficient  conditions  for  the  azide  reduction  reaction,  compound  6  was  mixed  
with  tin  chloride  and  thiophenol  in  acetonitrile  (CH3CN)  at  room  temperature  for  1  hour  to  
yield  72%  of  primary  amine  87.240  The  second  step  in  the  alkylation  linker  80  synthesis  was  
the  protection  of  the  primary  amine  by  Boc  group,   followed  by  addition  of  CDI  59   to  give  
amine-­‐reactive  imidazolide  89  (scheme  37).234,227    
 
The  following  steps  in  the  planned  synthesis  of  the  alkylation  linker  80  were  the  formation  of  
the  carbamate  by  replacing  the  imidazole  of  compound  89  by  the  primary  amine  of  the  mono-­‐
Fmoc  ethylene  diamine  hydrochloride  (Fmoc-­‐EDA.HCl)  followed  by  Fmoc  deprotection  under  
basic   conditions.   Therefore,   the   amine-­‐reactive   imidazolide   89   was   treated   with   the  
commercially   available   Fmoc-­‐EDA.HCl   in   dichloromethane   in   the   presence   of   5   equiv.   of  
triethylamine  at  room  temperature.228  Unfortunately,  imidazole  89  was  apparently  unstable  
in  the  basic  conditions    and  the  Fmoc  group  in  Fmoc-­‐EDA.HCl  was  also  deprotected  to  some  
















and  imidazole.  Therefore,  we  decided  to  decrease  the  amount  of  triethylamine  to  1  equiv.  
instead  of  5  equiv.,  however  no  reaction  occurred  after  24  hours,  therefore  we  added  more  
2   equiv.   triethylamine,   however   once   again   the   Fmoc   group  was   not   stable   and   1H  NMR  
showed  mixtures  of  products.  In  a  final  attempt  to  optimise  the  reaction,  2.8  equiv.  of  N,N-­‐
diisopropylethylamine  (DIPEA)  was  used  instead  of  triethylamine.  Unfortunately,  the  Fmoc  
group   was   deprotected   and   1H   NMR   showed   mixtures   of   products   after   1   hour.   Our  
conclusion  was   that   both   imidazole  89   and  Fmoc-­‐EDA.HCl  are  unstable  under   these  basic  
conditions,  therefore,  we  tried  to  avoid  adding  base  by  neutralizing  the  primary  amine  before  
mixing  with   imidazole  89.   Therefore,   Fmoc-­‐EDA.HCl   in  methanol  was   passed   through   the  
strong  cation  exchange  (SCX)  chromatography  column,  eluting  with  methanolic  ammonia  to  
offer   neutral   Fmoc-­‐EDA.   Following   concentration   this   was   added   to   imidazole   89   in  
dichloromethane   at   room   temperature.   Unfortunately,   there   was   still   evidence   of   Fmoc  
deprotection  even  in  the  absence  of  the  additional  base,  although  it  is  possible  this  occurred  
during  neutralisation.  
We  therefore  decided  to  add  ethylenediamine  directly  followed  by  reaction  with  chloroacetyl  
chloride  without  purification,  which  saved  2  steps  in  the  synthesis  of  the  alkylation  linker  80  
(scheme  39).228   Therefore,   the   imidazole  89  was   treated  with   excess   of   the   commercially  
available  ethylenediamine  (10  equiv.)  in  dichloromethane  at  room  temperature  for  2  hours.  
To  avoid  issues  with  purification  of  the  primary  amine  this  intermediate  was  taken  into  the  
next  step  without  any  purification,  therefore  it  is  treated  with  chloroacetyl  chloride  in  THF  in  
presence   of   triethylamine   for   24   hours   to   offer   compound   85.232   The   final   step   in   the  





Scheme  39:  Optimised  synthesis  of  the  alkylation  linker  80.  
2.3.2  A  model  system  to  investigate  the  immobilisation  and  release  
Ethanolamine  (ETA)  was  used  as  a  simple  water-­‐soluble  primary  amine  in  order  to  investigate  
the   best   conditions   for   the   immobilisation   of   the   primary   amine   onto   the   NHS-­‐activated  
agarose  93   (scheme  40).      The  detection  conditions  were  validated  by   incubating  different  
concentrations  of   the  ethanolamine   in  PBS  with  1  mM  fluorescamine   in  acetonitrile   (1:1).  
Fluorescence   was   directly   proportional   to   the   ethanolamine   concentration   across   a  
concentration   range   from   1   µM   to   125   µM   (figure   60).   To   make   sure   the   fluorescence  
produced  is  due  to  the  reaction  of  the  unreacted  primary  amine  with  fluorescamine  some  
additional   controls   were   undertaken.   No   fluorescence   was   observed   when   N-­‐
hydroxysuccinimide  and  triethylamine  were  treated  with  fluorescamine  (figure  61,  A)  or  when  
the  NHS-­‐activated  agarose  was   incubated  with  PBS  and  then  the  washed  solvents  treated  
with  fluorescamine  (figure  61,  B).        
  
Scheme  40:  Immobilisation  of  ethanolamine  onto  NHS-­‐agarose.  
  
1. Ethylenediamine, CH2Cl2, 2 h, RT
2. ClCH2COCl, Et3N,THF, 24 h, RT
















































Figure  60:  A-­‐  The  florescence  of  the  Ethanolamine  treated  with  fluorescamine;  B-­‐  The  
standard  curve  of  ethanolamine  fluorescence  in  PBS.  
  
Figure  61:  A-­‐  Emission  spectra  of  N-­‐Hydroxysuccinimide  and  triethylamine  treated  with  
fluorescamine;  B-­‐  Emission  spectra  of  the  washed  solvents  of  NHS-­‐agarose  treated  with  
fluorescamine.  
 
To  investigate  the  coupling  time  to  NHS-­‐agarose,  0.25  equiv.  of  ethanolamine  (relative  to  the  
reported  NHS  loading)  in  PBS  was  mixed  with  the  NHS-­‐activated  agarose  for  2  hours  and  24  
hours   at   room   temperature.   Unreacted   amine   was   isolated   by   repeated   washing   until  
fractions   showed   no   amine   content   on   analysis.   The   fluorescence   of   the   unreacted  
ethanolamine  confirmed  that  most  of  the  amine  (82%)  was  immobilised  onto  agarose  after  
just  2  hours  reaction,  while  increasing  the  reaction  time  improved  the  coupling  yield  to  91%  
(table  16).    
  
  
































































4.2   1.1   2   PBS   0.2   0.9   82%  
4.2   1.1   24   PBS   0.1   1.0   91%  
  
Table  16:  Investigation  of  coupling  time  in  the  reaction  between  NHS-­‐agarose  93  and  
ethanolamine.  
  
With   the   loading   and   detection   methods   established,   amine   allyl   carbamate   N-­‐Boc  
ethylenediamine   92   was   used   to   investigate   the   loading   efficiency   of   the   NHS-­‐activated  
agarose  93  with  the  primary  amine  and  the  release  from  the  solid  support  by  Pd  catalysis  in  
aqueous  conditions  (scheme  41).  The  NHS-­‐activated  agarose  93  was  mixed  with  0.25  equiv.  
of   the   amine   allyl   carbamate   N-­‐Boc   92   in   PBS   for   24   hours   at   room   temperature.   The  
fluorescence   of   the   washed   unreacted   amine   confirmed   that   69%   of   the   amine   allyl  
carbamate  N-­‐Boc  was  immobilised  onto  agarose  95  (table  17,  entry  1).  
  
Scheme  41:  The  loading  of  the  NHS-­‐activated  agarose  with  the  model  primary  amine  







































Et3N, RT, 24 h
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Given  the  increased  lipophilicity  of  the  Boc  containing  compound  92  relative  to  ethanolamine  
it   is  possible   the   loading   is   limited  by  poor  aqueous   solubility.   Therefore,   to   optimise   the  
coupling  efficiency,  acetonitrile  was  used  as  the  coupling  solvent.  The  reaction  of  the  NHS-­‐
activated  agarose  93  with  0.25  equiv.  of  the  amine  allyl  carbamate  N-­‐Boc  92  in  acetonitrile  
for  24  hours  at  room  temperature  resulted  in  100%  of  amine  immobilisation  onto  the  agarose  
95  (table  17,  entry  2).  In  addition  to  increased  solubility,  the  improvement  when  the  reaction  
is  carried  out  in  acetonitrile  is  also  likely  to  be  due  to  the  increased  stability  of  the  NHS  ester  
in  non-­‐aqueous  media,  whereas  in  PBS  the  amide  formation  reaction  is  competing  with  the  
hydrolysis  of  the  NHS  ester.  
  














1   20.0   5.0   24  H   PBS   1.6   3.4   69%  
2   20.0   5.0   24  H   CH3CN   0   5.0   100%  
  
Table  17:  The  loading  of  the  NHS-­‐activated  agarose  with  the  model  primary  amine  92  in  
different  coupling  solvent.  
  
  
To  investigate  the  stability  of  the  NHS  ester,  the  NHS-­‐activated  agarose  93  was  mixed  with  
ethanolamine  at  room  temperature  for  24  hours.  The  unreacted  ethanolamine  was  washed  
with  the  coupling  solvent  and  detected,  followed  by  the  addition  of  further  ethanolamine  to  
the  agarose  to  evaluate  the  capacity  for  further  loading  (i.e.  the  presence  of  residual  NHS-­‐
ester).  
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In   the   first   coupling   reaction  between  0.5  equiv.     of  ethanolamine  and   the  NHS-­‐activated  
agarose   93   in   PBS,   47%   of   the   NHS   ester   was   converted   to   the   amide   94   (97%   of   the  
ethanolamine   reacted).   Following   the   second   addition   of   1.0   equiv.   ethanolamine   to   the  
agarose,   just   12%   of   the   ethanolamine   was   coupled   with   the   agarose,   suggesting   the  
remaining  41%  of  the  NHS  ester  93  had  been  hydrolyzed  during  the  initial  incubation  (table  
18,  entry  2).    In  keeping  with  this  result,  when  the  NHS-­‐activated  agarose  93  was  kept  in  PBS  
at   room  temperature   for   24   hours  before  ethanolamine  addition,   the   fluorescence  of   the  
washed   ethanolamine   was   proportional   to   the   amount   of   the   added   ethanolamine   (8.0  





























1   4.2   0   24   PBS   0   0   0   8   8.8   0  
2   4.4   2.1   24   PBS   0.1   2.0   97%   4.2   3.7   0.5  
3   4.2   4.2   24   PBS   2.5   1.7   41%   NA        
4   4.4   8.4   24   PBS   5.3   3.1   71%   4.2   5.9     
5   4.2   1.1   24   CH3CN   0   1.1   100%   4.2   0.1   4.1  
6   4.4   2.1   24   CH3CN   0   2.1   100%   4.2   0.3   3.9  
7   4.4   4.2   24   CH3CN   0   4.2   100%   4.2   0.2   4.0  
8   4.2   4.2   24   CH3CN   0   4.2   100%   4.2   0.4   3.8  
9   4.4   8.4   24   CH3CN   0.5   7.9      4.2   0.4   3.8  
10   4.2   1.1   24   DMF   0.1   1.0   91%   4.2   0.4   3.8  
11   4.4   2.1   24   DMF   0   2.1   100%   4.2   1.0   3.2  
12   4.4   4.2   24   DMF   0.2   4.0   95%   4.2   1.7   2.5  
13   4.4   8.4   24   DMF   1.0   7.4      4.2   1.4   2.8  
  
Table  18:  Investigation  of  the  stability  of  the  NHS  ester  in  different  coupling  solvents.  
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To  optimise  the  coupling  efficiency  in  PBS,  the  ratio  between  the  NHS-­‐activated  agarose  93  
and  the  primary  amine  was  further  investigated.    Therefore,  the  NHS-­‐activated  agarose  93  
was  mixed  with  0.25  equiv.,  0.5  equiv.,  1.0  equiv.    and  2.0  equiv.  of  the  ethanolamine  in  PBS  
at  room  temperature  for  24  hours.    As  expected  the  best  coupling  yield  with  respect  to  the  
NHS  ester  was  obtained  when  the  ethanolamine  was  used  in  excess,  however  the  reaction  
was  more  efficient  at  lower  equiv.  (table  19).    
The   use   of   acetonitrile   or  DMF   as   the   coupling   solvent   optimised   the   coupling   efficiency,  
resulting   in  better   coupling  yield   in   the   first  addition  and  more  coupling  after   the   second  
addition   (table   18,   entry   5-­‐13).   100%   of   the   ethanolamine   was   reacted   when   the   NHS-­‐
activated  agarose  93  mixed  with  0.25  equiv.,  0.5  equiv.    and  1.0  equiv.    of  the  ethanolamine  
in  acetonitrile  (table  18,  entry  5-­‐8),  confirming  the  stability  of  the  NHS  ester  in  the  acetonitrile.  
The  reaction  of  the  NHS-­‐activated  agarose  93  with  0.25  equiv.,  0.5  equiv.    and  1.0  equiv.    of  
ethanolamine   in   DMF   for   24   hours   at   room   temperature   produced   91%,   100%   and   95%  

















4.2   1.1   24   PBS   0.1   1.0   91%  
4.4   2.1   24   PBS   0.1   2.0   95%  
4.2   4.2   24   PBS   2.5   1.7   40%  
4.4   8.4   24   PBS   5.3   3.1   70%  
  
Table  19:  Investigation  of  the  ratio  between  the  NHS-­‐activated  agarose  93  and  the  primary  
amine  to  optimise  the  coupling  reaction.  
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However,   the   fluorescence   of   the   unreacted   ethanolamine   after   the   second   addition   in  
acetonitrile  and  DMF  was   less  than  expected  based  on  the   initial  agarose   loading;  e.g.  1.1  
µmole  ethanolamine  mixed  with  4.2  µmole  NHS-­‐activated  agarose  resulted  in  all  1.1  µmole  
ethanolamine  coupling  with  26%  of   the  agarose-­‐NHS  sites  via   amide   linkage,   to   leave  3.1  
µmole  of  the  NHS  ester  free.  When  another  4.2  µmole  ethanolamine  was  added  to  this  3.1  
µmole  NHS  ester,  surprisingly  just  0.1  µmole  ethanolamine  was  washed  following  the  second  
addition  (table  18,  entry  5-­‐13).  Moreover,  when  the  NHS-­‐activated  agarose  was  mixed  with  
excess   of   ethanolamine   in   acetonitrile   or   DMF   in   the   first   addition,   the   recovery   of   the  
unreacted  ethanolamine  is  less  than  the  expected  (table  18,  entry  9  and  13).    
We  were  concerned  that  the  difference  between  solvents  may  be  partly  driven  by  differences  
in  their  ability  to  ‘swell’  the  agarose  particles,  resulting  in  ineffective  washing  of  the  amine  
when  using  organic  solvents.  To  examine  this  unactivated  agarose  was  used  to  investigate  the  
reactivity/affinity  of  ethanolamine  toward  the  agarose  itself  in  these  solvents,  to  explain  the  
apparent  overloading  of  the  NHS-­‐activated  agarose.  The  unactivated  agarose  was  mixed  with  
different   concentrations   of   the   ethanolamine   in   the   different   coupling   solutions   at   room  
temperature   for   24   hours,   then   the   unreacted   ethanolamine   washed   with   the   coupling  
solvent  and  treated  with  fluorescamine.  The  fluorescence  of  the  washed  ethanolamine  was  
proportional  to  the  amount  of  the  added  ethanolamine  when  the  reaction  was  occurred  in  
PBS  (table  20,  entry  1-­‐3).  While  4%  of  the  ethanolamine  was  lost  at  higher  concentration,  this  
is   probably   due   to   measurement   and   dilution   errors   (table   20,   entry   1).   However,   the  
concentration  of  the  washed  ethanolamine  in  the  acetonitrile  and  DMF  is  significantly  less  
than  expected,  with  more  than  20%  of  the  ethanolamine  lost.  While  this  may  be  explained  by  
the   lower   solubility  of   the  ethanolamine   in   these  aprotic   solvents,   it   is  most   likely  due   to  
changes   in   the   structure  of   the  agarose  beads   (which   swell   less   in  non-­‐aqueous   solvents)  
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and/or  the  inability  of  the  solvents  to  out-­‐compete  the  hydrogen  bonding  of  ethanolamine  to  
the  agarose  (table  20,  entry  4-­‐9).  
  
   ETA  (µmole)   Coupling  solution   Washed  ETA  (µmole)   lost  ETA  (µmole)  
1   8.4   PBS   8.1   0.3  
2   4.2   PBS   4.6     
3   2.1   PBS   2.1   0  
4   8.4   CH3CN   6.8   1.6  
5   4.2   CH3CN   2.9   1.3  
6   2.1   CH3CN   1.2   0.9  
7   8.4   DMF   6.1   2.3  
8   4.2   DMF   2.6   1.6  
9   2.1   DMF   1.2   0.9  
  
Table  20:  Reactivity  of  ethanolamine  toward  inactivated  agarose  in  different  coupling  
solvents.  
 
Given  the  best  coupling  was  obtained  when  the  reaction  was  carried  in  acetonitrile  due  to  
stability   of   the  NHS   ester   under  more   anhydrous   conditions,   the   issue   of   poor   elution   of  
unreacted   amine   could   be   solved   by   conducting   the   immobilisation   in   acetonitrile   then  
washing  the  unreacted  amine  using  PBS.  The  NHS-­‐activated  agarose  93  was  mixed  with  the  
amine  allyl  carbamate  N-­‐Boc  92  in  acetonitrile  or  DMF  at  room  temperature  for  24  hours  then  
the  unreacted  amine  92  was  washed  with  the  coupling  solvents  followed  by  PBS.  The  using  
amine   in  excess   resulted   in  100%   immobilisation  95   (based  on  NHS)  when   the   reaction   is  
carried  in  acetonitrile  and  88%  immobilisation  in  DMF  (table  18,  entry  2  and  3),  while  using  1  
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equiv.  of   the  amine  allyl  carbamate  N-­‐Boc  92   in  acetonitrile  produced  64%  immobilisation  
onto  the  agarose  95  (table  21,  entry  1).  
  
















1   4.0   3.9   24   CH3CN   1.4   2.5   64%  
2   4.0   8.0   24   CH3CN   3.9   4.1   100%  
3   4.0   5.6   24   DMF   2.1   3.5   88%  
  
Table  21:  Investigation  of  acetonitrile  and  dimethylformamide  in  the  coupling  of  primary  
amine  92  with  NHS-­‐agarose  93,  with  unreacted  amine  washed  with  PBS.  
  
After   Optimisation   of   the   loading   of   the   agarose   with   primary   amines,   we   turned   our  
attention   to   the   release   from   agarose.   A   simple   water-­‐soluble   molecule   (amine   allyl  
carbamate   ethanolamine   98)   was   prepared   (scheme   42)   and   used   as   a  model   system   to  
investigate  the  immobilisation  onto  the  NHS-­‐activated  agarose  93  and  the  release  from  the  




Scheme  42:  Synthesis  of  the  simple  water-­‐soluble  molecule  (amine  allyl  carbamate  
ethanolamine  98).  
  
Scheme  43:  A  model  system  to  investigate  the  immobilisation  onto  the  NHS-­‐activated  
agarose  93  and  the  release  from  the  solid  support  by  Pd  catalysis.  
 
 
The  NHS-­‐activated  agarose  93  was  mixed  with  0.25  equiv.  of  the  amine  98   in  PBS  at  room  
temperature  for  24  hours.  The  unreacted  amine  98  was  washed  away,  and  any  unreacted  
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complex   in   PBS   was   added   to   the   allyl   carbamate   agarose   99   in   the   presence   of   the  
dimethylbarbaturic  acid  76  to  release  the  primary  amine  (ethanolamine),  which  was  detected  
by  fluorescamine.  The  fluorescence  of  the  released  ethanolamine  after  the  treatment  with  5  
mol%  of  the  Pd-­‐o-­‐DANPHOS  complex  shows  that  only  15%  of  the  amine  had  been  recovered.  
Adding  more  Pd-­‐o-­‐DANPHOS  complex  results  in  release  more  amine  to  improve  the  cleavage  
to  17%  (based  on  amine  recovery,  table  22,  entry  1).  When  10  mol%  Pd-­‐o-­‐DANPHOS  complex  
was  added  directly  to  the  amine  allyl  carbamate  N-­‐Boc  ethylenediamine   immobilised  onto  
the   agarose   95,   23%   of   the   N-­‐Boc   ethylenediamine   96   was   released   (table   22,   entry   2).  
Increasing  the  Pd(0)  to  100  mol%  resulted  in  improvement,  leading  to  recovery  of  30%  of  the  



























1   23   5.8   24   PBS   22   3.5   61%   10  mol%   0.6   17%  
2   4.0   5.6   24   DMF   2.1   3.5   63%   10  mol%   0.8   23%  
3   20.0   15.0   24   PBS   3.6   11.4   76%   100  mol%   3.5   30%  
  
Table  22:Pd  catalysed  de-­‐allylation  in  aqueous  conditions.  
  
To  ensure  the  resulting  cleavage  is  due  to  Pd  catalysed  deallylation  rather  than  hydrolysis,  the  
amine  allyl  carbamate  N-­‐Boc  ethylenediamine  immobilised  onto  the  agarose  95  was  treated  
with  all   cleavage   reagents  without  Pd.  After  24   hours,  washed  with  PBS  and   treated  with  




Figure  62:  A-­‐Fluorescence  spectrum  of  the  released  amine  by  Pd  catalysis;  B-­‐  Fluorescence  
spectrum  of  the  control  cleavage  reaction  without  Pd.  
 
  
The  low  cleavage  yield  could  be  due  to  the  detection  method,  for  example  it  is  possible  the  
Pd  complex  quenches  the  fluorescence.  To  investigate  the  effect  of  the  Pd  complex  on  the  
fluorescence   of   the   primary   amine,   ethanolamine  was   treated  with   fluorescamine   in   the  
presence  and  absence  of  the  Pd  complex,  each  one  repeated  three  times  to  minimise  error  
(figure  63).  100  µM  ethanolamine  was  treated  with  1  mM  fluorescamine  then  the  emission  
@  479  was  measured  to  give  a  fluorescence  reading  of  1244  (100%)  (table  23,  entry  1).  The  
presence   of   the   Pd-­‐o-­‐DANPHOS   complex   and   dimethylbarbituric   acid   76   reduced   the  
fluorescence  to  70%  of  the  expected  level  (table  23,  entry  3),  while  the  presence  of  the  Pd  
without  the  phosphine  ligand  and  dimethylbarbituric  acid  76  caused  greater  reduction  in  the  
fluorescence  to  44%  (table  23,  entry  4).  The  phosphine  ligand  and  dimethylbarbituric  acid  76  
did  not  affect  the  fluorescence  (table  23,  entry  5  and  6).  It  is  clear  that  the  Pd  species  used  to  
cleave  the  linker  can  quench  the  reactivity  and/or  fluorescence  in  the  fluorescamine  assay,  
therefore,  the  cleavage  in  the  previous  model  system  is  likely  to  be  higher  than  suggested  by  





























































Figure  63:  Investigation  of  the  effect  of  the  Pd  complex  on  the  fluorescence  of  the  primary  
amine,  (amine  1,  amine  2  and  amine  3  are  ETA  ,repeated  three  times).  
  
Table  23:  Investigation  of  the  effect  of  the  Pd  complex  on  the  fluorescence  of  the  primary  
amine.  
 
To   solve   this   quenching   issue,   any   Pd  would   ideally   be   removed   from   the   system  before  
treating  with  fluorescamine,  or  otherwise  an  alternative  detection  method  used  that  is  not  






















amine1 ,Pd,o-DAN,Ba and FLURAM
amine 1,Pd-o-DAN,Ba and FLURAM
amine 1,Pd, and FLURAM
amine 1,Pd-o-DAN and FLURAM
amine 1,Pd,Ba and FLURAM
amine 2+fluram
amine 2,Pd,o-DAN,Ba and FLURAM
amine 2 ,Pd-o-DAN,Ba and FLURAM
amine 2,Pd, and FLURAM
amine 2,Pd-o-DAN and FLURAM
















amine1 ,Pd,o-DAN,Ba and FLURAM
amine 1,Pd-o-DAN,Ba and FLURAM
amine 1,Pd, and FLURAM
amine 1,o-DAN and FLURAM
amine 1,Ba and FLURAM
amine 1,Pd-o-DAN and FLURAM
amine 1,Pd,Ba and FLURAM





ETA Pd(0) o*DANPHOSE DMBA Pd*o*DAN FLURAM Flourescence Flourescence Flourescence Average
1 x x 1275 1226 1230 1243.66667
2 x x x x x 905 864 926 898.333333
3 x x x x 866 840 903 869.666667
4 x x x 487 595 563 548.333333
5 x x x 1179 1267 1347 1264.33333
6 x x x 1139 1222 1278 1213
7 x x x 800 770 988 852.666667
8 x x x x 513 499 583 531.666667
9 x x x x 1158 1239 1287 1228
10 x x x 6 10 12 9.33333333
11 x -1 -1 -2 -1.3333333
12 x x 5 3 3 3.66666667
13 x x x 2 1 3 2
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alkylation  which  will  allow;  1)  separation  of  protein  products  from  the  cleavage  reagents  by  
size  exclusion  chromatography  and/or  dialysis  and  2)   detection  by  e.g.  direct  UV  analysis,  
HPLC,  and  protein  quantification  methods  such  as  BCA.  
  
2.3.3  The  solid-­‐phase  thiol  alkylation  linker  
After   finding   the   best   immobilisation   and   release   conditions,   we   turned   our   efforts   to  
immobilisation  of  the  thiol  alkylation  linker  80  onto  the  solid  support  and  evaluate  the  use  of  
catch-­‐release   methodology   to   selectively   alkylate   cysteine.   The   alkylation   linker   80   was  
synthesised  as  a  salt,  which  is  insoluble  in  acetonitrile  even  after  addition  of  the  triethylamine,  
therefore  PBS  was  used  as  the  coupling  solution.  The  NHS-­‐activated  agarose  93  was  mixed  
with  the  thiol  alkylation  linker  80  in  PBS  for  24  hours  at  room  temperature  (scheme  44).  The  
fluorescence  of  the  unreacted  alkylation  linker  80  confirmed  that  84%  of  agarose  was  loaded  
with  alkylation  linker  when  1.0  equiv.  had  been  added,  while  the  loading  was  77%  (based  on  
amine)  when  0.4  equiv.  was  added  (table  24).  While  the  aqueous  conditions  are  likely  to  have  
hydrolysed  any  ‘unreacted’  NHS  ester  93  was  blocked  with  1M  ethanolamine,  to  avoid  the  
risk  of  side  reactions  this  was  still  blocked  by  reaction  with  ethanolamine  before  the  next  
alkylation  step.  
  






















































1   17.6   35.2   (1:2)   22.8   12.4   72%  
2   42   42   (1:1)   6.7   35.3   84%  
3   21   8.5   (1:0.4)   1.9   6.6   77%  
  
Table  24:  Immobilisation  of  the  thiol  alkylation  linker  80  onto  the  NHS-­‐Agarose  93.  
 
2.3.4  Cysteine  thiol  alkylation  
After  successfully  preparing  the  novel  solid  phase  thiol  alkylation  system  100,  we  turned  our  
attention  to  investigating  the  thiol  alkylation  agents  and  comparing  between  the  selectivity  
of  the  alkylation  agents  (chloroacetamide  and  iodoacetamide)  toward  thiols.  Therefore,  the  
solid   phase   iodoacetamide   linker   101   was   prepared   by   incubating   the   solid   phase  
chloroacetamide   linker   100  with   excess   of   sodium   iodide   in   PBS   for   24   hours   at   room  
temperature  (scheme  45).    The  standard  protein  (BSA)  was  used  to  investigate  these  novel  
solid  phase  thiol  alkylation  systems  100  and  101   in  combination  with  a  second  solid  phase  
reducing   agent   (the   solid   phase   TCEP)   to   allow   the   direct   reduction   and   alkylation   of   the  
protein,  then  the  release  of  the  alkylated  protein  investigated  using  catalytic  Pd  (scheme  45).    
BSA  is  an  ideal  model  system  as  it  contains  a  single  reactive  surface  cysteine,  and  there  is  a  
wealth  of  literature  using  this  protein  as  a  model  for  novel  cysteine  alkylation  reactions.  The  
methods  selected  to  detect  the  unreacted  protein  were  the  established  fluorescamine  assay,  
as  well  as  the  bicinchoninic  acid  (BCA)  assay  and  HPLC.243,244  
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Scheme  45:  Catch-­‐release  methodology  to  selectively  alkylate  cysteine.  
 
The  fluorescamine  assay  was  initially  used  to  detect  the  primary  amine  of  the  BSA  based  on  
the  standard  curve  generated  with  BSA  sample  used  in  the  reaction,  while  the  bicinchoninic  
acid  (BCA)  assay  was  used  to  detect  total  protein  in  the  solution.245    245    The  BCA    solution  is  
an  alkaline  solution  consisting  of  bicinchoninic  acid,  sodium  carbonate,  sodium  bicarbonate,  
sodium   tartrate     and   copper   (II)   sulfate   pentahydrate.245   The   BCA   assay   is   based   on   the  
formation   of   a   strong   complex   between   Cu+   and   BCA   to   forms   a   species   with   a   strong  
chromophore.246  The   reduction  of   the  Cu2+  ions   to  Cu+  can  occur  by  oxidation  of   cysteine,  

























































































Cu2+  ions   can   also   be   reduced   to   Cu+  by   binding   of   the   Cu2+  ions  with   the   nitrogen   atoms  
present   in   the  peptide  bonds   in   the  protein,   resulting   in   reduction  of   the  Cu2+  ions   to  Cu+  
(Biuret   test)   which   is   temperature   dependent   reaction.246   The   Cu+  ions   formed   by   these  
processes  are  chelated  by  two  molecules  of  bicinchoninic  acid  to  provide  a  purple  coloured  
complex  that  strongly  absorbs  light  at  562  nm  (figure  64).245  The  concentration  of  protein  is  
proportional   to   the  absorbance  at   562  nm  based  on  a   standard  curve  generated  with   the  
protein   sample   used   in   the   reaction.   The   reversed   phase   high   performance   liquid  
chromatography  (RP-­‐HPLC)  with  UV  detector  was  used  to  analyse  the  total  amount  of  protein  
in   the   solution  based  on  a   standard  curve  generated  with   the  protein   sample  used   in   the  
reaction  using  absorbance  at  280  nm  to  directly  detect  the  protein  concentration.247,248,249  
  
Figure  64:  The  bicinchoninic  acid  (BCA)  assay  to  detect  total  protein  in  the  solution.245  
  
2.3.4.1  BSA  alkylation  in  the  solution  phase  
In  order  to  investigate  the  ability  of  the  iodoacetamide  to  alkylate  BSA  in  the  solution  phase  
a  simple  thiol  alkylation  agent  105  was  prepared  (scheme  46)  and  incubated  with  BSA  for  24  
hours  at  room  temperature  in  the  presence  of  the  solid  phase  TCEP  (scheme  46).  Ellman’s  
reagent   (5,5'-­‐dithio-­‐bis-­‐[2-­‐nitrobenzoic   acid]   or   DTNB)  was   used   to   analyse   the   alkylation  













Cu+1Protein  +   Cu+2 Cu+1
2 BCA- OH
BCA-Cu+1 Complex
      Purple colour
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that  absorbs  light  at  412  nm  (scheme  47).252,253    Ellman’s  reaction  confirmed  about  50%  of  
the  protein  has  been  alkylated  106  by  comparing  with  concentration  of  control  BSA  (figure  
65).  HPLC  appeared  to  show  a  mixture  of  BSA  and  alkylated  BSA  106  (figure  66),  suggesting  
that   the   alkylated   products  may   be   directly   distinguished   from   unreacted   BSA   using   this  
technique,   however   further  mass   spectrometry   studies  would   be   required   to   confirm   the  
site(s)  of  reaction.  
  
  
Scheme  46:  Synthesis  of  the  N-­‐Boc  ethylenediamine  iodoacetamide  105  and  BSA  alkylation  




























































































BSA and Ellman's reagent
Control BSA





Figure  66:  HPLC  of  the  BSA  alkylation  in  the  solution  phase  (Top:  control  with  no  BSA.  
Middle:  BSA  alone.  Bottom:  alkylated  mixture).  
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2.3.4.2  BSA  alkylation  in  the  solid  phase  
Before   investigating  the  alkylation  of  BSA  with  the  solid  phase  alkylation  system,  we  were  
interested   to   investigate   if   there   is   any   reactivity   or   affinity   between   BSA   and   agarose.  
Therefore,  the  unactivated  agarose  was  mixed  with  different  concentrations  of  the  BSA  in  PBS  
at  room  temperature  for  24  hours,  then  the  unreacted  BSA  washed  with  PBS  and  detected.  
The   fluorescamine  assay,  BCA  assay  and  RP-­‐HPLC  confirmed   that   the  washed  protein  was  
effectively  equiv.  to  the  amount  of  added  protein  (table  25).  To  investigate  if  there  was  any  
reactivity  between  BSA  and  the  solid  phase  TCEP,  BSA  was  mixed  with  the  solid  phase  TCEP  
in  PBS  at  room  temperature  for  24  hours.    The  fluorescamine  assay,  BCA  assay  and  RP-­‐HPLC  
confirmed  that  the  washed  protein  was  again  effectively  equiv.  to  the  amount  of  the  added  
protein  (table  25).  
  
   0.40  µmole  
BSA  +  control  
agarose  
0.20  µmole  
BSA  +  control  
agarose  
0.10  µmole  
BSA  +  control  
agarose  
0.05  µmole  
BSA  +  control  
agarose  
0.02  µmole  
BSA  +  control  
agarose  





BSA  +  solid  
phase  TCEP  
Fluorescamine   0.43  µmole   0.21  µmole   0.07  µmole   0.03  µmole   0.02  µmole   0.01  µmole   0.12  µmole  
BCA   0.37  µmole   0.20  µmole   0.11  µmole   0.05  µmole   0.02  µmole   0.01  µmole   0.11  µmole  
RH-­‐HPLC   0.42  µmole   0.21  µmole   0.10  µmole   0.05  µmole   0.02  µmole   0.01  µmole   0.08  µmole  
  
Table  25:  BSA  affinity  toward  Agarose  and  TCEP  immobilised  onto  agarose  analysed  by  
fluorescamine,  BCA  and  HPLC.  
  
In  order  to  investigate  the  utility  of  our  catch-­‐release  system,  BSA  was  incubated  with  the  
solid   phase   alkylation   linker   (100   or   101)   for   24   hours   at   room   temperature,   then   the  
unreacted   protein   washed   with   PBS   and   detected.   The   fluorescamine   detection   of   the  
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unreacted   protein   showed   that   65%   of   protein   was   immobilised   when   the   solid   phase  
chloroacetamide  100  was  used  in  combination  with  TCEP  immobilised  onto  agarose  (figure  
67)   with   the   RP-­‐HPLC   confirming   that   66%   of   the   protein   had   been   lost   (figure   67).   The  
replacement  of  chloroacetamide  100  by  iodoacetamide  101  improved  the  alkylation  yield  to  
93%  according  to  fluorescence  of  the  unreacted  protein  and  92%  according  to  the  BCA  assay.    
However,  the  RP-­‐HPLC  suggested  a  lower  loading,  with  80%  of  the  BSA  reacted  (figure  67).    
  
Figure  67:  Percentage  of  unreacted  BSA  after  the  solid  phase  alkylation  analyzed  by  
fluorescamine,  BCA  and  RP-­‐HPLC.  A:  solid  phase  alkylation  101  without  reducing  agent,  B:  
solid  phase  alkylation  101  in  the  presence  of  TCEP-­‐agarose,  C:  solid  phase  alkylation  100  in  
the  presence  of  TCEP-­‐agarose  and  D:  TCEP-­‐agarose  used  to  reduce  the  disulfide  bond  of  the  





















To  investigate  the  importance  of  keeping  the  reducing  agent  in  the  system,  BSA  was  incubated  
with  the  solid  phase  iodoacetamide  linker  101  for  24  hours  at  room  temperature  with  and  
without  TCEP  immobilised  onto  agarose.  The  fluorescamine  detection  of  the  washed  protein  
suggested  no  reaction  occurred  in  the  absence  of  the  reducing  agent  (figure  67),  with  the  BCA  
assay  and  RP-­‐HPLC  confirming  the  lack  of  reaction,  presumably  as  a  result  of  the  BSA  thiol  
being  oxidised  (figure  67).  This  strongly  suggests  that  the  alkylation  is  specific  for  the  cysteine  
as   any   non-­‐specific   immobilisation   through,   for   example,   amine   alkylation   would   not   be  
dependent  on  TCEP.  
When  the  TCEP  was  used  to  reduce  the  disulfide  bond  of  the  BSA  then  removed  from  the  
system   immediately   before   the   alkylation   step,   about   half   of   the   BSA   thiol   was   loaded,  
suggesting  that  re-­‐oxidation  of  the  BSA  thiol  competes  with  the  alkylation  reaction.  This  was  
confirmed  by  the  fluorescamine  detection  of  the  washed  protein  which  showed  51%  of  BSA  
has  been  alkylated,  and  the  RP-­‐HPLC  showing  58%  alkylation  (figure  67).  
  
2.3.5  Pd  catalysed  release  of  the  alkylated  protein  from  the  solid  phase  
Following  the  successful  BSA  alkylation  and  purification,  we  were  interested  to  investigate  
the   release  of   the  alkylated  protein   from   the   solid  phase  by   catalytic  Pd.  Given   the  Pd-­‐o-­‐
DANPHOS   complex   quenched   the   formation/fluorescence   of   the   fluorescamine   primary  
amine  products  with  the  model  system,  the  effect  of  the  Pd  on  the  BSA  analysis  methods  was  
investigated.   A   known   concentration   of   BSA   in   PBS  was  mixed  with   fluorescamine   in   the  
presence  of  the  Pd-­‐o-­‐DANPHOS  complex  then  the  fluorescence  of  the  mixture  measured  at  
479   nm   and   compared   to   the   fluorescence   of   BSA   in   the   absence   of   the   Pd-­‐o-­‐DANPHOS  
complex.      As   suspected,   the   Pd-­‐o-­‐DANPHOS   complex   quenched   the   fluorescence   of   BSA  




Figure  68:  The  effect  of  the  Pd-­‐o-­‐DANPHOS  on  BSA  fluorescence.  
 
To   investigate   the   effect   of   the   Pd-­‐o-­‐DANPHOS   complex   on   the   BCA   assay,   a   known  
concentration  of  BSA  in  PBS  mixed  with  BCA  solution  in  the  presence  and  absence  of  the  Pd-­‐
o-­‐DANPHOS  complex  then  the  absorbance  of  the  mixture  measured  at  562  nm.  The  Pd-­‐o-­‐
DANPHOS  complex  increased  the  absorbance  of  the  BCA-­‐BSA  mixture  absorbance  similar  to  
the  absorbance  of   the  mixture  of  BCA  solution  with  Pd-­‐o-­‐DANPHOS  complex  without  BSA  
(figure  69).    To  use  BCA  or  fluorescamine  assays  to  analyse  the  total  amount  of  the  released  
protein,   the   protein   should   first   be   separated   from   the   cleavage   reagents   before   analysis  
methods,    however  the  use  of  HPLC  to  analyse  the  released  alkylated  protein  proved  to  be  
more  straightforward,  as  the  Pd-­‐o-­‐DANPHOS  complex  can  be  separated  from  the  alkylated  
protein  and  the  concentration  of  released  protein  directly  determined  based  on  the  standard  
curve  generated  with  the  protein  sample  used  in  the  reaction  (figure  70).  
  












































Figure  70:  HPLC  of  released  BSA  from  the  solid  support  with  Pd  complex.  
  
Following  immobilisation  of  BSA  under  optimised  conditions,  any  remaining  iodoacetamide  
101  was  quenched  with  excess  of  glutathione  to  prevent  either  reaction  between  this  species  
and  the  phosphine  ligand,  or  perhaps  more  importantly  the  alkylated  BSA  reacting  again  after  
cleavage  (scheme  48).  The  solid  phase  alkylated  BSA  was  then  treated  with  5  mol%  Pd-­‐o-­‐
DANPHOS  complex  and  barbituric  acid  76   in  PBS  at  room  temperature   for  24  hours.  After  
cleavage  process  the  released  protein  was  separated  from  the  cleavage  reagents  by  using  a  
PD-­‐10  size  exclusion  column,  then  treated  with  fluorescamine,  however  no  fluorescence  was  
observed.  Unfortunately,  the  HPLC  confirmed  that  the  release  of  alkylated  BSA  from  the  solid  
support  by  using  catalytic  Pd  had  not  proceeded  as  expected.    
  
Scheme  48:  Quenching  of  unreacted  solid  phase  iodoacetamide  101  with  excess  glutathione  










































We  were  concerned   that   the  presence  of  protein   in   the   solid  phase  alkylated  BSA  had  an  
effect   on   the   cleavage   reaction,   resulting   ineffective   release   of   alkylated   BSA,   as   Pd-­‐o-­‐
DANPHOS  was  able  to  successfully  catalyse  the  deallylation  reaction  in  solution  phase  and  in  
the  model  solid  phase  systems  95  and  99.  To  examine  this  the  allyl  carbamate  67  was  used  to  
investigate  the  Pd  catalysed  deallylation  reaction  in  the  solution  phase  (scheme  49).  The  allyl  
carbamate  67  was  treated  with  5  mol%  Pd-­‐o-­‐DANPHOS  in  PBS  for  24  hours  in  the  presence  of  
agarose,  solid  phase  TCEP  or  BSA.  The  efficiency  of  the  cleavage  catalysed  by  each  Pd  species  
was  evaluated  by  1H  NMR  and  mass  spectrometry.  In  the  reactions  the  BSA  was  attached  to  
the  solid  support  in  order  to  avoid  its  signal  in  1H  NMR  (scheme  50)  using  a  linker  that  was  
designed  not  to  have  any  reactive  sites  that  could  be  cleaved  by  Pd  (scheme  50).  In  all  control  
reactions   the   allyl   carbamate   67   was   successfully   cleaved,   this   was   confirmed   by   mass  
spectrometry  showed  the  presence  of  the  1,3-­‐dimethylbarbituric  allyl  molecule  77  (where  its  
acidic   CH   proton   is   exchanged   with   deuterium).   1H   NMR   showed   the   presence   of  
ethylenediamine  78  protons  at  3.4  ppm,  to  confirm  the  desired  product  had  formed  we  added  
more   ethylenediamine   78   to   the   reaction   after   cleavage   completion,   resulting   in   the  
ethylenediamine  4  protons  at  3.4  ppm  shifting  into  2.9  ppm,  however  no  new  signals  were  
observed. 
  





























The  control  reactions  strongly  support  the  conclusion  that  the  BSA  has  been  immobilised  via  
the   expected   linker-­‐cysteine   alkylation.   Coupled   with   the   apparently   successful   (if   not  
absolutely   quantified)   cleavage   of   the   model   amine   this   result   suggests   the   protein   is  
interfering  with  the  cleavage  reaction,  possibly  due  to  steric  hindrance  as  the  agarose  and  
BSA   are   large  molecules   that  may   prevent   the   large   and   highly   charged   Pd   species   from  















































































































The  aim  of  this  project  was  to  develop  a  solid  phase  catch-­‐release  alkylation  system  to  reliably  
provide  clean  products  of  nucleophilic  cysteine  thiol  alkylation.    
In  the  first  attempt  towards  the  project  target,  the  alkylation  linker  was  designed  to  include  
an   azide   group   to   attach   to   the   solid   phase   by   using   a   copper   (I)-­‐catalysed   alkyne-­‐azide  
cycloaddition  (CuAAC)  reaction  and  designed  to  include  allyl  ester  group  that  can  be  cleaved  
by  using  catalytic  Pd.  The  cleavage  of  the  allyl  ester  by  catalytic  Pd  under  basic  conditions  and  
the  thiol  alkylation  were  investigated  in  the  solution  phase,  however  the  instability  of  the  allyl  
ester  system  under  basic  conditions  meant  that  it  could  not  to  be  used  longer-­‐term  in  the  
project.    
To  address  this  issue,  several  different  allyl  carbamate  and  propargyl  carbamate  derivatives  
have  been  synthesised  in  order  to  investigate  their  cleavage  efficiency  by  catalytic  Pd  under  
mild  conditions.  Different  simple  and  complex  Pd(0)  and  Pd(II)  catalysts  were  evaluated  to  
study  their  efficiency  to  catalyse  the  cleavage  of  the  allyl  carbamate  and  propargyl  carbamate  
derivatives.  The  cleavage  reactions  were  monitored  by  using  1H  NMR  and  MS.    
The   Pd   tetrakis   complex   (Pd(PPh3)4)   was   the  most   efficiency   catalyst   for   the   deallylation  
reactions,   in   contrast,   none   of   the   four   simple   Pd   species   catalyse   the   allyl   carbamate  
cleavage.  The  allyl  Pd  (II)  chloride  dimer  (allyl2Pd2Cl2)  and  the  bis(dibenzylideneacetone)  Pd  
(0)   (Pd(dba)2)   were   the   most   efficiency   catalysts   for   the   depropargyltion   reactions,   in  
contrast,  the  Pd(PPh3)4  didn’t    catalyse  the  depropargyltion  reaction.  
The  water-­‐soluble  propargyl  carbamate  derivatives  were  not  stable  under  basic  conditions  
and  as  we  already  had  concerns  about  the  aqueous  solubility  of  allyl  Pd  (II)  chloride,  no  further  
work   was   conducted   on   this   linker   system.   Although   the   water-­‐soluble   allyl   carbamate  
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derivatives  were   stable  under  basic   conditions,   they  were  not   cleaved  by  Pd(PPh3)4  under  
basic  conditions  in  the  absence  of  the  external  nucleophile.  However,  the  combination  of  the  
Pd   species   with   the   electron-­‐deficient   water-­‐soluble   phosphine   o-­‐DANPHOS   and   the  
barbituric  acid  anion  as  a  water-­‐soluble  soft  nucleophile  resulted  in  efficient  cleavage  of  the  
allyl  carbamate  derivatives  in  aqueous  conditions  within  2  hours.    
In  the  second  attempt  toward  the  solid  phase  alkylation  linker  we  tried  to  optimise  several  
properties;  1-­‐  the  linker  stability  was  improved  by  using  allyl  carbamate  instead  of  allyl  ester,  
2-­‐  the  CuAAC  reaction  side  effect  on  the  agarose  was  removed  by  using  N-­‐hydroxysuccinimide  
ester  functionalised  agarose  to  immobilise  an  amine-­‐containing  linker  onto  agarose  by  amide  
formation,   3-­‐   the   estimation   method   for   the   immobilisation   onto   the   solid   support   was  
improved  by  using  fluorescamine  to  detect  the  concentration  of  the  unreacted  amine  directly.  
The  alkylation  linker  was  redesigned  to  include  the  primary  amine  for  immobilisation  onto  
the   NHS-­‐activated   agarose,   retaining   the   allyl   carbamate   as   a   cleavable   group.   The  
immobilisation  of  the  primary  amine  model  molecule  onto  NHS-­‐activated  agarose  and  the  
cleavage  of  the  allyl  carbamate  on  the  solid  support  were  then  investigated,  demonstrating  
that  most  of  the  amine  was  immobilised  onto  agarose  after  24  hours  of  incubation  at  room  
temperature  in  PBS.  However,  the  best  coupling  of  the  model  molecules  with  NHS-­‐activated  
agarose  was  obtained  when  the  reaction  was  carried   in  acetonitrile  due  to  the  stability  of  
NHS-­‐activated  agarose  under  more  anhydrous  conditions.  
The  selectivity  of  the  solid  phase  iodoacetamide  linker  and  the  solid  phase  chloroacetamide  
linker  toward  a  protein  cysteine  thiols  was  investigated  by  using  BSA  in  the  presence  of  the  
solid  phase  TCEP.    Fluorescamine,  BCA  and  HPLC  assays  were  used  to  estimate  the  efficiency  
of  the  alkylation  process,  with  the  best  alkylation  yield  of  BSA  obtained  when  the  solid  phase  
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iodoacetamide  linker  was  used  in  the  presence  of  the  solid  phase  TCEP.  However,  the  release  
of  the  alkylated  protein  using  the  Pd-­‐o-­‐DANPHOS/barbituric  acid  conditions  did  not  proceed  
as  expected.   Further   control   reactions   demonstrated   there   is   no  apparent   incompatibility  
between  the  components  of  this  system,  therefore  we  hypothesise  the  failure  of  the  cleavage  
was  due  to  the  steric  hindrance  affect  of  the  large  molecules  (BSA  and  agarose)  preventing  














3.1  Future  Work    
The  majority  of  the  project  aims  have  been  achieved;  1)  the  solid  phase  thiol  alkylation  linker  
has  been  optimised,  prepared  and  shown  to  selectively  alkylate  cysteine  thiols  in  the  model  
protein   BSA   to   capture   the   alkylated   protein   on   the   solid   phase,   2)   the   cleavage   of   the  
alkylation  linker  in  the  solution  phase  has  been  confirmed  by  1H  NMR  and  MS.  However,  the  
release  of  the  alkylated  protein  did  not  proceed  as  expected  meaning  the  system  is  not  yet  
ready  for  application  to  the  synthesis  of  CCL2-­‐conjugates.  
To  progress  this  project,  we  propose  to  synthesise  a  longer  linker  that  will  provide  more  space  
for  the  Pd  species  to  access  the  cleavage  site.  The  longer  linker  could  be  synthesised  in  10  
steps  starting  with  commercially  available  2-­‐[2-­‐(2-­‐chloroethoxy)ethoxy]ethanol  (Figure  71).  
We  would  propose  to  investigate  the  cleavage  of  the  linker  allyl  carbamate  in  both  solution  
and  solid  phases  by  using  the  Pd-­‐o-­‐DANPHOS  complex.      
Once  the  cleavage  reaction  is  confirmed,  we  would  propose  to  investigate  the  thiol  alkylation  
in  solution  phase  by  using  a  simple  thiol  compound  such  as  cystamine  or  mercaptoethanol.  
The  success  of  the  alkylation  process  in  solution  phase  would  be  determined  by  NMR  and  MS.  
Moreover,  we  would  propose  to  investigate  the  alkylation  to  simple  protein  (such  as  BSA)  in  
combination  with  a  second  solid  phase  reducing  agent  and  more  fully  quantify  the  effect  of  
this   on   the   final   protein   yield   and   purity.   The   success   of   the   alkylation   process   could   be  
determined  by  amount  of  the  unreacted  protein  that  can  be  determined  by  several  technique  
such  as  fluorescamine  assay,  BCA  or  HPLC.    
  
In  addition,  in  order  to  more  fully  understand  the  cleavage  efficiency  we  would  propose  to  
directly  quantify  the  amount  of  protein  level  onto  the  solid  phase.  This  may  be  possible  BCA,  
however   as  we   have  we  used   agarose   as   solid   support   there  may   be   side   reactions  with  
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copper  in  the  BCA  assay.  Once  the  protein  alkylation  level  is  confirmed,  we  would  propose  to  
investigate  the  release  of  protein  from  the  solid  support  by  using  catalytic  Pd  (5  mol%).  The  








In  addition  to  this  work,  we  would  propose  to  synthesise  a  longer  linker  with  a  maleimide  
thiol   alkylation   agent   to   compare   with   haloacetamide   thiol   alkylation   agents   (figure   72).  
Moreover,   we   would   propose   to   investigate   the   alkylation   reactions   of   the   simple   thiol  
compounds  and  protein  by  solid  maleimide  linker.      
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Figure  72:  Plan  to  synthesise  longer  maleimide  linker.  
  
Following  this  work,  we  would  propose  to   investigate  the  alkylation  of  a  CCL2-­‐Cys  protein  
using  either  the  current  or  optimised  system,  since  this  molecule  contains  a  more  exposed  
cysteine  residue.  Once  the  alkylation  of  the  CCL2-­‐Cys  protein  is  confirmed  we  would  redesign  
the  alkylation  linkers  to  include  an  orthogonal  functional  group,  such  as  an  azide,  that  would  
allow  for  the  subsequent  modification  of  the  alkylated  protein  with  a  range  of  species  (for  
example  fluorophores)  using  CuAAC  or  SPAC  chemistry.  
Finally,   redesign   of   the   alkylation   linker   could   allow   direct   alkylation  with   an   FK866   drug  















































































































































4.1  General  Experimental  Procedures.  
Reagents  and  solvents  that  are  available  commercially  are  used  without  further  purification  
and  purchased  from  Sigma-­‐Aldrich,  Acros,  Alfa  Aesar,  Fisher  Chemicals,  Fluorochem  or  Strem  
chemical.   Anhydrous   solvents   are   supplied   via   a   solvent   purification   system   (SPS)   and  
maintained  under   inert   (N2)  atmosphere.  The   reactions  were  monitored  by   the   thin   layer  
chromatography  (TLC)  was  carried  out  on  Merck  aluminium  backed  TLC  plates  silica  gel  60  
F254  (0.25  mm  thickness)  and  stained  with  standard  TLC  stains   (potassium  permanganate  
solution,  KMnO4)  followed  by  heating  with  a  hot-­‐air  gun  (~300  °C,  10  seconds)  then  visualised  
using  a  short  wavelength  UV  lamp.  The  silica  gel  (particle  size  40-­‐63  μm  mesh)  was  used  in  
Flash   column   chromatography.      1H  NMR   spectra  were   recorded   at   300  MHz   on   a   Bruker  
AVIII300  NMR  Spectrometer  and  at  400  MHz  on  a  Bruker  AV400  Bruker  Spectrometer.  13C  
NMR   spectra  were   recorded   using   the   standard   and   Pendant   techniques   at   100  MHz   on  
Bruker  AVIII400  and  AV400  Spectrometers,  and  were  proton  decoupled.  Chemical  shifts  (δ)  
are  reported   in  parts  per  million  (ppm)  relative  to  TMS   (δ  0.00)   for  1H  NMR  and  13C  NMR  
measurements.   Coupling   constants   (J)   are   expressed   in   Hertz   (Hz).   Infrared   spectra  were  
collected  using  a  Perkin  Elmer  Spectrometer  and  signals  are  expressed  in  cm-­‐1.  Mass  spectra  
were  recorded  with  an  electrospray  MS  Waters  LCT  Time  of  Flight  Mass  Spectrometer  using  
electrospray  ionisation  (ESI).  High-­‐resolution  mass  spectrometry  (HRMS)  were  recorded  on  
an  LCT  spectrometer  utilising  a  lock-­‐mass  incorporated  into  the  mobile  phase.  Reverse  phase  
(RP)  HPLC  analysis  was  run  through  a  Kinetex®  C18-­‐EVO  column  (Phenomenex®):  5  μm,  100  
Å,  250  x  4.60  mm,  eluting  with   (A)  H2O/0.1%  TFA  and   (B)  CH3CN/0.1%  TFA.  The   following  
gradient  was   used:   70%   (A)   to   50%   (B)   over   15  min   at   1  mL/min,   and   compounds  were  
detected  using  UV-­‐Vis  detector  and  absorbance  at  220  nm,  280  nm  and  350  nm.  All  solvents  
used  were  HPLC  grade  and  the  column  was  maintained  at  40  °C.  UV-­‐Vis  spectra  were  recorded  
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on   a   Shimadzu   UV-­‐1800   spectrometer   or   CLARIOstar   BMG   labtech   microplate   reader  
sampling  a  wavelength  range  from  250  -­‐  800  nm  at  1.0  nm  intervals.  Fluorescence  spectra  
were  recorded  on  96-­‐well  plate  CLARIOstar  BMG  labtech  microplate  reader.  
4.2   General   procedure   for   fluorescamine   assay,   adapted   from   a   known  
procedure.231    
A  stock  solution  of  primary  amine  ligand  in  PBS  was  prepared,  and  the  same  stock  used  in  the  
experimental  work  (e.g.  coupling  with  NHS-­‐agarose)  and  to  make  the  standard  curve.    From  
the   primary   amine   ligand   stock   solution,   the   standards   solutions  were   prepared   by   serial  
dilution.      In  96  well  black-­‐walled  microplate,  100  μL  of  each  standard  or  unknown  sample  
were  added  in  replicate.  Then  100  μL  of  1M  fluorescamine  (Alfa  Aesar)  in  CH3CN  were  added  
to  each  well  and  the  fluorescence  measured  at  37  °C,  exciting  at  390  nm  and   reading  the  
emission  at  479  nm.  The  standard  curve  was  prepared  by  plotting  the  average  measurement  
at  479  nm  for  each  primary  amine  ligand  standard  vs.  its  concentration  in  µM.    
4.3  General  procedure  for  BCA  assay  (adapted  from  the  Thermo  ScientificTM  
PierceTM  BCA  Protein  Assay  protocol).    
The  BCA  Protein  Assay  kit  was  purchased  from  the  Thermo  Science.  The  working  reagent  (WR)  
was  prepared  by  mixing  BCA  Reagent  A  (50  parts)  with  BCA  Reagent  B  (1  part).  Bovine  serum  
albumin  (BSA)  (99  mg)  was  dissolved  in  PBS  (2  mL)  and  this  stock  solution  used  in  the  thiol  
alkylation  reaction  and  to  make  the  BSA  standard  curve.    From  the  BSA  stock  solution,  the  
standards  solutions  in  PBS  were  prepared  by  serial  dilution  in  range  from  20  µM  to  1  µM.    In  
96  well  microplate,  25  μL  of  each  standard  or  unknown  sample  were  pipetted  in  duplicate  
alongside  protein-­‐free  controls  (blanks).  Then  200  μL  of  the  WR  was  added  to  each  well  and  
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mixed  for  30  seconds  using  a  plate  shaker.  The  microplate  was  covered  and  incubated  at  37  
°C  for  30  minutes,  then  cooled  to  room  temperature  and  the  absorbance  was  measured  at  
562  nm  on  a  microplate  reader.  The  average  of  the  blank  standard  replicates  absorbance  at  
562   nm   was   subtracted   from   each   absorbance   of   the   individual   standard   and   unknown  
sample  replicates  at  562  nm.  The  standard  curve  was  prepared  by  plotting  the  average  blank-­‐
corrected  562  nm  measurement  for  each  BSA  standard  vs.  its  concentration  in  µM.    
4.4  Abbreviations.  
Abbreviation   Full  meaning   Abbreviation   Full  meaning  
s   Singlet   EtOAc   Ethyl  acetate  
d   Doublet   Et2O   Diethyl  ether  
dd   Doublet  of  Doublets   Na2SO4   Sodium  sulfate  
  
ddd   Doublet  of  Doublets  of  
Doublet  
MgSO4   Magnesium  sulfate  
dddd   Doublet  of  Doublets  of  
Doublet  of  Doublets  
NaOH   Sodium  hydroxide  
t   Triplet   NaHCO3   Sodium  bicarbonate  
dt   Doublet  of  Triplet   t-­‐BuOH   tert-­‐Butanol  
m   Multiplet   PBS   Phosphate  buffer  
solution  
CH2Cl2   Dichloromethane   HCl   Hydrochloric  acid  
THF   Tetrahydrofuran   TFA   Trifluoroacetic  acid  
CH3CN   Acetonitrile   Abs.   Absorbance  
DMF   Dimethylformamide   FI   Fluorescence  intensity  






4.5  Synthesis  and  characterisation  of  the  compounds.    
4.5.1  Preparation  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐chloroacetyl)glycinate  1,  adapted  from  a  known  
procedure.171  
  
1-­‐Ethyl-­‐3-­‐(3-­‐dimethylaminopropyl)carbodiimide   (EDC)   (253  mg,   1.32  mmol)  was   added   to   a  
solution   of   alcohol   6   (50.0   mg,   0.44   mmol),   acid   7   (433   mg,   1.77   mmol),   and  
dimethylaminopyridine  (DMAP)  (54.0  mg,  0.44  mmol)  in  anhydrous  CH2Cl2  (3.5  mL)  under  argon  
at   ambient   temperature.   The   reaction   mixture   was   stirred   until   TLC   indicated   complete  
consumption  of  the  alcohol  starting  material.  After  24  hours  the  reaction  was  cooled  to  0  °C.  
The   urea   by-­‐product   was   removed   via   vacuum   filtration.   The   filtrate   was   washed   with  
saturated   aqueous   NaHCO3   and   brine,   then   the   organic   layer   dried   over   Na2SO4   and  
concentrated  in  vacuo.  The  residue  was  purified  by  silica  gel  column  chromatography  (1%  -­‐  
10%      CH3OH   /   CH2Cl2)   to   afford   the   1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl   (2-­‐chloroacetyl)glycinate   1   as   a  
viscous  oil  (89.9  mg,  83%  yield);  Rf  =  0.6,  CH3OH  /  CH2Cl2,  1:9;  IR  (thin  film)/cm-­‐1  umax  ;  3309,  
2935,  2099,  1748,  1662,  1534,  1187,  938,  661;  1H  NMR  (300  MHz,  CDCl3)  δ  7.07  (s,  1H),  5.81  
(ddd,  J  =  17.1,  10.5,  6.4  Hz,  1H),  5.52  –  5.32  (m,  3H),  4.16  (dd,  J  =  5.4,  1.5  Hz,  2H),  4.10  (s,  2H),  
3.47  –  3.40  (m,  2H);  13C  NMR  (100  MHz,  CDCl3)  δ:  168.3,  166.2,  132.0,  120.0,  74.9,  53.5,  42.3,  
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4.5.2   Preparation   of   1-­‐azidobut-­‐3-­‐en-­‐2-­‐ol   6   from   ((1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl)oxy)(tert-­‐
butyl)dimethylsilane  11,  adapted  from  a  known  procedure.164  
  
A  THF  solution  of  tetra-­‐  butylammonium  fluoride  (Bu4NF)  (0.68  mL,  0.68  mmol)  was  added  to  
a  0  °C,  THF  solution  (4  mL)  of  ((1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl)oxy)(tert-­‐butyl)dimethylsilane  11  (70.0  
mg,  0.31  mmol).  The  resulting  mixture  was  allowed  to  warm  ambient  temperature  and  after  
24  hours  saturated,  aqueous  NH4Cl  (5  mL)  and  brine  (10  mL)  were  added.  The  phases  were  
separated,  and  the  aqueous  phase  was  then  extracted  with  EtOAc  (3  x  20  mL).  The  combined  
organic  phase  was  washed  with  brine  (2  x  20  mL),  dried  over  MgSO4,  filtered  and  concentrated  
in  vacuo.  The  crude  material  was  purified  by  silica  gel  column  chromatography  (10%  -­‐  50%    
EtOAc  /  hexane)  to  afford  1-­‐azidobut-­‐3-­‐en-­‐2-­‐ol  6  (20  mg,  57%)  as  a  light  yellow  oil;  IR  (thin  
film)/cm-­‐1  umax;  2918,  2096,  1650,  1437,  1278,  1278,  1073,  991,  928;  1H  NMR  (400  MHz,  CDCl3)  
δ  5.84  (ddd,  J  =  17.2,  10.5,  5.7  Hz,  1H),  5.35  (dt,  J  =  17.2,  1.4  Hz,  1H),  5.21  (dt,  J  =  10.5,  1.4  Hz,  
1H),  4.33  –  4.27  (m,  1H),  3.35  –  3.24  (m,  2H);  13C  NMR  (100  MHz,  CDCl3)  δ:  137.1,  116.9,  71.9,  
56.4;  Data  agrees  with  literature  values.164    
4.5.3  Preparation  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐ol  6,  that  was  adapted  from  a  known  procedure.2  
  
A  DMF  solution  (20  mL)  of  2-­‐hydroxybut-­‐3-­‐en-­‐1-­‐yl  4-­‐methylbenzenesulfonate  9  (3.0  g,  12.0  
mmol),  tetrabutylammonium  iodide  (TBAI)  (0.6  g,  0.6  mmol),  and  sodium  azide  (NaN3)  (2.7  g,  
37.0  mmol)  was  maintained  at  75  °C.  After  24  hours  brine  (20  mL)  was  added,  the  phases  


















combined   organic   phase  was  washed  with   brine   (50  mL),   dried   over   Na2SO4,   filtered   and  
concentrated  in  vacuo  to  afford  1-­‐azidobut-­‐3-­‐en-­‐2-­‐ol  6  (1.2  g,  82%)  as  brown  oil.164  IR  (thin  
film)/cm-­‐1  umax;  2918,  2096,  1650,  1437,  1278,  1278,  1073,  991,  928;  1H  NMR  (400  MHz,  CDCl3)  
δ  5.84  (ddd,  J  =  17.2,  10.5,  5.7  Hz,  1H),  5.35  (dt,  J  =  17.2,  1.4  Hz,  1H),  5.21  (dt,  J  =  10.5,  1.4  Hz,  
1H),  4.33  –  4.27  (m,  1H),  3.35  –  3.24  (m,  2H);  13C  NMR  (100  MHz,  CDCl3)  δ:  137.1,  116.9,  71.9,  
56.4;  Data  agrees  with  literature  values.164  
4.5.4  Preparation  of  (2-­‐chloroacetyl)glycine  7,  adapted  from  a  known  procedure.170  
  
Glycine  15  (1  g,  13.3  mmol)  was  dissolved  in  2.5  N  NaOH  (400  mL),  and  diethyl  ether  (7  mL)  
was  added.  The  mixture  was  cooled  (0  °C),  and  the  solution  of  chloroacetyl  chloride  16  (1.5  
mL,  13.3  mmol)  in  5  mL  of  ether  was  added  dropwise  over  30  min.  The  mixture  was  stirred  
for  45  min  at  0  °C,  then  allowed  to  gradually  warm  up  to  ambient  temperature  while  stirring  
for  further  72  hours.  The  organic  layer  was  separated,  and  the  aqueous  layer  was  extracted  
with  diethyl  ether  (10  mL).  The  aqueous  layer  was  acidified  (pH  2)  and  extracted  with  EtOAc  
(4  ×  15  mL).  The  combined  EtOAc  extracts  were  washed  with  100  mL  of  brine,  dried  over  
Na2SO4,  filtered  and  concentrated   in  vacuo  to  afford  a  colourless  oil.  Hexane  (10  mL)  were  
added   to   the  obtained   oil,   and   the   solvent  was   removed   to  give  a  white   solid.  The  crude  
product  was   recrystallised   from  diethyl   ether   to   afford   (2-­‐chloroacetyl)glycine  7   (800  mg,  
40%);  1H  NMR  (300MHz,  CD3OD)  δ:  4.10  (s,  2H),  4.00  (s,  2H);  13C  NMR  (100MHz,  CD3OD)  δ:  

















4.5.5   Preparation   of   2-­‐hydroxybut-­‐3-­‐en-­‐1-­‐yl   4-­‐methylbenzenesulfonate  9,   adapted   from  a  
known  procedure.162  
  
To  a  solution  of  the  3-­‐buten-­‐1,2-­‐diol  8  (10.0  g,  114  mmol)  in  anhydrous  CH2Cl2  (100  mL)  were  
added  dibutyl   tin  oxide  (0.56  g,  2.30  mmol),  p-­‐Toluenesulfonyl  chloride  (TsCl)   (21.7  g,  114  
mmol),  and  triethylamine  (15.8  mL,  114  mmol).  The  reaction  mixture  was  stirred  until  TLC  
indicated  complete  consumption  of  the  starting  material.  The  reaction  was  quenched  with  
water  (100  mL),  and  the  layers  were  separated.  The  aqueous  layer  was  extracted  with  CH2Cl2  
(2  x  100  mL),  the  combined  organic  layers  were  washed  sequentially  with  water  (100  mL)  and  
brine  (100  mL),  dried  over  Na2SO4,  and  filtered,  and  the  filtrate  was  concentrated  in  vacuo.  
The  residue  was  purified  by  silica  gel  column  chromatography  (10%  EtOAc  /  hexane)  to  afford  
the  desired  2-­‐hydroxybut-­‐3-­‐en-­‐1-­‐yl  4-­‐methylbenzenesulfonate  9  (19.6  g,  71%)  as  colourless  
oil;  Rf  =  0.7,  EtOAc  /  petroleum  ether,  1:1;  1H  NMR  (300  MHz,  CDCl3)  δ  7.78  (d,  J  =  8.0  Hz,  2H),  
7.38  (d,  J  =  8.0  Hz,  2H),  5.78  (ddd,  J  =  17.3,  10.5,  5.5  Hz,  1H),  5.40  (dt,  J  =  17.3,  1.4  Hz,  1H),  
5.27  (dt,  J  =  10.5,  1.4  Hz,  1H),  4.42  (dddd,  J  =  7.0,  5.5,  3.3,  1.6  Hz,  1H),  4.09  (dd,  J  =  10.2,  3.3  
Hz,  1H),  3.93  (dd,  J  =  10.2,  7.0  Hz,  1H),  2.48  (s,  3H);  13C  NMR  (100  MHz,  CDCl3)  δ  145.5,  135.1,  













4.5.6  Preparation  of  2-­‐((tert-­‐butyldimethylsilyl)oxy)but-­‐3-­‐en-­‐1-­‐yl  4-­‐methylbenzenesulfonate  
10,  adapted  from  a  known  procedure.164  
  
tert-­‐Butyldimethylsilyl  chloride  (TBDMSCl)  (12.4  g,  82.4  mmol)  and  triethylamine  (11.5  mL,  
82.4   mmol)   were   added   to   a   0   °C,   DMF   solution   (80   mL)   of   2-­‐hydroxybut-­‐3-­‐en-­‐1-­‐yl   4-­‐
methylbenzenesulfonate  9  (5  g,  20.6  mmol).  The  reaction  mixture  was  allowed  to  warm  to  
ambient  temperature.  After  24  hours  brine  (80  mL)  was  added  and  the  aqueous  phase  was  
then  extracted  with  diethyl  ether  (2  x  100  mL).  The  combined  organic  layers  were  dried  over  
MgSO4,   filtered   and   concentrated   in   vacuo.   The   residue  was   purified   by   silica   gel   column  
chromatography  (10%  EtOAc  /  hexane)  to  afford  2-­‐((tert-­‐butyldimethylsilyl)oxy)but-­‐3-­‐en-­‐1-­‐yl  
4-­‐methylbenzenesulfonate  10  (6.0  g,  82%);  Rf  =  0.9,  EtOAc  /  hexane,  1:1;  1H  NMR  (300MHz,  
CDCl3)  δ:  7.77  (d,  J  =  8.1  Hz,  2H),  7.  34  (d,  J  =  8.1  Hz,  2H),  5.76  -­‐  5.63  (m,  1H),  5.30  (d,  J  =  17.2  
Hz,  1H),5.18  -­‐  5.12  (m,  1H),4.33  (m,  1H),  3.92  -­‐  3.77  (m,  2H),  2.45  (s,  3H),  0.85  (s,  9H),  0.02  (s,  
6H);  13C  NMR  (100MHz,  CDCl3)  δ:  144.8,  136.1,  133.0,  129.8,  117.2,  73.0,  71.3,  30.90,  25.7,  

















4.5.7  Preparation  of  ((1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl)oxy)(tert-­‐butyl)dimethylsilane  11,  adapted  from  a  
known  procedure.164  
  
A   DMF   solution   (4   mL)   of   2-­‐((tert-­‐butyldimethylsilyl)oxy)but-­‐3-­‐en-­‐1-­‐yl   4-­‐
methylbenzenesulfonate  10  (297  mg,  0.834  mmol),  tetrabutylammonium  iodide  (TBAI)  (30.8  
mg,  0.08  mmol),  and  sodium  azide  (NaN3)  (162  mg,  2.50  mmol)  was  maintained  at  75  °C.  After  
24  hours  brine  (5  mL)  was  added,  the  phases  were  separated,  and  the  aqueous  phase  was  
extracted  with  diethyl  ether  (5  x  10  mL).  The  combined  organic  phase  was  washed  with  brine  
(50  mL),  dried  over  Na2SO4,  filtered  and  concentrated  in  vacuo  to  afford  ((1-­‐azidobut-­‐3-­‐en-­‐2-­‐
yl)oxy)(tert-­‐butyl)dimethylsilane  11  (70.0  mg,  37%)  as  brown  oil;  1H  NMR  (300MHz,  CDCl3)  δ:  
5.88  -­‐  5.73  (m,  1H),  5.35  -­‐  5.27  (dt,  J  =  17.2,  1.3  Hz,  1H),  5.21  -­‐  5.15  (dt,  J  =  10.7,  1.3  Hz,  1H),  
4.32  -­‐  4.25  (m,  1H),  3.17  (d,  J  =  5.4,  2H),  0.92  (S,  9H),  0.09  (s,  6H);  13C  NMR  (100MHz,  CDCl3)  δ:  
138.0,  116.3,  73.5,  57.1,  25.8,   18.1,   -­‐  4.6;  MS  m/z   (AP+)   228.2   (M  +  H).  Data  agrees  with  
literature  values.164  
4.5.8  Preparation  of  2-­‐((trimethylsilyl)oxy)but-­‐3-­‐en-­‐1-­‐yl  4-­‐methylbenzenesulfonate  13.164  
  
Trimethylsilyl  chloride  (TMSCl)  (0.21  mL,  1.65  mmol)  and  pyridine  (5  mL)  were  added  to  a  0  
°C,   DMF   solution   (5  mL)   of   2-­‐hydroxybut-­‐3-­‐en-­‐1-­‐yl   4-­‐methylbenzenesulfonate   9   (100  mg,  
0.413  mmol).  The  reaction  mixture  was  allowed  to  warm  to  ambient  temperature.  After  24  
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(2  x  8  mL).  The  combined  organic  layers  were  dried  over  MgSO4,  filtered  and  concentrated  in  
vacuo   to  afford  2-­‐((trimethylsilyl)oxy)but-­‐3-­‐en-­‐1-­‐yl  4-­‐methylbenzenesulfonate   13   (100  mg,  
78%);  1H  NMR  (300MHz,  CDCl3)  δ:  7.70  (d,  J  =  8.0  Hz,  2H),  7.  25  (d,  J  =  8.0  Hz,  2H),  5.68  -­‐  5.55  
(m,  1H),  5.24  (dt,  J  =  17.2,  1.2  Hz,  1H),  5.11  -­‐  5.05  (dt,  J  =  10.4,  1.2  Hz,  1H),  4.28  -­‐  4.20  (m,  1H),  
3.86  -­‐  3.71  (m,  2H),  2.36  (s,  3H),  0.00  (s,  9H);  13C  NMR  (100MHz,  CDCl3)  δ:  144.8,  135.9,  133.1,  
129.9,  128.0,  117.3,  72.9,  71.2,  21.6,  0.0;  MS  m/z  (ES+)  337.1  (M  +  Na).  
4.5.9  Preparation  of  2-­‐((tert-­‐butyldiphenylsilyl)oxy)but-­‐3-­‐en-­‐1-­‐yl  4-­‐methylbenzenesulfonate  
14.164  
  
To  a  solution  of  2-­‐hydroxybut-­‐3-­‐en-­‐1-­‐yl  4-­‐methylbenzenesulfonate  9  (200  mg,  0.826  mmol)  
in  DMF  (6.6  mL)  at  0  °C  were  added  tert-­‐Butyldiphenylsilyl  chloride  (TBDPSCl)  (0.86  mL,  3.30  
mmol)  and  triethylamine  (0.46  mL,  3.30  mmol).  The  reaction  mixture  was  allowed  to  warm  to  
ambient  temperature.  After  72  hours  brine  (7  mL)  was  added  and  the  aqueous  phase  was  
then  extracted  with  diethyl  ether  (2  x  20  mL).  The  combined  organic  layers  were  dried  over  
MgSO4,   filtered   and   concentrated   in   vacuo.   The   residue  was   purified   by   silica   gel   column  
chromatography  (10%    EtOAc  /  hexane)  to  afford  2-­‐((tert-­‐butyldiphenylsilyl)oxy)but-­‐3-­‐en-­‐1-­‐yl  
4-­‐methylbenzenesulfonate   14   (110   mg,   28%);   Rf   =   0.97,   EtOAc   /   hexanes,   1:1;   1H   NMR  
(300MHz,  CDCl3)  δ:  7.70  -­‐  7.60  (m,  7H),  7.40  -­‐  7.25  (m,  7H),  5.76-­‐5.63  (m,  1H),  5.15  -­‐  5.00  (m,  
2H),  4.33   (m,   1H),  3.92-­‐3.77   (m,   2H),  2.15   (s,  3H),  0.95   (s,  9H);   13C  NMR   (100MHz,  CDCl3)  
δ:137.3,  135.9,  134.8,  133.4,  129.9,  127.7,  117.1,  74.1,  48.4,  30.9,  29.7,  26.9,  19.4;  MS  m/z  












4.5.10   Preparation   of   1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl   acetylglycinate   18,   adapted   from   a   known  
procedure.171  
  
Prepared  using  an  identical  method  to  4.5.1;  Rf  =  0.6,  CH3OH  /  CH2Cl2,  1:9;  IR  (thin  film)/cm-­‐1  
umax;  3309,  2096,  1742,  1655,  1545,  1437,  1375,  1209,  996,  688;  1H  NMR  (400  MHz,  CDCl3)  δ  
6.16  (s,  1H),  5.84  –  5.74  (m,  1H),  5.48  –  5.29  (m,  3H),  4.17  –  4.01  (m,  2H),  3.47  –  3.36  (m,  2H),  
2.03  (d,  J  =  3.0  Hz,  3H);  13C  NMR  (100MHz,  CDCl3)  δ:  170.1,  168.9,  131.9,  119.5,  74.4,  53.3,  
41.2,  22.7;  MS  m/z  (ES+)  235.1  (M  +  Na+),  HRMS  C8H12N4O3Na  requires  M,  235.0807,  Found  
(M)  235.0810.  
4.5.11  Preparation  of  1-­‐(4-­‐((1,3-­‐dioxoisoindolin-­‐2-­‐yl)methyl)-­‐1H-­‐1,2,3-­‐triazol-­‐1-­‐yl)but-­‐3-­‐en-­‐2-­‐
yl  acetylglycinate  22,  that  was  adapted  from  a  known  procedure.173  
  
1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  acetylglycinate  18  (114  mg,  0.54  mmol),  2-­‐(prop-­‐2-­‐yn-­‐1-­‐yl)isoindoline-­‐1,3-­‐dione  
21   (100   mg,   0.54   mmol),   Copper   (II)   sulfate   (1.87   mg,   0.01   mmol),   and   tris(3-­‐
hydroxypropyltriazolylmethyl)amine  (THBTA)  (5.00  mg,  0.01  mmol)  were  stirred  in  t-­‐BuOH.H2O  
solution   (1:1,   1  mL),   followed  by   addition   of   sodium  ascorbate   (   46.6  mg,   0.24  mmol).   The  
reaction   mixture   was   stirred   until   TLC   indicated   complete   consumption   of   the   starting  
material.  After  24  hours  of  the  reaction,  brine  (7  mL)  was  added  and  the  aqueous  phase  was  
then  extracted  with  EtOAc  (2  x  20  mL).  The  combined  organic  layers  were  dried  over  MgSO4,  
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1,2,3-­‐triazol-­‐1-­‐yl)but-­‐3-­‐en-­‐2-­‐yl  acetylglycinate  22  (180  mg,  86%  yield);  Rf  =  0.5,  CH3OH  /  CH2Cl2,  
5%;  IR  (thin  film)/cm-­‐1  umax;  1714,  1547,  1396,  1187,  938,  715;  1H  NMR  (400  MHz,  CDCl3)  δ  
7.84  (dd,  J  =  5.5,  3.0  Hz,  2H),  7.72  (dd,  J  =  5.5,  3.0  Hz,  2H),  7.67  (s,  1H),  6.17  (s,  1H),  5.77  (ddd,  
J  =  17.0,  10.6,  6.3  Hz,  1H),  5.65  –  5.59  (m,  1H),  5.43  –  5.30  (m,  2H),  5.05  –  4.92  (m,  2H),  4.60  
(dd,  J  =  14.4,  3.8  Hz,  1H),  4.51  –  4.43  (m,  1H),  4.13  –  4.06  (m,  1H),  3.92  (dd,  J  =  18.3,  5.0  Hz,  
1H),  2.04  (s,  3H);  13C  NMR  (100MHz,  CDCl3)  δ:  170.3,  168.7,  167.7,  134.2,  132.0,  131.2,  123.6,  
123.5,   120.5,   73.4,   52.7,   41.3,   33.1,   22.9;   MS   m/z   (ES+)   420.1   (M   +   Na+);   HRMS  
C19H19N5O523Na  requires  M,  420.1284,  Found  (M)  420.1283.  
  
4.5.12  Preparation  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐iodoacetyl)glycinate  24,  that  was  adapted  from  
a  known  procedure.256  
  
To   the   solution   of   1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl   (2-­‐chloroacetyl)glycinate   1   (80.0  mg,   0.33  mmol)   in  
acetone,  sodium  iodide  (197.85  mg,  1.32  mmol)  was  added.  The  reaction  mixture  was  stirred  
until  TLC  indicated  complete  consumption  of  the  starting  material.  The  sodium  chloride  salt  
was  removed  by  filtration  and  the  filtrate  was  washed  with  brine,  then  the  organic  layer  dried  
over  Na2SO4  and  concentrated  in  vacuo  to  afford  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐iodoacetyl)glycinate  
24  (83.5  mg,  76%  yield);  IR  (thin  film)/cm-­‐1  umax;  3330,  2945,  2832,  1651,  1411,  1019;  1H  NMR  
(400  MHz,  CDCl3)  δ  6.56  (s,  1H),  5.81  (ddd,  J  =  17.1,  10.6,  6.4  Hz,  1H),  5.48  (tdt,  J  =  6.4,  4.6,  1.2  
Hz,  1H),  5.44  –  5.33  (m,  2H),  4.13  (dd,  J  =  5.3,  1.2  Hz,  2H),  3.75  (s,  2H),  3.49  –  3.38  (m,  2H);  13C  
NMR  (100  MHz,  CDCl3)  δ  168.6,  167.3,  132.1,  120.1,  75.0,  53.6,  42.3,  29.8;  MS  m/z  (ES+)  361.0  
(M  +  Na+),  HRMS  C8H11N4O3NaI  requires  M,  360.9774,  Found  (M)  360.9770.  
1 24
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4.5.13  Preparation  of  1-­‐(4-­‐(((tert-­‐butoxycarbonyl)amino)methyl)-­‐1H-­‐1,2,3-­‐triazol-­‐1-­‐yl)but-­‐3-­‐
en-­‐2-­‐yl  (2-­‐chloroacetyl)glycinate  26,  that  was  adapted  from  a  known  procedure.173  
  
Prepared  using  an  identical  method  to  4.5.11;  IR  (thin  film)/cm-­‐1  umax;    3350,  2850,  1650,  1500,  
1130;  1H  NMR  (400  MHz,  CDCl3)  δ  7.57  (s,  1H),  7.16  (d,  J  =  6.7  Hz,  1H),  5.78  (ddd,  J  =  17.0,  10.5,  
6.3  Hz,  1H),  5.71  –  5.62  (m,  1H),  5.46  –  5.24  (m,  3H),  4.62  (dd,  J  =  14.4,  3.9  Hz,  1H),  4.50  (dd,  J  
=  14.4,  7.5  Hz,  1H),  4.37  (d,  J  =  5.9  Hz,  2H),  4.09  (s,  2H),  4.05  (dd,  J  =  5.6,  3.0  Hz,  2H),  1.43  (s,  
9H)  ;  13C  NMR  (100  MHz,  CDCl3)  δ  167.7,  166.4,  155.8,  145.6,  131.0,  122.8,  120.4,  79.5,  73.6,  
52.4,  42.2,  41.3,  36.0,  28.2;  MS  m/z  (ES+)  424.1  (M  +  Na+);  HRMS  C16H24N5O5NaCl  requires  M,  
424.1364,  Found  (M)  424.1358.    
  
4.5.14   Preparation   of   1-­‐(4-­‐(aminomethyl)-­‐1H-­‐1,2,3-­‐triazol-­‐1-­‐yl)but-­‐3-­‐en-­‐2-­‐yl   (2-­‐
chloroacetyl)glycinate  27,  that  was  adapted  from  a  known  procedure.257  
  
To  a  solution  of  molecule  26  (0.17  g,  0.42  mmol)  in  CH2Cl2  (10  mL)  at  0  °C  was  added  TFA  (10  
mL).  The  reaction  mixture  was  stirred  for  2  hours,  until  TLC  indicated  complete  consumption  
of  the  starting  material,  then  diluted  with  diethyl  ether  and  concentrated  under  vacuo  and  
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(aminomethyl)-­‐1H-­‐1,2,3-­‐triazol-­‐1-­‐yl)but-­‐3-­‐en-­‐2-­‐yl  (2-­‐chloroacetyl)glycinate  27  (0.12  g,  90  %);  
1H  NMR  (300  MHz,  D2O)  δ  8.17  (s,  1H),  5.98  –  5.82  (m,  1H),  5.74  (dddd,  J  =  7.0,  5.2,  4.3,  1.2  
Hz,  1H),  5.43  –  5.32  (m,  2H),  4.89  –  4.80  (m,  1H),  4.79  –  4.66  (m,  1H),  4.34  (s,  2H),  4.18  (s,  2H),  
4.10  –  4.03  (m,  2H);  13C  NMR  (100  MHz,  CD3OD)  δ  169.5,  168.9,  140.6,  132.4,  126.2,  119.3,  
74.0,  53.2,  42.3,  41.8,  34.9.        
4.5.15  Preparation  of  N-­‐(9-­‐(2-­‐(((1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl)oxy)carbonyl)phenyl)-­‐6-­‐(diethylamino)-­‐
3H-­‐xanthen-­‐3-­‐ylidene)-­‐N-­‐ethylethanaminium  34.  
  
Prepared  using  an  identical  method  to  4.5.1;  Rf  =  0.6,  CH3OH  /  CH2Cl2,  1%;  IR  (thin  film)/cm-­‐1  
umax;  3392,  2100,  1587,  1467,  1413,  1338,  1180,  1132,  1074,  682;  1H  NMR  (400  MHz,  CDCl3)  δ  
8.31  (dd,  J  =  7.6,  1.3  Hz,  1H),  7.80  (dtd,  J  =  33.2,  7.6,  1.4  Hz,  2H),  7.34  (dd,  J  =  7.6,  1.3  Hz,  1H),  
7.08  (t,  J  =  9.7  Hz,  2H),  6.92  (ddd,  J  =  14.9,  9.7,  2.5  Hz,  2H),  6.83  (d,  J  =  2.5  Hz,  2H),  5.54  (ddd,  
J  =  17.1,  10.5,  6.4  Hz,  1H),  5.32  –  5.26  (m,  1H),  5.20  –  5.11  (m,  2H),  3.70  –  3.60  (m,  8H),  3.33  –  
3.19  (m,  2H),  1.32  (t,  J  =  7.1  Hz,  12H);  13C  NMR  (100  MHz,  CDCl3)  δ  164.1,  158.2,  157.9,  157.7,  
155.5,  133.5,  133.4,  131.8,  131.4,  131.2,  130.5,  129.7,  119.7,  114.4,  113.6,  96.4,  74.2,  53.4,  






















4.5.16  Preparation  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  (4-­‐bromophenyl)carbamate  37,  that  was  adapted  
from  a  known  procedure.258  
  
A  flame-­‐dried  round-­‐  bottomed  flask  was  degassed,  flushed  with  argon,  and  charged  with  4-­‐  
bromophenyl  isocyanate  36  (0.2  mL,  2.1  mmol),  anhydrous  CH2Cl2  (4  mL),  triethylamine  (0.3  mL,  
2.1  mmol)  and  1-­‐azidobut-­‐3-­‐en-­‐2-­‐ol  6   (80  mg,  0.7  mmol).     The  reaction  mixture  was  stirred  at  
room  temperature  until  TLC   indicated  complete  consumption  of  the  starting  material.  The  
reaction  mixture  was  then  diluted  with  CH2Cl2  (5  mL),  washed  with  1M  HCl  (3  x  5  mL),  water  
(5  mL),  and  brine  (5  mL),  and  then  concentrated  in  vacuo.  The  crude  product  was  purified  by  
silica  gel  column  chromatography  (5%-­‐10%-­‐20%    EtOAc  /  hexane)  to  afford  the  1-­‐azidobut-­‐3-­‐
en-­‐2-­‐yl  (4-­‐bromophenyl)carbamate  37  (50  mg,  55%);  Rf  =  0.8,  EtOAc  /  petroleum  ether,  1:1;  
1H  NMR  (400  MHz,  CD3OD)  δ  7.75  –  7.68  (m,  1H),  7.60  (dd,  J  =  8.0,  1.5  Hz,  1H),  7.38  –  7.31  (m,  
1H),  7.08  (td,  J  =  7.8,  1.6  Hz,  1H),  5.93  (ddd,  J  =  17.3,  10.7,  5.8  Hz,  1H),  5.50  –  5.28  (m,  3H),  
3.50  (dd,  J  =  5.5,  3.4  Hz,  2H);  13C  NMR  (100  MHz,  CD3OD)  δ  137.1,  134.6,  133.7,  129.0,  127.3,  






















4.5.17  Preparation  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  benzylcarbamate  39.  
  
Prepared  using  an  identical  method  to  4.5.16;  Rf  =  0.8,  EtOAc  /  petroleum  ether,  1:1;  IR  (thin  
film)/cm-­‐1  umax;  3327,  2098,  1703,  1522,  1453,  1245,  1135,  1028,  934,  698;  1H  NMR  (300  MHz,  
CDCl3)  δ  7.39  –  7.27  (m,  5H),  5.84  (ddd,  J  =  16.9,  10.6,  5.9  Hz,  1H),  5.47  –  5.28  (m,  3H),  5.12  (s,  
1H),  4.40  (d,  J  =  6.0  Hz,  2H),  3.49  –  3.32  (m,  2H);  13C  NMR  (100  MHz,  CDCl3)  δ  138.6,  133.9,  
129.2,   129.1,   128.1,   128.0,   119.0,   74.5,   54.4,   45.6;  MS  m/z   (ES+)   269.1   (M   +Na+),   HRMS  
C12H14N4O2Na  requires  M,  269.1014,  Found  (M)  269.1016.  
4.5.18  Preparation  of  (E)-­‐but-­‐2-­‐en-­‐1-­‐yl  benzylcarbamate  41.  
  
Prepared  using  an  identical  method  to  4.5.16;  1H  NMR  (300  MHz,  CD3OD)  δ  7.36  –  7.12  (m,  
5H),  5.77  (dp,  J  =  14.8,  8.4,  7.4  Hz,  1H),  5.67  –  5.44  (m,  1H),  4.47  (dt,  J  =  6.2,  1.3  Hz,  2H),  4.27  
(s,  2H),  1.75  –  1.62  (m,  3H);  13C  NMR  (100  MHz,  CD3OD)  δ  140.7,  131.2,  129.4,  128.2,  128.1,  
127.2,   66.5,   45.4,   17.9;   MS  m/z   (EI+)   205.1   (M),   HRMS-­‐EI+   (M)   calc.   mass   for   C12H15NO2  
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4.5.19  Preparation  of  But-­‐3-­‐en-­‐2-­‐yl  benzylcarbamate  43.  
  
Prepared  using  an  identical  method  to  4.5.16;  1H  NMR  (300  MHz,  CD3OD)  δ  7.37  –  7.17  (m,  
5H),  5.88  (ddd,  J  =  16.6,  10.6,  5.6  Hz,  1H),  5.30  –  5.15  (m,  3H),  4.27  (s,  2H),  1.30  (d,  J  =  6.5  Hz,  
3H);  13C  NMR  (100  MHz,  CD3OD)  δ  164.8,  140.0,  129.7,  128.4,  128.3,  115.6,  72.8,  45.6,  20.9;  
MS  m/z  (EI+)  205.1  (M),  HRMS-­‐EI+  (M)  calc.  mass  for  C12H15NO2  205.1103,  found  205.1108.  
4.5.20  Preparation  of  Prop-­‐2-­‐yn-­‐1-­‐yl  benzylcarbamate  45.  
  
Prepared  using  an  identical  method  to  4.5.16;  1H  NMR  (400  MHz,  CDCl3)  δ  7.36  –  7.22  (m,  5H),  
5.10  (s,  1H),  4.68  (d,  J  =  2.3  Hz,  2H),  4.35  (d,  J  =  5.9  Hz,  2H),  2.44  (t,  J  =  2.3  Hz,  1H);  13C  NMR  
(100  MHz,  CDCl3)  δ  155.6,  138.2,  128.8,  127.7,  127.7,  78.4,  74.8,  52.8,  45.4;  MS  m/z  (EI+)  189.1  
(M).  Data  agrees  with  literature  values.259  
4.5.21  Preparation  of  But-­‐2-­‐yn-­‐1-­‐yl  benzylcarbamate  47.  
  
Prepared  using  an  identical  method  to  4.5.16;  IR  (thin  film)/cm-­‐1  umax;  3337,  2483,  1695,  1525,  
1442,  1352,  1248,  1153,  1040,  975;  1H  NMR  (300  MHz,  CD3OD)  δ  7.37  –  7.15  (m,  5H),  4.62  (q,  
J  =  2.4  Hz,  2H),  4.29  (s,  2H),  1.82  (t,  J  =  2.4  Hz,  3H);  13C  NMR  (100  MHz,  CD3OD)  δ  158.4,  140.5,  
129.5,  128.3,  128.1,  83.2,  74.9,  53.9,  45.5,  3.1;  MS  m/z  (EI+)  203.1  (M),  HRMS-­‐EI+  (M)  calc.  
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4.5.22  Preparation  of  But-­‐3-­‐yn-­‐2-­‐yl  benzylcarbamate  49.  
  
Prepared  using  an  identical  method  to  4.5.16;  1H  NMR  (300  MHz,  CDCl3)  δ  7.36  –  7.16  (m,  5H),  
5.40  (qd,  J  =  6.7,  2.1  Hz,  1H),  4.99  (s,  1H),  4.34  (s,  2H),  2.43  (d,  J  =  2.1  Hz,  1H),  1.47  (d,  J  =  6.7  
Hz,  3H);  13C  NMR  (100  MHz,  CDCl3)  δ  155.3,  138.3,  128.8,  127.7,  82.7,  72.9,  60.9,  45.1,  21.7;  
MS  m/z  (EI+)  203.1  (M),  HRMS-­‐EI+  (M)  calc.  mass  for  C12H13NO2  203.0946,  found  203.0950.  
Data  agrees  with  literature  values.260    
4.5.23  Preparation  of  (E)-­‐but-­‐2-­‐en-­‐1-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  60,  that  was  adapted  from  
a  known  procedure.227  
  
To  a  solution  of  1,1’-­‐carbonyldiimidazole  (CDI)  59  (337  mg,  2.08  mmol)  in  CH2Cl2  at  0  °C  was  
added  (E)-­‐but-­‐2-­‐en-­‐1-­‐ol  58  (0.27  ml,  3.12  mmol)  dropwise  under  argon.  The  reaction  mixture  
was  stirred  at  0  °C  for  1  h,  and  then  allowed  to  warm  to  room  temperature  and  stirred  until  
TLC   indicated   complete   consumption   of   the   starting   material.   The   reaction   mixture   was  
diluted  CH2Cl2,  washed  with  water  (2  times),  dried  over  Na2SO4,  and  concentrated  in  vacuo  to  
afford  the  (E)-­‐but-­‐2-­‐en-­‐1-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  60  (303  mg,  88%);  1H  NMR  (400  MHz,  
CDCl3)  δ  8.13  (t,  J  =  1.0  Hz,  1H),  7.42  (t,  J  =  1.5  Hz,  1H),  7.05  (dd,  J  =  1.5,  1.0  Hz,  1H),  5.94  (dqt,  
























–  1.73  (m,  3H);  13C  NMR  (100  MHz,  CDCl3)  δ  148.7,  137.3,  134.3,  130.7,  123.6,  117.3,  69.0,  
18.0;  MS  m/z  (EI+)  166.1  (M).  Data  agrees  with  literature  values.261  
4.5.24   Preparation   of   (E)-­‐but-­‐2-­‐en-­‐1-­‐yl   tert-­‐butyl   ethane-­‐1,2-­‐diyldicarbamate  62,   that  was  
adapted  from  a  known  procedure.228  
  
To  a  solution  of  the  (E)-­‐but-­‐2-­‐en-­‐1-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  60  (291  mg,  1.75  mmol)  in  
CH2Cl2  at  room  temperature  was  added  a  solution  of  N-­‐Boc-­‐ethylenediamine  61  (0.28  ml,  1.75  
mmol)  dissolved  in  CH2Cl2,  dropwise  under  argon.  The  reaction  mixture  was  stirred  at  30  °C  
until  TLC  indicated  complete  consumption  of  the  starting  material.  Then  the  reaction  mixture  
was  diluted  CH2Cl2,  washed  with  water   (3   times),  dried  over  Na2SO4,  and  concentrated   in  
vacuo  to  afford  the  (E)-­‐but-­‐2-­‐en-­‐1-­‐yl  tert-­‐butyl  ethane-­‐1,2-­‐diyldicarbamate  62  (371  mg,  90%);  
IR   (thin  film)/cm-­‐1  umax;  3325,  2934,  1680,  1540,  1264,  1150,  964,  640;  1H  NMR  (300  MHz,  
CD3OD)  δ  5.84  –  5.70  (m,  1H),  5.58  (dtd,  J  =  14.9,  6.2,  1.6  Hz,  1H),  4.52  –  4.36  (m,  2H),  3.19  –  
3.05  (m,  4H),  1.70  (dq,  J  =  6.2,  1.3  Hz,  3H),  1.43  (s,  9H);  13C  NMR  (100  MHz,  CDCl3)  δ  157.0,  
156.5,  131.0,  125.8,  79.6,  65.8,  41.5,  40.8,  28.5,  17.9;  MS  m/z  (ES+)  281.15  (M  +  Na+);  HRMS-­‐





















4.5.25   Preparation   of   (E)-­‐2-­‐(((but-­‐2-­‐en-­‐1-­‐yloxy)carbonyl)amino)ethan-­‐1-­‐aminium   63,   that  
was  adapted  from  a  known  procedure.229  
  
  
A  solution  of  concentrated  HCl  in  diethyl  ether  (2N)  (3  ml)  was  added  to  the  (E)-­‐but-­‐2-­‐en-­‐1-­‐yl  
tert-­‐butyl  ethane-­‐1,2-­‐diyldicarbamate  62  (87.0  mg,  0.34  mmol)  at  ambient  temperature.  The  
reaction   mixture   was   stirred   at   ambient   temperature   until   TLC   indicated   complete  
consumption  of   the   starting  material   and  a   salt  product  precipitated   in  diethyl  ether.  The  
precipitated  product  was  isolated  by  filtration,  then  transferred  to  a  round  bottom  flask  by  
washing   with   diethyl   ether   and   concentrated   from   diethyl   ether   in   vacuo   at   ambient  
temperature   (8   times)   to   afford   the   (E)-­‐2-­‐(((but-­‐2-­‐en-­‐1-­‐yloxy)carbonyl)amino)ethan-­‐1-­‐
aminium  63  as  an  HCl  salt  (60.2  mg,  92%);  IR  (thin  film)/cm-­‐1  umax;  3450,  2357,  2158,1652,  
1506,  1264,  1025,  668;  1H  NMR  (400  MHz,  CD3OD)  δ  5.80  (dq,  J  =  13.2,  6.4  Hz,  1H),  5.65  –  5.54  
(m,  1H),  4.48  (d,  J  =  6.4  Hz,  2H),  3.38  (t,  J  =  5.9  Hz,  2H),  3.04  (t,  J  =  5.9  Hz,  2H),  1.71  (dq,  J  =  6.4,  
1.3  Hz,  3H);    13C  NMR  (100  MHz,  CD3OD)  δ  131.6,  127.2,  67.1,  41.4,  39.7,  18.1;  MS  m/z  (ES+)  
159.11  (M  +  H+),  HRMS-­‐ES+  (M  +  H+)  Calc.  for  C7H15N2O2  159.1134,  Found  159.1133.  
4.5.26  Preparation  of  But-­‐3-­‐en-­‐2-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  65.  
  
Prepared  using  an  identical  method  to  4.5.23;  1H  NMR  (400  MHz,  CDCl3)  δ  8.13  (t,  J  =  1.1  Hz,  
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5.53  (pt,  J  =  6.5,  1.1  Hz,  1H),  5.38  (dt,  J  =  17.0,  1.1  Hz,  1H),  5.27  (dt,  J  =  10.5,  1.1  Hz,  1H),  1.50  
(d,  J  =  6.5  Hz,  3H);  13C  NMR  (100  MHz,  CDCl3)  δ  148.1,  137.2,  136.1,  130.7,  118.0,  117.2,  76.14,  
20.0;  MS  m/z  (EI+)  166.1  (M).  
4.5.27  Preparation  of  But-­‐3-­‐en-­‐2-­‐yl  tert-­‐butyl  ethane-­‐1,2-­‐diyldicarbamate  66.  
  
Prepared  using  an  identical  method  to  4.5.24;  IR  (thin  film)/cm-­‐1  umax;  3331,  2938,  2831,  1680,  
1532,  1265,  1158,  1021,  639;  1H  NMR  (400  MHz,  CD3OD)  δ  5.87  (ddd,  J  =  17.3,  10.6,  5.6  Hz,  
1H),  5.28  –  5.06  (m,  3H),  3.14  (ddt,  J  =  9.0,  7.0,  5.0  Hz,  4H),  1.43  (s,  9H),  1.28  (d,  J  =  6.5  Hz,  
3H);  13C  NMR  (100  MHz,  CD3OD)  δ  140.0,  115.5,  72.7,  41.9,  41.5,  29.0,  20.9;  MS  m/z   (ES+)  
281.15  (M  +  Na+);  HRMS-­‐ES+  (M  +  Na+)  Calc.  for  C12H22N2O4Na  281.1477,  Found  281.1478.  
4.5.28  Preparation  of  2-­‐(((but-­‐3-­‐en-­‐2-­‐yloxy)carbonyl)amino)ethan-­‐1-­‐aminium  67.  
  
Prepared  using  an  identical  method  to  4.5.25;  IR  (thin  film)/cm-­‐1  umax;  3019,  2933,  1692,  1526,  
1258,  1140,  1050,  993,  929,  777;  1H  NMR  (400  MHz,  CD3OD)  δ  5.95  –  5.82  (m,  1H),  5.30  –  5.06  
(m,  3H),  3.39  (t,  J  =  6.0  Hz,  2H),  3.05  (t,  J  =  6.0  Hz,  2H),  1.30  (d,  J  =  6.5  Hz,  3H);  13C  NMR  (100  
MHz,  CD3OD)  δ  158.8,  139.5,  115.6,  73.0,  41.0,  39.4,  20.6;  MS  m/z   (ES+)  159.11  (M  +  H+);  
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4.5.29  Preparation  of  But-­‐2-­‐yn-­‐1-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  69.  
  
Prepared  using  an  identical  method  to  4.5.23;  1H  NMR  (400  MHz,  CDCl3)  δ  8.09  (t,  J  =  1.0  Hz,  
1H),  7.38  (t,  J  =  1.4  Hz,  1H),  7.01  (dd,  J  =  1.7,  0.8  Hz,  1H),  4.89  (q,  J  =  2.4  Hz,  2H),  1.82  (t,  J  =  2.4  
Hz,  3H);  13C  NMR  (100  MHz,  CDCl3)  δ  148.3,  137.2,  130.7,  117.2,  85.4,  71.6,  56.4,  3.7;  MS  m/z  
(EI+)  164.1  (M).  
4.5.30  Preparation  of  But-­‐2-­‐yn-­‐1-­‐yl  tert-­‐butyl  ethane-­‐1,2-­‐diyldicarbamate  70.  
  
Prepared  using  an  identical  method  to  4.5.24;  IR  (thin  film)/cm-­‐1  umax;  3326,  1684,  1524,  1366,  
1249,  1162,  995,  780;  1H  NMR  (300  MHz,  CD3OD)  δ  4.58  (q,  J  =  2.4  Hz,  2H),  3.21  –  3.07  (m,  
4H),  1.81  (t,  J  =  2.4  Hz,  3H),  1.43  (s,  9H);  13C  NMR  (100  MHz,  CD3OD)  δ  158.4,  83.1,  80.1,  74.9,  
53.8,  41.9,  41.2,  28.7,  3.1;  MS  m/z   (ES+)  279.13   (M  +  Na+);  HRMS-­‐ES+   (M  +  Na+)  Calc.   for  
C12H20N2O4Na  279.1321,  Found  279.1322.  
4.5.31  Preparation  of  2-­‐(((but-­‐2-­‐yn-­‐1-­‐yloxy)carbonyl)amino)ethan-­‐1-­‐aminium  71.  
  
Prepared  using  an  identical  method  to  4.5.25;  IR  (thin  film)/cm-­‐1  umax;  2471,  1673,  1203,  1120,  
971,  822;  1H  NMR  (300  MHz,  D2O)  δ  4.60  (q,  J  =  2.4  Hz,  2H),  3.41  (t,  J  =  5.8  Hz,  2H),  3.09  (t,  J  =  
N N
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5.8  Hz,  2H),  1.79  (t,  J  =  2.4  Hz,  3H);  MS  m/z  (ES+)  157.1  (M  +  H+);  HRMS-­‐ES+  (M  +  H+)  Calc.  for  
C7H13N2O2  157.0977,  Found  157.0977.  
4.5.32  Preparation  of  But-­‐3-­‐yn-­‐2-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  73.  
  
Prepared  using  an  identical  method  to  4.5.23;  IR  (thin  film)/cm-­‐1  umax;  1746,  1252,  1088,  1062,  
1020,  894,  825,  747,  669;  1H  NMR  (400  MHz,  CDCl3)  δ  8.15  (t,  J  =  1.0  Hz,  1H),  7.44  (t,  J  =  1.4  
Hz,  1H),  7.07  (dd,  J  =  1.4,  1.0  Hz,  1H),  5.63  (qd,  J  =  6.7,  2.1  Hz,  1H),  2.60  (d,  J  =  2.1  Hz,  1H),  1.68  
(dd,  J  =  6.7,  0.7  Hz,  3H);  13C  NMR  (100  MHz,  CDCl3)  δ  147.8,  137.3,  130.9,  117.3,  80.3,  75.2,  
64.8,  21.3;  MS  m/z  (EI+)  164.1  (M),  HRMS-­‐EI+  (M)  calc.  mass  for  C8H8N2O2  164.0586,  found  
164.0587.  
4.5.33  Preparation  of  But-­‐3-­‐yn-­‐2-­‐yl  tert-­‐butyl  ethane-­‐1,2-­‐diyldicarbamate  74.  
  
Prepared  using  an  identical  method  to  4.5.24;  IR  (thin  film)/cm-­‐1  umax;  3327,  2359,  1683,  1542,  
1267,  1171,  988,  668;  1H  NMR  (400  MHz,  CD3OD)  δ  5.30  (qd,  J  =  6.7,  2.1  Hz,  1H),  3.25  –  3.06  
(m,  4H),  2.86  (d,  J  =  2.1  Hz,  1H),  1.46  (d,  J  =  6.7  Hz,  3H),  1.43  (s,  9H);  13C  NMR  (100  MHz,  CD3OD)  
δ  157.9,  83.6,  80.1,  74.1,  61.6,  41.8,  41.2,  28.7,  22.0;  MS  m/z  (ES+)  279.14  (M  +  Na+);  HRMS-­‐






























4.5.34  Preparation  of  22-­‐(((but-­‐3-­‐yn-­‐2-­‐yloxy)carbonyl)amino)ethan-­‐1-­‐aminium  75.  
  
Prepared  using  an  identical  method  to  4.5.25;  IR  (thin  film)/cm-­‐1  umax;  2923,  1698,  1523,  1253,  
1089,  1027,  955,  755;  1H  NMR  (300  MHz,  D2O)  δ  5.23  (qd,  J  =  6.8,  2.0  Hz,  1H),  3.40  (t,  J  =  5.8  
Hz,  2H),  3.08  (t,  J  =  5.8  Hz,  2H),  2.88  (d,  J  =  2.0  Hz,  1H),  1.45  (d,  J  =  6.8  Hz,  3H);  13C  NMR  (100  
MHz,  CD3OD)  δ  158.0,  83.3,  74.4,  62.0,  41.0,  39.4,  22.0;  MS  m/z  (ES+)  157.1  (M  +  H+);  HRMS-­‐
ES+  (M  +  H+)  Calc.  for  C7H13N2O2  157.0977,  Found  157.0978.  
4.5.35  Preparation  of  1-­‐aminobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐(2-­‐chloroacetamido)ethyl)carbamate  80.  
  
Prepared  using  an  identical  method  to  4.5.25;  IR  (thin  film)/cm-­‐1  umax;  3396,  2944,  2389,  1651,  
1426,  1251,  1163,  994,  771;  1H  NMR  (300  MHz,  CD3OD)  δ  5.86  (s,  1H),  5.51  –  5.31  (m,  3H),  
4.08  (s,  2H),  3.58  –  3.40  (m,  2H),  3.29  –  3.03  (m,  4H);  13C  NMR  (100  MHz,  CD3OD)  δ  170.1,  
157.7,  134.1,  119.6,  72.6,  43.8,  43.5,  41.7,  40.6;  MS  m/z  (ES+)  250.31  (M  +  H+);  HRMS-­‐ES+  (M  
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4.5.36  Preparation  1-­‐aminobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐(2-­‐chloroacetamido)ethyl)carbamate  80  by  azide  
reduction  by  using  tin  chloride  in  CH3OH,  that  was  adapted  from  a  known  procedure.233  
  
To   a   suspension   of   tin   (II)   chloride   (375   mg,   1.98   mmol)   in   CH3OH   (5.0   mL)   at   room  
temperature   were   added   1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl   (2-­‐(2-­‐chloroacetamido)ethyl)carbamate   84  
(182   mg,   0.66   mmol)   and   stirred   at   room   temperature   until   TLC   indicated   complete  
consumption  of  the  starting  material.  After  24  hours,  the  reaction  solvent  was  concentrated  
in  vacuo.  The  residue  was  purified  twice  by  silica  gel  column  chromatography  (10%  CH3OH  /  
CH2Cl2)  to  offered  1-­‐aminobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐(2-­‐chloroacetamido)ethyl)carbamate  80  (29.7  mg,  
18%);  IR  (thin  film)/cm-­‐1  umax;  3396,  2944,  2389,  1651,  1426,  1251,  1163,  994,  771;  1H  NMR  
(300  MHz,  CD3OD)  δ  5.86  (s,  1H),  5.51  –  5.31  (m,  3H),  4.08  (s,  2H),  3.58  –  3.40  (m,  2H),  3.29  –  
3.03  (m,  4H);  13C  NMR  (100  MHz,  CD3OD)  δ  170.1,  157.7,  134.1,  119.6,  72.6,  43.8,  43.5,  41.7,  
40.6;  MS  m/z  (ES+)  250.31  (M  +  H+);  HRMS-­‐ES+  (M  +  H+)  Calc.  for  C9H17N3O3  35Cl  250.0958,  
Found  250.0956.  
4.5.37  Preparation  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  81.  
  
Prepared  using  an  identical  method  to  4.5.23;  IR  (thin  film)/cm-­‐1  umax;  2098,  1757,  1473,  1389,  
1280,  1238,  1172,  1095,  997,  832;  1H  NMR  (300  MHz,  CDCl3)  δ  8.16  (t,  J  =  1.1  Hz,  1H),  7.44  (t,  
SnCl2, CH3OH
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J  =  1.5  Hz,  1H),  7.08  (dd,  J  =  1.7,  0.9  Hz,  1H),  5.91  (ddd,  J  =  17.2,  10.5,  6.6  Hz,  1H),  5.61  –  5.42  
(m,  3H),  3.65  –  3.50  (m,  2H);  13C  NMR  (100  MHz,  CDCl3)  δ  147.5,  136.9,  131.0,  130.7,  120.9,  
116.9,  77.4,  53.3;  MS  m/z  (EI+)  207.1  (M);  HRMS-­‐EI+  (M)  calc.  mass  for  C8H9N5O2  207.0756,  
found  207.0757.  
4.5.38  Preparation  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  tert-­‐butyl  ethane-­‐1,2-­‐diyldicarbamate  82.  
  
Prepared  using  an  identical  method  to  4.5.24;  IR  (thin  film)/cm-­‐1  umax;  3340,  2098,  1690,  1517,  
1365,  1250,  1165,  987;  1H  NMR  (400  MHz,  CDCl3)  δ  5.92-­‐5.73  (m,  1H),  5.45  –  5.24  (m,  4H),  
4.93  (s,  1H),  3.37  (t,  J  =  4.8  Hz,  2H),  3.27  (ddd,  J  =  13.3,  8.1,  3.7  Hz,  4H),  1.42  (s,  9H);  13C  NMR  
(100  MHz,  CDCl3)  δ  156.9,  155.4,  133.2,  118.3,  79.4,  73.6,  53.7,  41.4,  40.3,  28.2;  MS  m/z  (ES+)  
322.15  (M  +  Na+);  HRMS-­‐ES+  (M  +  Na+)  Calc.  for  C12H21N5O4Na  322.1491,  Found  322.1489.  
4.5.39  Preparation  of  2-­‐((((1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl)oxy)carbonyl)amino)ethan-­‐1-­‐aminium  83.  
  
Prepared  using  an  identical  method  to  4.5.25;  IR  (thin  film)/cm-­‐1  umax;  3015,  2942,  2328,  2108,  
1710,  1534,  1442,1260,  1155;  1H  NMR  (300  MHz,  CD3OD)  δ  5.98  –  5.79  (m,  1H),  5.38  (dt,  J  =  
17.2,  1.4  Hz,  1H),  5.34  –  5.21  (m,  2H),  3.60  –  3.35  (m,  4H),  3.07  (t,  J  =  6.1  Hz,  2H);  13C  NMR  
(100  MHz,  CD3OD)  δ  156.9,  133.6,  117.1,  74.0,  53.5,  39.5,  38.1;  MS  m/z  (ES+)  200.1  (M  +  H+);  































24 h, RT, 93%
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4.5.40  Preparation   of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl   (2-­‐(2-­‐chloroacetamido)ethyl)carbamate  84,   that  
was  adapted  from  a  known  procedure.262  
  
To  a  solution  of  a  2-­‐((((1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl)oxy)carbonyl)amino)ethan-­‐1-­‐aminium  83  (1.43  g,  
6.08  mmol)  in  anhydrous  CH2Cl2  at  -­‐50  °C  under  argon  was  added  triethylamine  (4.20  ml,  30.0  
mmol)  then  chloroacetyl  chloride  (1.50  ml,  18.0  mmol)  dropwise  and  the  reaction  mixture  
stirred  under  argon  for  2  hours  at  -­‐50  0C.  The  reaction  mixture  was  then  allowed  to  warm  to  
ambient  temperature  and  stirred  until  TLC  indicated  complete  consumption  of  the  starting  
material.  Then  the  reaction  mixture  was  diluted  with  brine  and  extracted  with  CH2Cl2.  The  
combined  organic  layers  were  dried  over  Na2SO4,  filtered  and  concentrated   in  vacuo,  then  
the  residue  was  purified  by  silica  gel  column  chromatography  (100%  CH2Cl2)  to  afford  the  1-­‐
azidobut-­‐3-­‐en-­‐2-­‐yl   (2-­‐(2-­‐chloroacetamido)ethyl)carbamate   84   (757   mg,   45%);   IR   (thin  
film)/cm-­‐1  umax;  3362,   2943,  2415,  2101,  1652,  1424,  1252,  1160,  972;  1H  NMR   (300  MHz,  
CDCl3)  δ  7.19  (t,  J  =  5.8  Hz,  1H),  5.77  (ddd,  J  =  16.9,  10.6,  6.0  Hz,  1H),  5.63  (t,  J  =  5.8  Hz,  1H),  
5.50  –  4.98  (m,  3H),  3.99  (s,  2H),  3.41  (dt,  J  =  6.0,  3.4  Hz,  2H),  3.34  (td,  J  =  4.9,  4.4,  2.0  Hz,  4H);  
13C  NMR  (100  MHz,  CDCl3)  δ  167.1,  156.0,  133.3,  118.8,  74.3,  53.9,  42.6,  40.7,  40.5;  MS  m/z  


















CH2Cl2, (-50 °C, RT)
         24 h, 45%
84
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4.5.41   Preparation   of   1-­‐((tert-­‐butoxycarbonyl)amino)but-­‐3-­‐en-­‐2-­‐yl   (2-­‐(2-­‐
chloroacetamido)ethyl)carbamate  85,  that  was  adapted  from  a  known  procedure.234  
  
A  suspension  of  NaOH  (0.34  g,  8.50  mmol)  in  CH3OH  (20  mL)  was  heated  to  reflux  to  allow  
dissolution.  This  solution  was  cooled  to  room  temperature  and  the  1-­‐aminobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐
(2-­‐chloroacetamido)ethyl)carbamate   80   (0.41   g,   4.71  mmol)   was   added   under   argon   and  
stirred  for  30  min.    Then  a  solution  of  di-­‐tert-­‐butylcarbonate  (2.1  g,  9.43  mmol)  in  anhydrous  
THF  (20  mL)  was  added  dropwise  at  room  temperature.  Stirred  at  room  temperature  until  TLC  
indicated  complete  consumption  of  the  starting  material.  After  24  hours,  the  reaction  was  
concentrated   in  vacuo   to  offer  a  white  solid  residue.  The  residue  was  purified  by  silica  gel  
column   chromatography   (50%   ethyl   acetate   /   hexane)   to   provide   the   1-­‐((tert-­‐
butoxycarbonyl)amino)but-­‐3-­‐en-­‐2-­‐yl   (2-­‐(2-­‐chloroacetamido)ethyl)carbamate   85   (0.25   g,  
15%);  IR  (thin  film)/cm-­‐1  umax;  3317,  2928,  2495,  1675,  1540,  1426,  1248,  1163,  954;  1H  NMR  
(300  MHz,  CDCl3)  δ  7.17  (s,  1H),  6.11  –  5.89  (m,  1H),  5.77  (ddd,  J  =  16.9,  10.6,  5.9  Hz,  1H),  5.45  
–  5.11  (m,  3H),  4.87  (s,  1H),  4.04  (d,  J  =  3.3  Hz,  2H),  3.55  –  3.09  (m,  6H),  1.42  (s,  9H);  13C  NMR  
(100  MHz,  CDCl3)  δ  166.9,  156.2,  133.8,  117.7,  79.4,  74.2,  43.5,  42.3,  42.3,  40.4,  40.3,  28.2;  

























4.5.42   Preparation   of   1-­‐((tert-­‐butoxycarbonyl)amino)but-­‐3-­‐en-­‐2-­‐yl   (2-­‐(2-­‐
chloroacetamido)ethyl)carbamate  85.    
  
To  a  solution  of  1-­‐((tert-­‐butoxycarbonyl)amino)but-­‐3-­‐en-­‐2-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  89  
(116  mg,  0.40  mmol)  in  anhydrous  CH2Cl2  at  0  °C  were  added  ethylenediamine  (EDA)  (  0.54  
mL,  8.10  mmol)  dropwise  under  argon.  The   reaction  mixture  was  stirred  at  0   °C  until   TLC  
indicated   complete   consumption   of   the   imidazole   carboxylate   after   2   hours.   Then   the  
reaction  mixture  was   concentrated   in   vacuo.  And  characterised  by   1HNMR  to  confirm   the  
complete  consumption  of  the  imidazole  carboxylate.  This  crude  product  was  dissolved  with  
dry  CH2Cl2  and  cooled  to  –70  °C  under  argon.  Triethylamine  (0.29  mL,  2.80  mmol)  was  added  
followed  by  chloroacetyl  chloride  (0.75  mL,  9.40  mmol)  dropwise  and  the  reaction  mixture  
stirred  under  argon  for  2  hours  at  –  70  °C,  then  allowed  to  warm  to  room  temperature  and  
stirred   until   TLC   indicated   complete   consumption   of   the   starting   material.   The   reaction  
mixture  was  diluted  with  brine  and  extracted  with  CH2Cl2.  The  combined  organic  layers  were  
dried  over  Na2SO4,  filtered  and  concentrated  in  vacuo.  The  residue  was  purified  by  silica  gel  
column  chromatography  (50%  EtOAc  /  hexane)  to  afford  1-­‐((tert-­‐butoxycarbonyl)amino)but-­‐
3-­‐en-­‐2-­‐yl  (2-­‐(2-­‐chloroacetamido)ethyl)carbamate  85  (47.6  mg,  21%  yield);  IR  (thin  film)/cm-­‐1  
umax;  3317,  2928,  2495,  1675,  1540,  1426,  1248,  1163,  954;  1H  NMR  (300  MHz,  CDCl3)  δ  7.17  
(s,  1H),  6.11  –  5.89  (m,  1H),  5.77  (ddd,  J  =  16.9,  10.6,  5.9  Hz,  1H),  5.45  –  5.11  (m,  3H),  4.87  (s,  
1H),  4.04  (d,  J  =  3.3  Hz,  2H),  3.55  –  3.09  (m,  6H),  1.42  (s,  9H);  13C  NMR  (100  MHz,  CDCl3)  δ  
166.9,  156.2,  133.8,  117.7,  79.4,  74.2,  43.5,  42.3,  42.3,  40.4,  40.3,  28.2;  MS  m/z  (ES+)  372.13  
1. Ethylenediamine, CH2Cl2, 2 h, RT
2. ClCH2COCl, Et3N,THF, 24 h, RT

















(M  +  Na+);  HRMS-­‐ES+  (M  +  Na  +)  Calc.  for  C14H24N3O5  NaCl  372.1302,  Found  372.1308.  
4.5.43  Preparation  of  1-­‐aminobut-­‐3-­‐en-­‐2-­‐ol  87,  that  was  adapted  from  a  known  procedure.240  
  
To  a  suspension  of  tin  chloride  (247  mg,  1.40  mmol)  in  acetonitrile  at  room  temperature  was  
added  thiophenol   (0.61  ml,  5.76  mmol)   followed  by  triethylamine  (0.60  ml,  4.32  mmol).  A  
solution  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐ol  6  (109  mg,  0.96  mmol)  in  acetonitrile  was  added  slowly  at  
room  temperature  and  the  reaction  mixture  stirred  at  room  temperature  until  TLC  indicated  
complete  consumption  of  the  starting  material  (~1  h).  The  reaction  solvent  was  concentrated  
in  vacuo,  then  the  residue  was  purified  by  silica  gel  column  chromatography  (  90:10:1,  CH2Cl2  
/   CH3OH   /   NH3   solution)   to   afford   the   1-­‐aminobut-­‐3-­‐en-­‐2-­‐ol   87   (60.2  mg,   72%)   ;   IR   (thin  
film)/cm-­‐1  umax;  3383,  2930,  1650,  1388,  1254,  1099,  1009;  1H  NMR  (400  MHz,  CD3OD)  δ  5.89  
(ddd,  J  =  17.2,  10.5,  5.4  Hz,  1H),  5.43  (dt,  J  =  17.2,  1.5  Hz,  1H),  5.26  (dt,  J  =  10.5,  1.5  Hz,  1H),  
4.37  (dtd,  J  =  8.9,  3.7,  1.5  Hz,  1H),  3.07  (dd,  J  =  12.7,  3.7  Hz,  1H),  2.85  (dd,  J  =  12.7,  8.9  Hz,  1H);  
13C  NMR  (100  MHz,  CD3OD)  δ  138.3,  117.6,  69.5,  45.5.  
4.5.44  Preparation  of  tert-­‐butyl  (2-­‐hydroxybut-­‐3-­‐en-­‐1-­‐yl)carbamate  88.  
  
Prepared  using  an  identical  method  to  4.5.41;  IR  (thin  film)/cm-­‐1  umax;  3353,  2977,  1686,  1514,  
1366,  1250,  1168,  991,  925;  1H  NMR  (300  MHz,  CD3OD)  δ  5.84  (ddd,  J  =  17.2,  10.5,  5.9  Hz,  1H),  



















3.20  –  2.98  (m,  2H),  1.43  (s,  9H);  13C  NMR  (100  MHz,  CD3OD)  δ  157.2,  138.6,  114.7,  78.7,  71.4,  
45.7,  27.3.  Data  agrees  with  literature  values.263    
4.5.45   Preparation   of   1-­‐((tert-­‐butoxycarbonyl)amino)but-­‐3-­‐en-­‐2-­‐yl   1H-­‐imidazole-­‐1-­‐
carboxylate  89.  
  
Prepared  using  an  identical  method  to  4.5.23;  IR  (thin  film)/cm-­‐1  umax;  1762,  1691,  1529,  1477,  
1389,  1281,  1240,  1166,  1061,  1001,  930,  824,  745,  661;  1H  NMR  (300  MHz,  CDCl3)  δ  8.15  (t,  
J  =  1.1  Hz,  1H),  7.44  (t,  J  =  1.5  Hz,  1H),  7.06  (dd,  J  =  1.7,  0.9  Hz,  1H),  5.86  (ddd,  J  =  17.1,  10.6,  
6.4  Hz,  1H),  5.52  –  5.35  (m,  3H),  5.13  (s,  1H),  3.62  –  3.35  (m,  2H),  1.40  (s,  9H);  13C  NMR  (100  
MHz,  CDCl3)  δ  137.3,  135.2,  132.1,  130.6,  122.0,  120.4,  117.3,  80.2,  78.5,  43.5,  28.4;  MS  m/z  
(EI+)  281.15  (M);  HRMS-­‐EI+  (M)  calc.  mass  for  C13H19N3O4  281.1376,  found  281.1374.  
4.5.46  Preparation  of  1-­‐aminobut-­‐3-­‐en-­‐2-­‐yl  tert-­‐butyl  ethane-­‐1,2-­‐diyldicarbamate  92.  
  
Prepared  using  an  identical  method  to  4.5.43;  IR  (thin  film)/cm-­‐1  umax;  3000,  2700,  2350,  1500,  
1450,  1050;  1H  NMR  (300  MHz,  CD3OD)  δ  5.87  (ddd,  J  =  17.2,  10.7,  5.4  Hz,  1H),  5.51  –  5.29  (m,  
3H),  3.28  –  3.00  (m,  6H),  1.43  (s,  9H);  13C  NMR  (100  MHz,  CD3OD)  δ  158.5,  136.3,  117.5,  80.1,  
77.3,  46.0,  41.8,  28.8;  MS  m/z  (ES+)  374.18  (M  +  H+);  HRMS-­‐ES+  (M  +  H  +)  Calc.  for  C12H24N3O4  














CH2Cl2, 24 h, RT
















4.5.47  Preparation  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐hydroxyethyl)carbamate  97.  
  
Prepared  using  an  identical  method  to  4.5.24;  IR  (thin  film)/cm-­‐1  umax;  2101,  1703,  1529,  1256,  
1145,  1069,  933;  1H  NMR  (300  MHz,  CDCl3)  δ  5.83  (ddd,  J  =  16.8,  10.6,  6.1  Hz,  1H),  5.44  –  5.15  
(m,  4H),  3.74  (d,  J  =  4.9  Hz,  2H),  3.46  –  3.30  (m,  4H);  13C  NMR  (100  MHz,  CD3OD)  δ  156.1,  
133.4,  118.8,  74.2,  62.2,  54.0,  43.6;  MS  m/z  (ES+)  223.08  (M  +  Na+);  HRMS-­‐ES+  (M  +  Na+)  Calc.  
for  C7H12N4O3  23Na  223.0807,  Found  223.0808.  
4.5.48  Preparation  of  1-­‐aminobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐hydroxyethyl)carbamate  98.  
  
Prepared  using  an  identical  method  to  4.5.43;  IR  (thin  film)/cm-­‐1  umax;  3338,  2943,  2831,  1646,  
1549,  1409,  1254,  1020;  1H  NMR  (400  MHz,  CDCl3)  δ  5.79  (ddd,  J  =  16.9,  10.6,  5.8  Hz,  1H),  5.40  
–  5.21  (m,  3H),  5.15  (d,  J  =  5.7  Hz,  1H),  3.72  (dt,  J  =  5.5,  3.6  Hz,  2H),  3.46  –  3.19  (m,  2H),  2.88  
(qd,  J  =  13.6,  5.8  Hz,  2H);  13C  NMR  (100  MHz,  CDCl3)  δ  135.1,  118.1,  76.9,  62.5,  45.8,  44.0;  MS  



















CH2Cl2, 12 h, 



















4.5.49  Preparation  of  tert-­‐butyl  (2-­‐(2-­‐chloroacetamido)ethyl)carbamate  104.  
  
Prepared  using  an  identical  method  to  4.5.40;  1H  NMR  (400  MHz,  CD3OD)  δ  4.07  (s,  2H),  3.34  
(t,  J  =  6.1  Hz,  2H),  3.20  (t,  J  =  6.1  Hz,  2H),  1.46  (s,  9H);  13C  NMR  (100  MHz,  CD3OD)  δ  169.6,  
158.6,  80.2,  43.1,  41.1,  40.5,  28.7;  MS  m/z  (ES+)  259.0  (M  +  Na+).  
4.5.50  Preparation  of  tert-­‐butyl  (2-­‐(2-­‐iodoacetamido)ethyl)carbamate  105.  
  
Prepared  using  an  identical  method  to  4.5.12;  IR  (thin  film)/cm-­‐1  umax;  3347,  3308,  2933,  1678,  
1650,  1528,  1283,  1164,  980,  867,  647;  1H  NMR  (400  MHz,  D2O)  δ  3.76  (s,  2H),  3.30  (t,  J  =  5.7  
Hz,  2H),  3.22  (t,  J  =  5.7  Hz,  2H),  1.43  (s,  9H);  13C  NMR  (100  MHz,  CD3OD)  δ  171.6,  158.5,  80.2,  
41.0,   40.5,   28.8,   -­‐2.2;   MS  m/z   (ES+)   351.02   (M   +   Na+),   HRMS   C9H17N2O3NaI   requires  M,  
351.0182,  Found  (M)  351.0181.  
4.6  Allyl  carbamate  cleavage  using  catalytic  Pd  in  the  solution  phase  
All  stock  solutions  were  prepared   just  before  use.     The  Pd-­‐o-­‐DANPHOS  complex  (1:8  Pd:o-­‐
DANPHOS  solution)  was  prepared  by  addition  of  a  solution  of  Na2PdCl4  in  D2O  to  a  solution  of  
o-­‐DANPHOS  dihydrate  (8.0  equiv.)  in  D2O  and  mixed  for  30  minutes.    The  stock  solution  of  
dimethyl  barbituric  acid  in  D2O  was  prepared.  To  the  allyl  carbamates  in  D2O  in  NMR  tubes  
were   added   the   solution   of   Pd-­‐o-­‐DANOHOSE   complex   in   D2O   (0.1   –   1.0   equiv.)   and   the  

































at  room  temperature  for  24  hours.  The  crude  products  were  characterised  by  1H  NMR  and  
MS.  
4.7  Immobilisation  onto  agarose  and  release  
4.7.1-­‐  General  procedure  for  immobilisation  onto  aldehyde-­‐  modified  agarose  
A.   Preparation  of  the  solid  alkyne  4  (reductive  amination  of  the  aldehyde  modified  agarose  
2):  
  
2-­‐(2-­‐(prop-­‐2-­‐yn-­‐1-­‐yloxy)ethoxy)ethan-­‐1-­‐amine  3   (0.90  mL,   6.30  mmol),   aldehyde  modified  
agarose  2  (15.0  mL,  0.60  mmol)  and  sodium  cyanoborohydride  (0.40  g,  6.30  mmol)  were  put  
in  5  mL  of  PBS  (pH  7.4),  then  the  mixture  was  rotated  at  room  temperature  for  24  hours.  The  
reaction  mixture  was  filtered  and  washed  with  3  mL  water  then  the  filtrate  was  dried  to  afford  
the  solid  alkyne  4  as  a  white  solid  (4.90  g).  
B.   General  procedure  of  the  copper  catalysed  azide-­‐alkyne  cycloaddition  reaction  (CuAAC)  
between  rhodamine  azide  34  and  the  solid-­‐phase  alkyne  4,  that  was  adapted  from  a  
known  procedure.173    
  
The  stock  solutions  of  the  rhodamine  azide  34  in  DMSO  were  prepared  just  before  use,  this  





























with  the  solid  alkyne  4.  To  the  solution  of  the  solid  alkyne  4  (1  equiv.)  in  DMSO  (1  mL)  in  the  
SPE  Tube  with  a  filter  at  the  bottom,  were  added  a  solution  of  rhodamine  azide  34  (0.25,  1  
and  4  equiv.),  copper  sulfate  (10  equiv.),   tris(2-­‐benzimidazolylmethyl)amine  (5  equiv.)  and  
sodium  ascorbate  (60  equiv.).  Then  the  SPE  tube  was  closed  and  reaction  mixtures  rotated  at  
room  temperature  for  24  hours.  The  unreacted  rhodamine  azide  34  was  washed  by  DMSO  
and  analysed  by  UV-­‐spectrometer  to  measure  the  rhodamine  azide  34  absorption  at  566  nm,  
and  the  washing  step  repeated  until  no  more  rhodamine  azide  34  elution  was  observed.  
  
Figure  74:  Calibration  curve  of  Rhodamine  Azide  34  at  (λ  max  =  566  nm).  
   4.0  equiv.   1.0  equiv.   0.25  equiv.  
Aldehyde  modified  agarose   1.2  µmole   1.2  µmole   4.8  µmole  
Rhodamine  azide  34   4.4  µmole   1.2  µmole   1.2  µmole  
Abs.  of  the  unreacted  Rhodamine  azide  34   0.501   0.617   0.271  
Conc.  of  the  unreacted  Rhodamine  azide  34   6.95  µM   8.44  µM   3.99  µM  
Total  wash  volume   0.035  L   0.016  L   0.008  L  
Dilution  factor   10   2   2  
Total  unreacted  Rhodamine  azide  34   2.43  µmole   0.27  µmole   0.06  µmole  
Total  reacted  Rhodamine  azide  34   1.97  µmole   0.93  µmole   0.56  µmole  
Observed  loading  yield   164  %   77  %   47  %  
  
Table  26:  The  calculation  of  the  loading  efficiency  and  the  CuAAC  reaction  efficiency  after  
CuAAC  reaction  between  Rhodamine  azide  34  and  solid-­‐phase  alkyne  4  based  on  the  
absorbance  of  the  unreacted  Rhodamine  azide  34  at  566  using  standard  curve  of  
Rhodamine  azide  34  in  the  figure  74.  







Standard curve of the Rhodamine azide 32










Y = 0.07782*X - 0.03976
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Figure  75:  Absorbance  of  the  unreacted  Rhodamine  azide  34  at  566  after  CuAAC  reaction  
between  Rhodamine  azide  34  and  solid  alkyne  4.  
 
 
C.  Deprotection  of  allyl  ester  in  the  solid  model  system  35  by  using  one  equiv.  Pd  to  afford  
rhodamine  B.  
Tetrakis(triphenylphosphine)Pd(0)  (2.60  mg,  2.2  µmol)  was  added  to  the  solid  model  system  
35    (1.2  µmol)  in  CH3OH  (0.5  mL).  After  24  h  of  rotation  at  room  temperature,  the  reaction  
mixture  was  filtered  by  washing  with  CH3OH  until  the  filter  paper  colour  changed  from  purple  
colour   to   white   to   make   sure   all   rhodamine   B   has   been   recovered.   The   rhodamine   B  
absorbance  was  measured  by  UV-­‐spectrometry  to  determine  concentration  (C).    















The bsorbance of the unreacted Rhodamine azide 32
 after addition of 4 equiv.















The bsorbance of the unreacted Rhodamine azide 32
 after addition of 1 equiv.















The bsorbance of the unreacted Rhodamine azide 32
 after addition of 0.25 equiv.
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Figure  76:  Calibration  curve  of  Rhodamine  B  at  (λ  max  =  545  nm).  
Absorbance  of  the  cleaved  Rhodamine  B   0.706  
Concentration  of  the  cleaved  Rhodamine  B   3.90  µM  
Total  wash  volume   0.001  L  
Total  cleaved  Rhodamine  B   0.004  µmole  
Loaded  Rhodamine  azide  34   0.930  µmole  
Cleavage  yield   0.4%  
  
Table  27:  The  calculation  of  the  cleavage  efficiency  of  the  allyl  ester  in  the  model  system  35  
based  on  the  absorbance  of  the  Rhodamine  B  at  545  using  standard  curve  of  Rhodamine  B  
in  the  figure  76.  
  
  
Figure  77:  UV  scan  of  rhodamine  B  recovered  from  cleavage  of  the  model  system  35  by  1  
equiv.  Pd.  
  

















Y = 0.1768*X + 0.01593

















The bsorbance of the released Rhodamine B 
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4.7.2  Immobilisation  into  NHS-­‐agarose  
A-­‐  General  procedure  for  immobilisation  into  NHS-­‐agarose  
The  NHS-­‐activated  agarose  gel  supplied  in  100%  isopropanol  was  pipetted  into  an  SPE  tube  
with  a  filter  at  the  bottom,  then  washed  with  cold  1  mM  HCI  (10  medium  volumes)  followed  
by  washing  with  PBS  immediate  before  use.  The  stock  solution  of  the  ligand  (primary  amine  
molecule)  in  PBS  was  prepared  and  added  to  the  washed  NHS-­‐activated  agarose  (the  ratio  of  
the  between  the  NHS-­‐activated  agarose  gel  and  coupling  solution  is  1.0:0.5),  then  5  equiv.  
TEA  added  to  the  reaction  mixture.  The  SPE  tube  was  closed  and  the  reaction  mixtures  were  
rotated  at  room  temperature  for  24  hours.    Then  the  unreacted  ligands  were  washed  by  PBS  
and  analysed  by  using   fluorescamine  assay,  and   the  washing   step   repeated  until  no  more  
amine  eluted  from  the  solid  phase.  
  
A.1  The  coupling  reaction  between  ethanolamine  (ETA)  and  NHS-­‐agarose  
  
  
Figure  78:  Calibration  curve  of  ethanolamine  using  fluorescamine  assay,  for  different  







































Y = 29.87*X + 16.96






Standard curve of ETA and FLURAM  

















WASHES   FI   CONC.  µM   Wash  
Volume  L  
Unreacted  ETA  µmole  
1st  washX100   1464   48.4   0.001   4.84  
2nd  wash  X10   1212   40.0   0.001   0.40  
3rd  wash   901   29.6   0.001   0.03  
4th  wash   29   0.403   0.001   0.00  
Washed  ETA            5.27  
Added  ETA            8.4  
Reacted  ETA            3.13  
NHS-­‐agarose            4.4  
Coupling  %            71  
  
Table  28:  The  calculation  of  the  coupling  %  after  reaction  of  2  equiv.  ethanolamine  with  






Figure  79:  The  fluorescence  of  the  unreacted  ethanolamine  after  reaction  of  2  equiv.  








































WASHES   FI   CONC.  µM   Wash  
Volume  L  
Unreacted  ETA  µmole  
1st  washX100   147   65.7   0.0001268   0.833  
2nd  wash  X100   151   67.9   0.0001   0.679  
3rd  wash  X10   624   324   0.0001   0.324  
4th  wash  X2   481   246   0.001   0.493  
5th  wash   244   118   0.001   0.118  
6th  wash   59   18.1   0.001   0.018  
7th  wash   26   0.259   0.001   0.000  
Washed  ETA            2.47  
Added  ETA            4.2  
Reacted  ETA            1.74  
NHS-­‐agarose            4.2  
Coupling  %            41  
  
Table  29:  The  calculation  of  the  coupling  %  after  reaction  of  1  equiv.  ethanolamine  with  
NHS-­‐agarose  by  using  standard  curve  in  figure  78B.  
  
  
Figure  80:  The  fluorescence  of  the  unreacted  ethanolamine  after  reaction  of  1  equiv.  




































WASHES   FI   CONC.  µM   Wash  
Volume  L  
Unreacted  ETA  µmole  
1st  wash   1291   42.7   0.001   0.043  
2nd  wash   338   10.7   0.001   0.011  
3rd  wash   34   0.571   0.001   0.001  
Washed  ETA            0.054  
Added  ETA            2.1  
Reacted  ETA            2.05  
NHS-­‐agarose            4.4  
Coupling  %            97  
  
Table  30:  The  calculation  of  the  coupling  %  after  reaction  of  0.5  equiv.  ethanolamine  with  
NHS-­‐agarose  by  using  standard  curve  in  figure  78A.  
  
Figure  81:  The  fluorescence  of  the  unreacted  ethanolamine  after  reaction  of  0.5  equiv.  












































Figure  82:  Calibration  curve  of  the  amine  92  using  fluorescamine  assay.  
WASHES   FI   CONC.  µM   Wash  
Volume  L  
Unreacted  ETA  µmole  
1st  washX4   570   298   0.0027306   3.25  
2nd  wash  X2   447   232   0.001   0.464  
3rd  wash  X2   130   62.9   0.001   0.126  
4th  wash  X2   41   15.4   0.001   0.031  
5th  wash  X2   26   7.45   0.001   0.015  
6th  wash  X2   13   0.515   0.001   0.001  
Washed  amine            3.89  
Added  amine            8  
Reacted  amine            4.11  
NHS-­‐agarose            4  
Coupling  %            102  
  
Table  31:  The  calculation  of  the  coupling  of  amine  92  with  NHS-­‐agarose  by  using  standard  


















































Y = 1.875*X + 12.04
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Figure  83:  The  fluorescence  of  the  unreacted  amine  92.  
A.3  The  coupling  reaction  between  amine  98  and  NHS-­‐agarose  93:  
  
  







































































Standard curve of Amine 90 and FLURAM  in PBS











Y = 2.859*X + 5.686
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WASHES   FI   CONC.  µM   Wash  
Volume  L  
Unreacted  amine  µmole  
1st  washX2   549   190   0.0056   2.13  
2nd  wash   266   91.0   0.001   0.091  
3rd  wash   22   5.71   0.001   0.006  
Washed  amine  90            2.23  
added  amine  90            5.75  
reacted  amine  90            3.53  
NHS-­‐agarose            23  
Coupling  %            61  
  
Table  32:  The  calculation  of  the  coupling  of  amine  98  with  NHS-­‐agarose  by  using  standard  
curve  in  figure  84.  
  













































Figure  86:  Calibration  curve  of  the  alkylation  linker  80  using  fluorescamine  assay.  
  








1st  washX100   376   5.87   0.003   1.76   1.84  
1st  washX100   407   6.40   0.003   1.92     
2nd  wash   1188   19.9   0.003   0.06   0.058  
2nd  wash   1144   19.1   0.003   0.06     
3rd  wash   426   6.73   0.003   0.02   0.020  
3rd  wash   434   6.87   0.003   0.02     
4th  wash   184   2.56   0.003   0.008   0.007  
4th  wash   155   2.06   0.003   0.006     
Washed  amine  73               1.93  
added  amine  73               8.5  
reacted  amine  73               6.57  
NHS-­‐agarose               21  
Coupling  %               77  
  
Table  33:  The  calculation  of  the  coupling  of  amine  80  with  NHS-­‐agarose  by  using  standard  



































PBS, TEA, 24 h, RT
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Standard curve of Amine 73 and FLURAM  in PBS











Y = 58.02*X + 35.71
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Figure  87:  The  fluorescence  of  the  unreacted  amine  80.  
B-­‐  General  procedure  for  NHS-­‐agarose  ester  93  quenching  
After  coupling  completed  and  washing  the  unreacted  ligand,  1M  ethanolamine  in  PBS  was  
added  to  the  unreacted  NHS-­‐agarose  ester.  After  24  hours,  the  unreacted  ethanolamine  was  
washed  with  PBS,with  the  washing  step  repeated  10  times  to  ensure  all  ethanolamine  has  
been  removed.  
C-­‐  General  procedure  for  BSA  alkylation  
  
The  stock  solution  of  BSA  in  PBS  (1  mM)  was  prepared  just  before  use.  To  the  solid  phase  thiol  
alkylation   system   in   the  SPE   tube  was  added   the   solid  phase  TCEP   (8  equiv.),   followed  by  
washing  with  PBS  two  times.  Then  BSA  in  PBS  was  added  and  the  reaction  mixture  rotated  at  
room  temperature  for  24  hours.  Unreacted  BSA  was  washed  with  PBS  and  analysed  by  using  
fluorescamine  assay,  BCA  assay  or  RP-­‐HPLC,  and  the  washing  step  repeated  until  no  more  


































































Figure  88:  Calibration  curve  of  BSA  using  fluorescamine  assay,  using  the  BSA  stock  solution  
that  used  in  the  reaction  of  BSA  with  the  solid  phase  alkylation  linker  101.  
 
 







1st  washX100   1315   1.73   0.003   0.052   0.046  
1st  washX100   1062   1.35   0.003   0.04     
2nd  wash   847   1.02   0.003   0.003   0.003  
2nd  wash   935   1.15   0.003   0.003     
3rd  wash   398   0.33   0.003   0.001   0.001  
3rd  wash   360   0.28   0.003   0.0008     
Washed  BSA               0.050  
Added  BSA               0.7  
Reacted  BSA               0.650  
Alkylation  %               93  
  
Table  34:  The  calculation  of  BSA  alkylation  by  the  solid  phase  alkylation  linker  101  by  using  









Standard curve of BSA and FLURAM  (PBS)











Y = 656.0*X + 178.4
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Figure  89:  The  fluorescence  of  the  unreacted  BSA  washed  after  reaction  of  BSA  with  the  
solid  phase  alkylation  linker  101.  
  
  
Figure  90:  Calibration  curve  of  BSA  using  BCA  protein  assay  (37°C/30-­‐minutes  incubation),  


















































Standard curve of BSA and BCA  (PBS)
Y = 0.06994*X + 0.03107
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Washed   Abs.  at  562  
nm  









0.156   1.78   0.003   0.053   0.047  
1st  
washX100  
0.143   1.60   0.003   0.048     
1st  
washX100  
0.123   1.31   0.003   0.039     
2nd  wash   0.194   2.33   0.003   0.007   0.007  
2nd  wash   0.198   2.38   0.003   0.007     
2nd  wash   0.206   2.50   0.003   0.007     
3rd  wash   0.055   0.34   0.003   0.001   0.001  
3rd  wash   0.059   0.40   0.003   0.001     
3rd  wash   0.071   0.57   0.003   0.002     
4th  wash   0.133   1.45   0.003   0.004   0.004  
4th  wash   0.144   1.61   0.003   0.005     
4th  wash   0.119   1.25   0.003   0.004     
Washed  BSA               0.051  
Added  BSA               0.7  
Reacted  BSA               0.65  
Alkylation  %               93  
  
Table  35:  The  calculation  of  BSA  alkylation  by  the  solid  phase  alkylation  linker  101  by  using  
standard  curve  in  figure  90.  
  



































Figure  92:  the  calibration  curve  of  BSA  in  HPLC.  
Washes   Peak  Area   Conc.  µM   Wash  Volume  L   unreacted  BSA  µmole  
1st  washX10   49.8   4.79   0.003   0.144  
Washed  BSA            0.144  
Added  BSA            0.7  
Reacted  BSA            0.556  
Alkylation  %            79  
  
Table  36:  The  calculation  of  BSA  alkylation  by  the  solid  phase  alkylation  linker  101  by  using  










Standard curve of BSA in HPLC







Y = 5.117*X + 68.26
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Figure  93:  HPLC  of  the  unreacted  BSA  washed  after  treatment  with  the  solid  phase  




Figure  94:  The  standard  curve  of  BSA  and  fluorescamine  in  PBS,  using  the  BSA  stock  solution  













Standard curve of BSA and FLURAM  (PBS)











Y = 859.8*X + 659.0
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Washed   FI  at  479  
nm  







1st  washX100   3180   2.93   0.002   0.586   0.584  
1st  washX100   3160   2.91   0.002   0.582     
2nd  wash  X100   2218   1.81   0.002   0.363   0.369  
2nd  wash  X100   2269   1.87   0.002   0.375     
3rd  wash   2979   2.70   0.002   0.005   0.006  
3rd  wash   3194   2.95   0.002   0.006     
Washed  BSA               0.958  
Added  BSA               2.72  
Reacted  BSA               1.77  
Alkylation  %               65  
  
Table  37:  The  calculation  of  BSA  alkylation  by  the  solid  phase  alkylation  linker  100  by  using  
standard  curve  in  figure  94.  
  
Figure  95:  The  fluorescence  of  the  unreacted  BSA  that  washed  after  reaction  of  BSA  with  the  







































Washes   Peak  Area   Conc.  µM   Wash  Volume  L   unreacted  BSA  
µmole  
1st  wash  X10   190   240   0.002   0.479  
2nd  wash  X10   170   21.2   0.002   0.425  
3rd  wash   58.6   6.001   0.002   0.012  
Washed  BSA            0.916  
Added  BSA            2.72  
Reacted  BSA            1.81  
Alkylation  %            66  
  
Table  38:  The  calculation  of  BSA  alkylation  by  the  solid  phase  alkylation  linker  100  by  using  




Figure  96:  HPLC  of  the  unreacted  BSA  after  treatment  with  the  solid  phase  alkylation  linker  
100,  showing  the  three  washes  of  the  unreacted  BSA.  
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D-­‐  The  allyl  carbamate  cleavage  by  using  catalytic  Pd  in  the  solid  phase  
All  stock   solutions  were  prepared   just  before  use.  The  Pd-­‐o-­‐DANPHOS  complex   (1:8  Pd-­‐o-­‐
DANPHOS  solution)  was  prepared  by  addition  of  a  solution  of  Na2PdCl4  in  PBS  to  a  solution  of  
o-­‐DANPHOS  dihydrate  (8.0  equiv.)   in  PBS  and  mixed  for  30  minutes.  The  stock  solution  of  
dimethyl  barbituric  acid  in  PBS  was  prepared.  The  solid  phase  system  in  PBS  was  treated  with  
a  solution  of  Pd-­‐o-­‐DANOHOS  complex  in  PBS  (0.1  –  1.0  equiv.)  and  the  solution  of  the  dimethyl  
barbituric  acid  in  PBS  (1.0  equiv.).  The  reaction  mixtures  were  rotated  at  room  temperature  
for  24  hours  then  the  cleaved  substrates  with  cleavage  reaction  reagents  were  washed  and  
analysed.      
  




Figure  97:  Calibration  curve  of  the  N-­‐Boc  ethylenediamine  (the  cleaved  product)  of  the  solid  

































Standard curve of N-Boc ethylenediamine and FLURAM 











Y = 0.7210*X + 22.35
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Figure  98:  The  fluorescence  of  the  cleaved  N-­‐Boc  ethylenediamine  after  deallylation  




Washes   FI  at  479  
nm  




1st  wash   472   624   0.001621   1.011  
2nd  wash   448   590   0.001   0.590  
3rd  wash   483   639   0.001   0.639  
4th  wash   374   488   0.001   0.488  
5th  wash   230   288   0.001   0.288  
6th  wash   157   187   0.001   0.187  
7th  wash   122   138   0.001   0.138  
8th  wash   84   85.5   0.001   0.086  
9th  wash   44   30.0   0.001   0.030  
10th  wash   32   13.4   0.001   0.013  
Washed  
amine  
         3.47  
Loaded  amine            11.4  
Cleavage  %            30  
  
Table  39:  The  calculation  of  the  cleavage  yield  of  the  solid  phase  allyl  carbamate  95  after  

































Figure  99:  The  fluorescence  of  the  cleaved  N-­‐Boc  ethylenediamine  after  deallylation  
reaction  of  the  solid  phase  allyl  carbamate  95  by  0.1  equiv.  Pd.  
 
 
Washes   FI  at  479  nm   Conc.  µM   Wash  Volume  L   Cleaved  
amine  µmole  
1st  wash   248   313   0.002   0.692  
2nd  wash   56   46.7   0.002   0.093  
3rd  wash   25   3.67   0.001   0.004  
Washed  amine            0.789  
Loaded  amine            3.5  
Cleavage  %            23  
  
Table  40:  The  calculation  of  the  cleavage  yield  of  the  solid  phase  allyl  carbamate  95  after  






































The  deallylation  reaction  of  the  solid  phase  allyl  carbamate  99  by  using  Pd:  
  
  
Figure  100:  The  fluorescence  of  the  cleaved  ethanolamine  after  deallylation  reaction  of  the  





















































































Washes   FI  at  479  
nm  





1st  wash   406   206   0.001   0.227  
2nd  wash   327   163   0.001   0.163  
3rd  wash   238   115   0.001   0.115  
4th  wash   68   23.0   0.001   0.023  
5th  wash   31   2.96   0.001   0.003  
1st  wash  after  second  addition  of  
0.05  equiv.  Pd  
87   33.3   0.001   0.037  
2nd  wash  after  second  addition  of  
0.05  equiv.  Pd  
74   26.2   0.001   0.026  
3rd  wash  after  second  addition  of  
0.05  equiv.  Pd  
44   10.0   0.001   0.010  
Total  washed  amine            0.604  
Loaded  amine            3.5  
Cleavage  %            17  
  
Table  41:  The  calculation  of  the  cleavage  yield  of  the  solid  phase  allyl  carbamate  99  after  
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(A)  1H  NMR  spectrum  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐chloroacetyl)glycinate  1.  
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(B)  13C  NMR  spectrum  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐chloroacetyl)glycinate  1.  
 241 
  
(C)  COSY  NMR  spectrum  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  (2-­‐chloroacetyl)glycinate  1.  
  
















(B)  13C  NMR  spectrum  of  1-­‐azidobut-­‐3-­‐en-­‐2-­‐yl  benzylcarbamate  39.  
  
  














(C)  COSY  NMR  spectrum  of  (E)-­‐but-­‐2-­‐en-­‐1-­‐yl  tert-­‐butyl  ethane-­‐1,2-­‐diyldicarbamate  62. 
 
 





















(A)  COSY  NMR  spectrum  of  But-­‐3-­‐en-­‐2-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  65. 
 
 














(C)  COSY  NMR  spectrum  of  2-­‐(((but-­‐3-­‐en-­‐2-­‐yloxy)carbonyl)amino)ethan-­‐1-­‐aminium  67. 
 
 













(C)  13C  NMR  spectrum  of  But-­‐2-­‐yn-­‐1-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  69. 
 
 




































(C)  COSY  NMR  spectrum  of  But-­‐3-­‐yn-­‐2-­‐yl  1H-­‐imidazole-­‐1-­‐carboxylate  73.  
  
 























































(A)  1H  NMR  spectrum  of  tert-­‐butyl  (2-­‐hydroxybut-­‐3-­‐en-­‐1-­‐yl)carbamate  88.  
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Figure  111:  NMR  spectra  of  tert-­‐butyl  (2-­‐hydroxybut-­‐3-­‐en-­‐1-­‐yl)carbamate  88. 
